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be assessed (the HALT PKD trials).12;13 Increased understanding of the genetic, molecular and 
cellular mechanisms underlying ADPKD has resulted in the development of potentially effective 
treatments.14 In this introduction, first, current markers of disease severity in ADPKD will be 
discussed. Second, we will address the role of vasopressin in normal physiology, and its potential 
unfavorable effects in chronic kidney disease, specifically in ADPKD. Third, we will discuss the 
potential value of vasopressin receptor antagonists as a new treatment option in ADPKD.
Markers for disease severity in ADPKD
The clinical course of ADPKD is highly variable.15 In Figure 2, the variability in age at which end 
stage renal disease is reached, is shown. The figure illustrates that there are differences between 
ADPKD patients with a mutation in the PKD1 gene and with a mutation in the PKD2 gene. 
Patients with a mutation in the PKD1 gene have significantly more severe renal disease than 
patients with a mutation in the PKD2 gene, with larger kidneys16 and earlier onset at end stage 
renal disease (median age at death or onset of end stage renal disease is 53.0 vs. 69.1 years).17 
But even within the specific genetic abnormality, there is variation. Furthermore, the figure 
illustrates that even within families, there is a large spread in age of reaching end stage renal 
disease.
With upcoming therapeutic regimens (see further in this introduction) and the existing variable 
disease course, markers are needed to assess disease severity in ADPKD. 
In most renal diseases, kidney function is measured for this purpose. However, measurements of 
glomerular filtration rate is suggested to be misleading in reporting the progression of ADP-
KD.19 Figure 3 illustrates the hypothesis that compensatory hyperfiltration of remaining glome-
ruli occurs, although glomeruli are lost due to the disease process. Consequently, GFR remains 
stable during a prolonged period, declining sharply thereafter (grey bullets). Without such a 
compensatory mechanism, GFR would have declined in a linear fashion (broken line). In black 
triangles, renal volume increase is depicted, following in parallel with the actual loss of functio-
ning glomeruli. So far however, there is no firm evidence to support this hypothesis. 
Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by progressive cyst 
formation in the kidneys, leading to renal enlargement (Figure 1), pain, haematuria and end 
stage renal disease.  It is the most common hereditary kidney disease, with a prevalence rate 
estimated between 1 in 400 (including observed and estimated autopsy cases) and 1 in 1,000 
(clinically diagnosed cases only).1 In the Netherlands, approximately 12,600 people need renal 
replacement therapy. For more than 1000 people, renal failure is due to ADPKD (8.6%). Of 
these 1,000 people, 37% undergo dialysis, whereas the other 63% live with a renal transplant 
(www.renine.nl). 
ADPKD is genetically heterogeneous with 2 genes identified. The PKD1 gene is located on 
chromosome 16, encodes for polycystin-1 and accounts for around 85% of ADPKD cases.3 The 
PKD2 gene is located on chromosome 4, encodes for polycystin-2 and accounts for around 15% 
of cases.4;5 Whether another gene is involved in a small number of unlinked families is yet uncer-
tain. In general, a mutation in the PKD1 gene is associated with a faster renal function decline 
than a mutation in the PKD2 gene, but there is considerable overlap.
Current treatment unfortunately is not able to prevent or postpone renal failure. Although 
successful in numerous renal diseases, there is not much evidence to support dietary protein 
restriction6 or strict blood pressure regulation7 as treatments for patients with ADPKD. The 
role of the renin-angiotensin-aldosterone system (RAAS) in the pathology of ADPKD is a mat-
ter of debate.8 Renal cyst enlargement is thought to cause bilateral ischemia, and subsequent 
an increased rennin release. This stimulation of the renin-angiotensin-aldosterone system is 
supposed to result in both hypertension and progression of cyst growth.9 However, treatment 
with angiotensin receptor blockers (ARBs) or ACE inhibitors has yet not been proven effective 
in prevention of renal function deterioration.10;11 The lack of finding a beneficial effect could 
however be explained by the study designs of the trials that have been performed thus far. Most 
studies had too short follow-up, too small patient groups or included a control group that had 
almost no renal function deterioration. At the moment, two large scale trials (in early and later 
stages of ADPKD) are conducted with 4 years of follow-up, in which the impact of intensive 
blockade of the renin-angiotensin-aldosterone system on progressive renal disease will hopefully 
Figure 1: MRI scan of a 45-year old male with ADPKD. Total renal 
volume is 3091 ml (normal 330 (200-600) ml). Figure derived 
from2. 
Figure 2: Age plot for ADPKD 
patients who developed end 
stage renal disease, grouped 
by family. Each dot represents 
the age at which an affected 
member of the same family de-






When vasopressin binds to the vasopressin V2 receptors in the collecting ducts in the kidney, 
this induces the insertion of the molecular water channel aquaporin-2 in the luminal membrane 
of principal cells. Activation of the vasopressin V2 receptor also increases the permeability of 
the inner medullary portion of the collecting duct to urea, allowing increased reabsorption of 
urea into the medullary interstitium. This increases the concentration gradient created from the 
removal of water in the connecting tubule, cortical collecting duct, and outer medullary col-
lecting duct. Both processes mediate water reabsorption, thereby reducing water excretion.28;29 
Thus, for concentrating urine, vasopressin is vital. Patients with central diabetes insipidus (who 
lack vasopressin) or with nephrogenic diabetes insipidus (where there is resistance against the 
action of vasopressin) experience a marked, sustained increase in water excretion. This requires 
virtually continuous drinking, day and night, to prevent dehydration, illustrating the importance 
of vasopressin for normal physiology.
Copeptin as a surrogate for vasopressin
Reliable measurement of vasopressin concentration in blood is problematic. This is caused by 
the fact that more than 90% of vasopressin in the circulation is bound to platelets. Vasopressin is 
furthermore, unstable in isolated plasma.30 Because of the small size of vasopressin, vasopressin 
cannot be measured by sandwich immunoassay, but only by less sensitive competitive immuno-
assays. 
This hypothesis in mind, it has been suggested that clinical evaluations of potential therapies for 
ADPKD should better monitor cyst and renal growth to indicate efficacy, instead of preserva-
tion of GFR. The Consortium for Renal Imaging Studies in Polycystic Kidney Disease (CRISP) 
showed that kidney enlargement results from the expansion of cysts in patients with ADPKD. 
This growth is continuous and quantifiable by MRI and is associated with decline of renal func-
tion.20 Higher rates of kidney enlargement are associated with a more rapid decrease in renal 
function.19;20 In a large number of animal studies, treatments that inhibited renal enlargement, 
also ameliorated renal function.19 Furthermore, several studies show that the rate of increase of 
renal volume can reliably be measured.21-22 
Other proposed markers to define ADPKD severity are renal blood flow and albuminuria. Renal 
blood flow was measured in a subgroup of 131 patients, drawn form the CRISP cohort, using 
magnetic resonance imaging. During follow-up, a reduction of renal blood flow paralleled the 
increase in total kidney volume, and importantly, preceded GFR decline and predicted structu-
ral and functional disease progression in this cohort. Several studies showed that in ADPKD, al-
buminuria is associated with renal volume,23;24 mean arterial blood pressure, filtration fraction,24 
renal growth and slope of glomerular filtration rate.25 Albuminuria is regarded to be a valuable 
biomarker indicating disease severity and predicting outcome. As such it has become a secon-
dary endpoint in intervention studies in ADPKD (Chapter 7).
Vasopressin in normal physiology
The antidiuretic hormone arginine vasopressin is crucial for water regulation in the body (Figu-
re 4). Its secretion is stimulated in response to an increase in plasma osmolarity or a decrease in 
plasma volume. Vasopressin can bind to three different receptors. The vasopressin 1A receptor is 
expressed among others on vascular smooth muscle cells and stimulation leads to vasoconstricti-
on.26 The vasopressin 1B receptor is expressed on brain cells and activation stimulates release of 
adrenocorticotropin from the anterior pituitary.27 
Figure 5: Schematic representation of the peptide precursor of arginine vasopressin, showing the signal sequence 
(white), vasopressin (VP, black), neurophysin II (light grey) and copeptin (dark grey). Numbers indicate amino acids 














































Figure 3: hypothetical associations between age, GFR and total renal volume for a patient with ADPKD. Figure 
adapted from19 published in2.
Figure 4: An increased plasma osmolarity and/or a 
decreased circulating volume stimulates secretion of va-
sopressin. Vasopressin is derived from a preprohormone 
precursor that is synthesized in the hypothalamus. It is 
stored in the posterior pituitary gland to be released 
into the blood stream in response to the two aforemen-
tioned stimuli. Vasopressin mediates water-reabsorption 
by stimulating the urea-recirculation and the water 





cilium projects into the lumen. It is likely that the polycystin complex acts as a mechanosensor 
on cilia, detecting changes in tubular urine flow, reacting by calcium influx, possibly through the 
polycystin-2 channel. This calcium influx induces release of calcium from intracellular stores.1 
In turn, calcium controls cell proliferation and regulation through growth factors and hormonal 
stimulation. Two aspects seem important in cyst formation: proliferation of tubular cells and 
cyst fluid secretion by these cells. Important players in this proliferation cascade, partly con-
trolled by calcium influx, are adenosine 3’,5’-cyclic monophosphate (cAMP)47 and mammalian 
target of rapamycin (mTOR).48 
Activation of the vasopressin V2 receptor on the basolateral side of renal tubular cells will 
result in an increase in cAMP, which in turn stimulates cell proliferation and fluid secretion and 
causes cyst enlarging.49 Stimulation of the vasopressin V2 receptor is caused by vasopressin in 
the circulation. It is described that ADPKD patients have high levels of vasopressin, compared to 
healthy controls,50;51 although the evidence for this is scarce. In addition to that, ADPKD patients 
also have an impaired urinary concentrating capacity. This might be caused by insensitivity for 
vasopressin and / or by anatomic disruption of the vasculotubular architecture.52-55 Apart from 
the general unfavorable effects of vasopressin, vasopressin will result in an increased intracellular 
cAMP concentration in ADPKD patients, thus aggravating the cystic disease. How the abnor-
malities in ciliary function that occur when PKD1 or PKD2 are mutated, are linked exactly to 
other components of cyst formation (such as cAMP accumulation, chloride-dependent cyst fluid 
secretion and regulation of mTOR) is not yet completely understood. Figure 7 is a simplified 
version of the hypothetical pathways in healthy subjects (A) and in patients with ADPKD (B). 
Recently, an assay has been developed to measure copeptin, the C-terminal portion of the pre-
cursor of vasopressin. Because this copeptin assay is a sandwich immunoassay, it is remarkably 
sensitive, the detection limit is 1.7 pmol/L. Copeptin has been shown to be a reliable marker of 
vasopressin secretion and a useful substitute for circulating vasopressin concentration in clinical 
routine.31-33 These characteristics make copeptin a promising marker, which allows for the first 
time (indirect) measurement of vasopressin in large populations. The structure of copeptin is 
depicted in Figure 5. In Figure 6, the principle of the copeptin sandwich immuno-assay is 
depicted.
Unfavorable renal effects of Vasopressin
Despite its relevance for normal physiology, several unfavorable effects of vasopressin have been 
reported on the kidney. Experimental studies have shown that a sustained vasopressin V2 recep-
tor stimulation results in increased renal plasma flow and particularly in increased GFR.34 This 
hyperfiltration may have deleterious consequences, in particular in diseased kidneys, resulting 
in renal hypertrophy,35 proteinuria,36 and accelerated renal function decline.37-39 This proposed 
mechanism is supported by studies in rats with chronic renal failure, showing that increased 
water intake or chronic infusion of a vasopressin V2-receptor antagonist reduced proteinuria and 
prevented glomerulosclerosis37;40 and tubulo-interstitial fibrosis.41 Similarly, chronic infusion of a 
vasopressin V2-receptor antagonist reduced albuminuria and kidney weight in diabetic rats.42 In 
humans, administration of 1-desamino-8-D-arginine vasopressin (a vasopressin receptor agonist) 
induced albuminuria.36
Unfavorable effects of vasopressin in the pathogenesis of ADPKD
Apart from these general unfavorable renal effects, vasopressin probably also has a specific 
detrimental role in the pathogenesis of ADPKD.  In 1999, it was discovered in the roundworm 
Caenorhabditis elegans that homologues of polycystin-1 and polycystin-2, the gene products of 
respectively PKD1 and -2, function as mechanosensors in specialized ciliated sensory neurons. 
This discovery prompted interest in the role of cilia in mammalian kidneys, specifically in 
ADPKD. Indeed, also in humans, the polycystins are located in the primary cilium. Other sup-
port for the involvement of primary cilia in ADPKD came from studies in rodent models for 
polycystic kidney disease, which all appeared to have defects in their cilia function.43;44 Polycys-
tin-1 and polycystin-2 probably form a functional complex,45 in which polycystin-2 is a non-
selective cation channel, capable of transporting calcium ions.46 In tubular epithelial cells, the 
Figure 6: Principle of the copeptin sandwich immunoassay. A polyclonal an-
tibody (1st AB) directed to amino acids 132-147 of human copeptin is bound 
on the solid phase; a second polyclonal antibody (2nd AB) directed to amino 






Vasopressin V2 receptor antagonists in ADPKD
In the past decade, studies in animal models of cystic renal diseases have suggested a final com-
mon pathway for cystogenesis, involving a major role for cAMP-stimulated signaling pathways in 
controlling both the rate of epithelial cell growth and fluid secretion in cysts.47;56 Since agonists 
of cAMP stimulate cell proliferation and fluid secretion and cause cyst enlarging, it follows that 
antagonists of cAMP-mediated processes could be therapeutic targets to reduce cyst volume. 
This appeared true for the vasopressin V2 receptor antagonist OPC-31260 (produced by the 
pharmaceutical company Otsuka) in animal models for autosomal recessive polycystic kidney 
disease (ARPKD) and nephronophthisis,57 and one year later in a model for ADPKD. Other 
experiments support the hypothesis that vasopressin plays an important role in the pathogenesis 
of ADPKD. By crossing PCK rats (a model for ARPKD, Pkhd1-/-) with Brattleboro rats (AVP 
-/-), rats were generated with ARPKD and varying amounts of endogenous vasopressin. Admi-
nistration of a vasopressin V2 receptor agonist recovered the cystic phenotype in this rat model 
(i.e. it brought back the cysts) without vasopressin and aggravated the cystic phenotype of those 
rats with ARPKD and with vasopressin but did not induce cystic formation in wild-type rats.58
In 2005, the effectiveness of another vasopressin V2 receptor antagonist, OPC-41061 (tol-
vaptan®, also from Otsuka) was proven in a rat model for ARPKD.59 This is an interesting 
finding since OPC-41061 has more affinity for the human vasopressin V2 receptor than OPC- 
31260. There is already some experience with Tolvaptan as a treatment in humans. In 2009, 
tolvaptan is approved by the FDA for treatment of hypervolemic and euvolemic hyponatraemia, 
including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic 
hormone. The EMA approved the drug for treatment of hyponatraemia due to the syndrome of 
inappropriate antidiuretic hormone. These approvals were based on studies of efficacy and safety 
in patients with hyponatriaemia60 and in patients with congestive heart failure, with or without 
hyponatraemia.61;62 These studies showed that the drug seems safe and well tolerated, with no 
major safety issues. An investigational new drug application has been filed by the manufacturer 
of Tolvaptan to examine its effect in clinical trials for cyst growth modification in ADPKD. Phase 
I and II trials have been completed. As yet however, no data are available on efficacy of vasopres-
sin receptor antagonists to delay disease progression in ADPKD. 
Besides knowledge whether these new drugs will indeed decrease cyst formation in subjects 
with ADPKD and preserve renal function, we need to learn about the adverse effects of these 
new drugs, the more since therapy probably has to be given life-long for this chronic condition. 
What might be problematic of the treatment with tolvaptan is the severe water diuresis and 
thirst that is induced by this agent. When given to healthy, normally hydrated male volunteers, 
tolvaptan causes an increase in urine volume (without natriuresis), which is dose dependent 
over 6 hours and which is increased by up to 4 times compared to placebo.63  Polyuria and 
especially nycturia are therefore expected to occur in ADPKD patients and will probably have 
a negative influence on quality of life. Given this side effect profile, it would be an option to 
use lower dosages of vasopressin receptor antagonists. This is likely to result in less adverse 
effects, but also in less effectivity. To overcome this decreased efficacy, a combination therapy 
Figure 7: Hypothetical pathogenetic pathways in ADPKD. 
Pathways depicted in bold are upregulated, pathways depicted in grey are downregulated.
A. Depicts an epithelial cell of the kidney’s collecting duct of a healthy individual. As long as there is urine 
flow in the tubule, the cilium will bend, inducing a calcium influx through the polycystin complex. This in turn indu-
ces release of calcium from the endoplasmatic reticulum. Cyclic AMP is inhibited by this calcium.
B. Depicts this same cell, but now derived from an individual with ADPKD. Because of a defect in the poly-
cystin complex, there is less calciuminflux, resulting in an increased intracellular cyclic AMP concentration. This will 
induce on the one hand more protein translation, causing a disturbed proliferation, adhesion, migration, differentia-
tion and maturation of the tubulule cells and on the other hand more chloride dependent fluidproduction, enabling 
the cysts to grow. 
How these processes are interrelated is at this moment still unknown. Vasopressin V2 receptor antagonists block the 
vasopressin V2 receptor (V2R) and thereby inhibit cAMP, inhibitors of mTOR inhibit protein translation. Figure 





Aims of this Thesis
In this thesis, measures of renal damage in ADPKD as well as detrimental effects of vasopressin 
in renal disease, and specifically in ADPKD, are studied. 
Part I focuses on measures of renal damage in ADPKD. With the variable disease course and up-
coming potentially effective therapeutic regimens, measurement of disease severity will become 
more important.  Chapter 2 therefore describes renal abnormalities that occur relatively early in 
the disease. This is of particular interest as assessment GFR is of limited value. Subsequently, in 
chapter 3 the potential value of urinary biomarkers to assess disease severity is investigated. The 
advantage of measuring urinary biomarkers compared to renal hemodynamic parameters is that 
urinary biomarkers are relatively easy to measure and low in costs. 
In part II, the focus is on potential detrimental effects of vasopressin. As described above, 
vasopressin is difficult to measure. Therefore, copeptin is used as a surrogate for vasopres-
sin. In chapter 4, we investigate whether cross-sectionally, copeptin is associated with micro-
albuminuria in a large general population-based cohort (the PREVEND-study). In chapter 5, 
we investigate in a cohort of renal transplant recipients the predictive value of baseline copeptin 
concentration for graft failure and rate of renal function decline during follow-up. Next, in 
chapter 6, copeptin is investigated in ADPKD. We investigate the potential association between 
copeptin and disease severity (as assessed by effective renal blood flow, total renal volume and 
albuminuria). 
Part III is the synthesis of the two previous parts: does inhibition of vasopressin ameliorate pro-
gression of disease severity in ADPKD? So far, no human data are available on this subject. The 
first, large worldwide phase III trial is conducted at this moment (the TEMPO study). In chapter 
7, the design and baseline characteristics of this study are given. It is a multicenter, double-blind, 
placebo controlled trial that will for the first time investigate the therapeutic effect, safety and 
tolerability of a vasopressin V2 receptor antagonist in patients with ADPKD. If proven effective, 
it will be essential to assess the dose-effect and dose side effect relationships of these drugs to 
assess at which dose these drugs are effective, while having an acceptable side effect profile. 
Furthermore, it is important to obtain information whether these drugs are effective in early 
as well as late stage disease. We therefore investigated the renal effects of different dosages of 
a vasopressin V2 receptor antagonist at different stages of the disease in an animal model for 
ADPKD.  The results of this experiment are described in chapter 8.
In chapter 9, the results of the previous chapters are described in their context. The implications 
of these studies and future perspectives are discussed.
 
could be instituted with other agents that are now being tested for efficacy in ADPKD. Of note, 
these agents also have side effects that will limit the probability of lifetime use in high dosages. 
Examples of such potential agents are mTOR inhibitors, like rapamycin and sirolimus64 and 
somatostatin analogues.65;66 Recent clinical trials did not show a clear beneficial effect of mTOR 
inhibitors in ADPKD,67;68 making them less favorable candidates for combination therapy.
Finally, when proven effective, an essential question will be when treatment should be initia-
ted: early or later in the disease? Because ADPKD is a progressive condition and probably the 
cysts that are formed early in life are the main contributor to eventual total cyst volume,69 it 
would make sense to start an intervention as early in this process as possible to delay or prevent 
long-term consequences as renal failure. Furthermore, vasopressin V2 receptor antagonists 
are believed to be preventive, not restorative. The effect of treatment in a later phase of the 
disease could therefore be less than treatment in an early phase. On the other hand, an early 
intervention would mean that every patient with ADPKD will be exposed for a lifetime to the 
adverse effects of the agents needed to intervene, while not all patients will reach end stage 
renal disease.70 Because of these reasons, it will be important to discover markers that identify 
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Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most prevalent inherited renal 
disease with an estimated prevalence between 1:400 and 1:1000.1 The disease is characterized 
by pain, haematuria and most importantly by progressive cyst formation in both kidneys, often 
leading to end stage renal disease. Annually, 7.8 male and 6.0 female individuals per million of 
the population start renal replacement therapy in Europe because of polycystic kidneys, which is 
6% of the new end-stage renal disease patients.2
Current treatment cannot prevent renal failure.3;4 However, a better understanding of the pa-
thophysiology of the disease and the availability of animal models identified promising candidate 
drugs for renal preservation.5 Clinical trials have been initiated for vasopressin-V2 receptor 
antagonists, long-acting somatostatin analogues and mammalian target of rapamycin inhibitors.6 
When efficacy of these agents has been established, pivotal question will become when to ini-
tiate such treatment. Given that ADPKD is a progressive condition, it seems most appropriate 
to initiate intervention as early in life as possible to delay or prevent long-term consequences, 
including renal failure and cardiac complications. On the other hand, ESRD occurs in approxi-
mately 50% of affected subjects,7;8 and it is not appropriate to expose those subjects that will 
not reach ESRD to excessive medical treatment to such an extent as to cause adverse events, 
especially because all candidate drugs have considerable side effects. Because of these reasons, 
it will be important to discover markers that identify ADPKD patients who will develop rapid 
disease progression. In such patients, therapy could be instituted in an early phase.
It will therefore become important to define disease severity in ADPKD. Criteria to make this 
distinction are not crystal clear. Glomerular filtration rate (GFR) is believed to be stable for a 
long period, despite progression of renal anatomical abnormalities, because of compensatory 
hyperfiltration. GFR is therefore assumed not to be representative of disease severity.9;10 Total 
renal volume has been proposed as a surrogate marker for disease progression.10 However, 
despite a significant overall association, there are subjects with a high total renal volume but 
normal renal function.11 Another parameter that is decreased early in the disease is urine con-
centrating capacity.12 Other candidate markers to define disease severity are albuminuria13;14 and 
renal blood flow. 15;16 Despite evidence for the importance of finding early renal abnormalities 
in ADPKD, systematic evaluation of hemodynamic parameters, especially with respect to renal 
blood flow, renal vascular resistance and filtration fraction, has received little attention. There-





One hundred and eighteen consecutive patients with ADPKD visiting our out-patient clinic, 
meeting our in- and exclusion criteria were asked to participate. Diagnosis of ADPKD was made 
upon Ravine criteria.17 Subjects were ineligible to participate if they were on renal replacement 
therapy, had undergone renal surgery, were unable to undergo magnetic resonance imaging (as 
having distorting foreign bodies or aneurysmal clips), had other systemic diseases potentially 
affecting renal function (as diabetes mellitus and malignancies), or had other medical conditions 
Abstract
Potential therapeutic interventions are being developed for Autosomal Dominant Polycystic 
Kidney Disease (ADPKD). A pivotal question will be when to initiate such treatment, and 
monitoring disease progression will thus become more important. Therefore, the prevalence of 
renal abnormalities in ADPKD at different ages was evaluated.
Included were 103 prevalent ADPKD patients (Ravine criteria). Measured were mean arterial 
pressure (MAP), total renal volume (TRV, MRI), GFR, effective renal plasma flow (ERPF), renal 
vascular resistance (RVR), and filtration fraction (FF). Twenty-four-hour urine was collected. 
ADPKD patients were compared with age- and gender matched healthy controls.
Patients and controls were subdivided into quartiles of age (median ages 28, 37, 42 and 52 
years). Patients in the first quartile of age had almost the same GFR when compared to con-
trols, but already a markedly decreased ERPF, and an increased FF (GFR 117 ±32 vs. 129±17 
ml/min, ERPF 374±119 vs. 527±83 ml/min and FF 32±4 vs. 25±2% and RVR 12(10 to 16) 
vs. 8(7 to 8) dynes/cm2, respectively). Young adult ADPKD patients also had higher 24-hour 
urinary volumes, lower 24-hour urinary osmolarity and higher urinary albumin excretion 
(UAE) than healthy controls, although TRV in these young adult patients was modestly enlarged 
(median 1.0L). 
Already at young adult age, ADPKD patients have marked renal abnormalities, including a 
decreased ERPF and increased FF and UAE, despite modestly enlarged TRV and near-normal 
GFR. ERPF, FF and UAE may thus be better markers for disease severity than GFR. 
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allowed during the measurement. After drawing a timepoint-0 blood sample, a priming solution 
containing 20 ml infusion solution (0.04 MBq of 125I-Iothalamate and 0.03 MBq of 131I Hippu-
ran) is given at 08.00 hours, followed by a constant infusion of 6 ml/h to 12 ml/h, with lowest 
infusion rates in subjects with impaired renal function, based on previously known serum crea-
tinine. Plasma concentrations of both tracers are allowed to stabilize during 1.5 hour equilibra-
tion, which is followed by two two-hour periods for simultaneous clearances of 125I-Iothalamate 
and 131I Hippuran.  Clearances are calculated as (U * V/Piot and (I * V)/ Phipp respectively. As 
urinary clearance of 131I-hippuran equals plasma clearance, in case of perfect urine collection, 
we routinely use the ratio of plasma-to-urinary clearance of 131I-hippuran to correct urinary 
clearance of 125I-Iothalamate for voiding errors24. This method to correct for urinary collection 
errors is extensively described and validated22-24. Coefficient of variation for GFR is 2.5% 
and for ERPF 5%.22 Renal blood flow (RBF) was calculated as ERPF / (1-Hct). Renal vascular 
resistance (RVR) was calculated as MAP / RBF * 80,000.16;25
Patients underwent a standardized abdominal magnetic resonance imaging protocol without the 
use of i.v. contrast.  Scanning was performed on a 1.5 Tesla MRI Magnetom Avento (Siemens, 
Erlangen, Germany) with the use of body matrix and spine matrix coils. T2 weighted fast ima-
ging (true FISP) series were scanned during breath-hold. T2 weighted turbo spin echo (HASTE) 
series were scanned during free breathing with breath triggering on the diaphragm (prospective 
acquisition correction – PACE). Transversal images were obtained with fixed slice thickness of 
5.0 mm. Coronal images were obtained with fixed slice thickness of 4.0 mm. Renal volume was 
measured on T2 weighted coronal images. Analyze Direct 8.0 (AnalyzeDirect, Inc., Overland 
Park, KS) software was used to analyse the volumes. Foxel size was forced to cubic to allow 
three dimensional viewing. Manual selection of the renal contours on every fifth slice with semi-
automated propagation was used to obtain full selection of the kidneys, excluding the pyelum. 
All contours were checked manually before assessing total renal volume.
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Parametric variables 
are expressed as mean ± standard deviation (SD), whereas non-parametric variables are given as 
median (interquartile range). A two sided p < 0.05 was considered to indicate statistical signifi-
cance. Differences between ADPKD patients and healthy controls were tested using an inde-
pendent sample T-test when normally distributed, or a Mann-Whitney test when not normally 
distributed. Analyses were performed for ADPKD patients and healthy controls, divided into 
quartiles of age, illustrating the differences between patients and controls in the different stages 
of disease. P values for differences between the age quartiles were obtained using an ANOVA 
or a Kruskal-Wallis test. To investigate whether total renal volume was associated with GFR, 
ERPF, FF and RVR, multiple regression analysis was performed. Logarithmic transformation of 
total renal volume and of RVR was applied to fulfil the requirement of equal distribution of the 
residuals.  Stepwise, various models were built to adjust for possible confounding. First these 
associations were investigated crude, and second adjusted for age and gender.
that included pregnancy, lactation, or who were less than 6 months postpartum. After screening, 
subjects underwent an extensive medical history. Thirteen patients refused to participate and 
two patients were not eligible to participate, leaving 103 patients for analyses. Subjects were 
scheduled for a 1-day outpatient clinic evaluation. 
Values of these patients were compared to healthy controls. These were drawn from a pool of 
subjects who were screened for live kidney donation and underwent the same evaluation, but 
without MRI (n=103). Values for healthy controls depicted in tables or figures are derived 
from these live kidney donors. Twenty-four hour urine collection was not available for all 
donor screenees. Values considering 24h urinary volume, -osmolarity and-albumin excretion 
were therefore drawn from subjects participating in the Prevention of Renal and Vascular End 
stage Disease (PREVEND) study (n=103).18;19 Controls were matched for age and gender with 
ADPKD patients and were considered healthy in case they had a history without cardiovascu-
lar and / or renal disease, used no medication (other than antihypertensive medication, but no 
ACEi/ ARB). All patients and controls were of Caucasian ethnicity. There was no difference in 
age (p=0.7), gender (p=0.9), mean arterial pressure (MAP, p=0.4), body surface area (BSA, 
p=0.5) or body mass index (BMI, p=0.7) between the two control groups (live kidney donors 
and the subjects from the PREVEND study). Study site and laboratory methods were the same 
for patients and the control groups (all subjects were seen in one institution).
This study was performed in adherence to the declaration of Helsinki. All subjects gave written 
informed consent.
Measurements and definitions
Blood pressure was assessed with an automatic device (Dinamap) for 15 minutes during the 
renal function measurement. Systolic and diastolic blood pressure values were used to calculate 
mean arterial pressure (MAP) using the standard formula [MAP = 2/3 * diastolic blood pres-
sure + 1/3 * systolic blood pressure]. Patients collected a 24h urine sample prior to the outpa-
tient visit. Weight and height were determined. Body mass index (BMI) was calculated as weight 
in kilograms (kg) divided by height2 (measured to the nearest 0.5 kg and 0.5 cm respectively).
Urinary albumin concentration was determined by nephelometry (BNII; Dade Behring Diagnos-
tics, Marburg, Germany). Blood samples were drawn prior to renal function measurement for 
determination of serum electrolyte, haemoglobin, creatinine and urea. Concentrations of hae-
moglobin, sodium, potassium, cholesterol, and glucose were measured in serum or urine using 
standard methods. Creatinine was measured with the Roche enzymatic creatinine assay. Crea-
tinine values were used to calculate an estimated glomerular filtration rate (eGFR), using the 
abbreviated MDRD formula.20 Micro-albuminuria was defined as a urinary albumin excretion of 
more than 30 mg/24h. Urinary osmolarity was calculated as [urinary osmolarity = 2 * (urinary 
sodium concentration + urinary potassium concentration) + urinary urea concentration].21 
This calculated osmolarity was not different from measured values (independent sample t-test 
p=0.94 in 100 samples, measured in our own lab).
Renal function measurements were performed using the constant infusion method with 125I-
Iothalamate and 131I-hippuran.22;23 Patients came non-fasting and were able to drink ad libitum 
but no caffeinated drinks. Antihypertensive medications were not withheld. Smoking was not 
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Results
A total of 103 ADPKD patients participated in this study; 60 (58%) were male. Mean age was 
40 years. Table 1 depicts characteristics of ADPKD patients and of healthy controls. MAP was 
higher in the ADPKD group, despite frequent use of antihypertensive medication. Total renal 
volume was not measured in these healthy controls, but from literature it is known to be ap-
proximately 330 (194-614) ml.26 Haemoglobin concentration was lower in ADPKD patients. 
Renal function, measured as clearance of iothalamate and estimated by the Modification of Diet 
in Renal Disease equation was also lower. In ADPKD patients, 24-hour urinary volume was 
2.4±0.8 L, whereas this was 1.6±0.6 L in 103 age- and gender-matched subjects participating 
in the PREVEND-study (p<0.001). Urinary albumin excretion was also higher in ADPKD 
patients (42 (14-131) vs. 7(6-10) mg/24h), whereas calculated urinary osmolarity was lower 
(421±147 vs. 568±181 mOsm/l), both p<0.001).
For further analyses, ADPKD patients and healthy controls were subdivided into quartiles of 
age, as shown in Table 2. It shows the same variables as Table 1, but depicted per quartile of age, 
illustrating differences in variables under study between the different age categories. Variables 
that were different for the quartiles of ADPKD patients were use of antihypertensive medica-
tion, serum creatinine, (e)GFR, ERPF and RVR. Variables that were different for the quartiles of 
healthy controls were Hb, (e)GFR, ERPF, RVR, and FF.
Parametric variables are expressed as mean ± SD, whereas non-parametric variables are given as median (25th-75-
th percentile). Abbreviations are: Hb, haemoglobin; eGFR, estimated Glomerular Filtration Rate; GFR, glomerular 
filtration rate; ERPF, effective renal plasma flow; FF, filtration fraction; RVR, renal vascular resistance.  
Table 1 Characteristics of ADPKD patients (n=103) and of age- and gender matched healthy controls (live kidney 
donors, n=103)
Variable ADPKD patients Healthy controls p-value 
Age (y) 40 ± 11 40 ± 10   0.92 
Male gender, n (%) 60 (58) 60 (58)   1.00 
Body mass index (kg/m2) 26.1 ± 4.6 25.6 ± 3.8   0.47 
Mean arterial pressure (mm Hg) 96 ±  9 92 ±  9 <0.001 
Antihypertensive medication, n (%) 80 (78) 2 (2) <0.001 
Total renal volume (l) 1.49 (0.95-2.19) -   - 
Hb (mmol/l) 8.4 ±  0.8 8.9 ±  0.8 <0.001 
Serum creatinine (umol/l) 111 ± 68 74 ± 11 <0.001 
GFR (ml/min) 92 ±  36 124 ± 20 <0.001 
ERPF (ml/min) 301 ±  125 475 ±  84 <0.001 
FF 30 ± 4 26 ± 3 <0.001 
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Renal hemodynamic parameters for quartiles of age are depicted in Figure 1. GFR, ERPF, FF 
and RVR are shown per quartile of age for ADPKD patients and for healthy controls in the same 
graph (mean ± 95% confidence interval of the mean and for RVR median and interquartile 
range is shown). ERPF was decreased in ADPKD patients already in the first quartile of age, 
with a further decline with increasing age. In the youngest age quartile, GFR was not signifi-
cantly different between ADPKD patients and healthy controls; consequently filtration fraction 
was considerably increased. In the older age cohorts, GFR decreased progressively in ADPKD, 
and much less steep in the healthy controls.  Consequent to the parallel decreases in ERPF and 
GFR in ADPKD with increasing age, the elevated FF remained constant over the age quartiles, 
whereas in the healthy controls, FF increased with age. Within the healthy controls, BMI (R2 = 
0.09, p=0.002) and age (R2 =0.07, p=0.008) were associated with FF, whereas these variables 
were not significantly associated with FF within the ADPKD patients (p=0.4 and 0.1, respec-
tively). Within the ADPKD patients, FF was significantly associated with female gender (R2 = 
0.05, p=0.02) and inversely with use of angiotensin converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARB’s) (R2 =0.07, p=0.01). Seventy-one of the 103 ADPKD 
patients used an ACEi/ARB; these patients had a lower FF than the patients who did not use an 
ACEi/ARB (30±4 vs. 32±4, p=0.01). Patients taking ACEi/ARB had the same Hb level as pa-
tients without these agents (p=0.45). As a consequence of the decreased RBF and the tendency 
towards a high MAP in ADPKD patients, renal vascular resistance (RVR) was high, with 12 
(10-16) dynes s/cm2 in the youngest quartile of age and 22 (18-33) dynes s/cm2 in the oldest 
quartile. 
In ADPKD patients, total renal volume was related to GFR (standardized  β(st β)= -0.31, 
p=0.002), ERPF (st β= -0.23, p=0.02), FF (st β=-0.33, p = 0.001) and RVR (st β=0.33, p = 
0.001). After adjustment for age and gender, these associations did not change materially (Table 
3). Although there was an association between total renal volume and GFR, there were several 
patients with large kidneys, but still a reasonable renal function and patients with relatively small 
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Urinary albumin excretion was elevated in the first quartile of age compared with healthy 
controls (70 (19 to 131) vs. 7(5 to 10) mg/24h). Sixty-eight percent of these patients in this age 
quartile were microalbuminuric, whereas 56% of the patients in this age quartile used ACEIs 
or ARBs. ADPKD patients with microalbuminuria had significantly larger kidneys than patients 
with normoalbuminuria (P<0.001). Of note, patients in the youngest quartile of age without 
microalbuminuria (n=8) already had a decreased ERPF and increased FF and RVR compared 
with healthy controls, while again GFR was again not different from healthy controls. 
Twenty-four-hour urinary volume was higher and urinary osmolarity was lower in ADPKD 
patients versus healthy controls in all quartiles of age. In the first quartile, these values were: 
2.1±0.9 vs. 1.4±0.5 l/24h (p=0.002), and 497±183 vs. 600±165 mOsm (p=0.04), respec-
tively, and in the fourth quartile: 2.5±0.9 vs. 1.8±0.5 l/24h (p=0.002), and 367±113 vs. 
controls 516±167 mOsm/l (p=0.001). In ADPKD patients, urinary volume tended to increase 
with age, whereas urinary osmolarity decreased (p=0.003). 
Discussion
In the study presented here, we found that young adult ADPKD patients (16 to 33 years) already 
had a markedly decreased ERPF when compared with healthy controls, despite an almost nor-
mal GFR and a modestly enlarged TRV. Because of the decreased ERPF and the tendency for a 
high MAP, young adult ADPKD patients had an increased RVR and an especially high FF. These 
abnormalities in ERPF and FF are an early phenomenon and remained present throughout the 
age quartiles. Also microalbuminuria was already present early in the disease. In the young adult 
ADPKD patients, 24-hour urinary volume was higher and 24-hour urinary osmolarity was 
lower compared with normal controls. Urinary volume tended to increase, whereas urinary 
osmolarity decreased over the age quartiles of ADPKD patients.
We found a slightly decreased GFR, accompanied by a much stronger decrease in ERPF, in 
young adult ADPKD patients. There are several possible explanations for this hemodynamic 
profile; for instance, that ADPKD is primarily a disease of the tubules and interstitium, and that 
extraction of hippuran could therefore be disturbed. However, the fact that we found the dif-
ference in these hemodynamic parameters in patients versus healthy controls, most pronounced 
in the young adult ADPKD subjects in whom tubular function and interstitium are still relatively 
preserved, suggests that this explanation is less likely. An alternative explanation for the ob-
served renal hemodynamic profile could be a state of predominantly efferent renal vasoconstric-
tion related to increased neurohumoral activation. Neurohumoral activation has been described 
to occur early in ADPKD,27 and efferent renal vasoconstriction related to increased neurohu-
moral activation is characteristic of other hypertensive conditions.28 We hypothesize that this 
hemodynamic profile indicates hyperfiltration. The loss of nephrons due to the disease process 
results in a decreased ERPF, whereas compensatory GFR goes up in the remnant nephrons. The 
presence of an elevated albuminuria already in the youngest quartile of ADPKD patients sup-
ports this hypothesis. The phenomenon of hyperfiltration could explain why GFR stays stable for 
a number of years and then rapidly declines.9;10 This hypothesis also indicates that GFR is indeed 
not an appropriate marker for disease severity, as has been suggested10, and underlines the 
importance of a search for better markers of disease severity. 
Figure 2: Association between total renal volume and glomerular filtration rate (GFR) for participating ADPKD 
patients (n=103).
Table 3: Univariate and multivariate associations between total renal volume and renal hemodynamics for ADPKD 
patients only
variable model St ! p R2 
GFR 1 -0.31 0.002 0.093 
 2 -0.37 0.001 0.269 
ERPF 1 -0.23 0.02 0.053 
 2 -0.29 0.008 0.241 
FF 1 -0.33 0.001 0.111 
 2 -0.24 0.01 0.237 
RVR 1 0.32 0.001 0.101 
 2 0.38 <0.001 0.292 
 Standardized beta’s and p values were calculated using multivariate linear regression. The R2 aplies to the whole 
model. Dependent variable is log transformed total renal volume. Independent variables are the above mentioned 
variables (GFR, ERPF, FF and log RVR). 
Model 1: crude
Model 2: adjusted for age and gender
Abbreviations are: GFR, glomerular filtration rate; ERPF, effective renal plasma flow; FF, filtration fraction and RVR, 
renal vascular resistance.
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In the first quartile of age, serum creatinine in ADPKD patients was significantly increased com-
pared with healthy controls. The fact that GFR was not different, suggests that other factors than 
renal function play a role (e.g., muscle mass). Hb levels were also different in the first quartile 
of age. Unexpectedly, ADPKD patients had lower Hb values compared to healthy controls. 
There was no association between use of ACEi/ARB therapy and Hb level. Patients taking these 
agents had the same Hb as patients without these agents (p=0.45), so use of ACEIs/ARBs is not 
a likely explanation. An explanation for the difference in Hb could be a diminished erythropoie-
tin production. Unfortunately, we do not have information on epo levels. 
The increased 24-hour urinary volume and decreased 24-hour urinary osmolarity that we found 
in the ADPKD patients is consistent with the decreased concentrating capacity that has been 
described in these patients.12 Also, albuminuria has been described to occur at early stages of the 
disease.13 We also found a high prevalence of microalbuminuria in young adult ADPKD patients. 
In addition, we found a decreased ERPF and increased filtration fraction, compared with healthy 
controls, even in young patients with no microalbuminuria yet. This suggests that early renal and 
vascular changes are present before occurrence of microalbuminuria, making ERPF and RVR 
likely to be early markers of disease severity. 
We acknowledge that this study has limitations. First, we studied age versus renal hemodynamic 
parameters in a cross-sectional study. In such a design, selection bias can occur. Also, patients 
were allowed to use their antihypertensive medication, potentially influencing renal hemodyna-
mics. However, a life time longitudinal investigation of renal hemodynamic parameters is almost 
not feasible. Second, we did not control water intake. However, our patients drank at libitum 
and did not receive advice to deliberately increase water intake. We believe that urine concentra-
ting capacity in ADPKD is indeed lower at increased age. The strengths of our study include that 
we simultaneously measured various renal hemodynamic parameters in a relatively large group 
of ADPKD subjects in various stages of the disease. The simultaneous measurement of GFR and 
ERPF using the gold standard (clearance of iothalamate and hippuran) is the best surrogate to 
study hyperfiltration. Previous studies investigating renal hemodynamics in ADPKD used only 
GFR measurements, from which it cannot be concluded whether hyperfiltration is present when 
there is no information on renal blood flow. Furthermore, we were able to compare ADPKD 
patients with age- and gender-matched healthy controls, enabling comparison with the normal 
situation.
In conclusion, already at young adult age, ADPKD patients have marked renal abnormalities, 
despite only modestly enlarged kidneys and a near-normal GFR. These data suggest that in 
ADPKD, a renal hemodynamic profile, characterized by decreased ERPF and increased FF may 
be an early sign indicating more outspoken disease severity. The finding furthermore indicates 
that ERPF and FF (in addition to renal volume and albuminuria) may indicate disease severity 
better than GFR. 
 
To the best of our knowledge, no previous studies looked directly at possible hyperfiltration in 
ADPKD patients. Two studies so far suggested that patients with ADPKD may hyperfiltrate. Di-
mitrakov et al suggested hyperfiltration on the basis of measurement of creatinine clearance and 
serum β2 microglobulin levels.29 Another study described a high GFR in very young ADPKD 
patients (9.8 ± 5.9 y), as measured with a technetium 99m DTPA single-injection technique.30 
Some of the ADPKD patients in our study, have a GFR comparable to the values described in 
these studies (Figure 2). Importantly, in both studies no information was obtained on ERPF 
and FF and no comparison with healthy controls was made. This makes it less possible to draw 
firm conclusions whether there is indeed hyperfiltration in those patients. We found that FF was 
especially high in young adult ADPKD patients, whereas in healthy controls FF is high in the 
older age groups. The latter is in line with previous analyses, showing that higher BMI and older 
age are the main determinants of a higher FF.31;32 These data, in combination with the fact that 
we found a negative correlation between total renal volume and filtration fraction (R=-0.28, 
p=0.004) suggests that hyperfiltration is a process that occurs early in the disease.
A high filtration fraction, reflecting elevated glomerular pressure, has been shown to contribute 
to progressive renal function loss in experimental studies.33-36 Evidence in humans is sparse, but 
recently,  in renal transplant recipients, a high FF was associated with increased graft loss, inde-
pendent of blood pressure, GFR and proteinuria, which also supports a role for elevated glome-
rular pressure in human.37 The finding of a high FF early in ADPKD could provide a rationale 
for prescription of agents that inhibit the renin angiotensin aldosterone system (RAAS) early in 
the disease, because these agents are known to decrease FF and intraglomerular pressure.38;39 As 
yet there is no evidence that inhibiting the RAAS is indeed beneficial in ADPKD. However, the 
studies that were performed to investigate the efficacy of RAAS intervention to preserve renal 
function in ADPKD patients may have been too underpowered and had a too short of follow-
up to reach firm conclusions.4;40 Of note, in our study, 71 of the 103 ADPKD patients used an 
ACEi/ARB, but the group still had a very high FF (although patients using an ACEi/ARB had a 
FF lower than the patients who did not use an ACEi/ARB (30±4 vs. 32±4, p=0.01)), suppor-
ting the fact that inhibiting the RAAS also results in a decreased FF in ADPKD patients. At the 
moment, a large-scale study is being performed with 4 years of follow-up in which the efficacy 
of complete RAAS blockade to preserve renal volume and renal function is investigated (HALT-
PKD). Hopefully, this study will answer the question whether RAAS blockade is effective in 
preventing renal function decline in ADPKD.41
Our findings on renal vascular resistance, renal blood flow, decreased urine concentration and 
albuminuria are in line with data from the literature. Renal vascular resistance and renal blood 
flow have been measured in only two studies performed on the same cohort15;16. Renal blood 
flow was measured in a subgroup of 131 patients using magnetic resonance imaging. During 
follow-up, a reduction of renal blood flow and an increase in renal vascular resistance paral-
leled the increase in total kidney volume, and importantly, preceded GFR decline and predicted 
structural and functional disease progression in this cohort. This suggests that low RBF and high 
RVR could be good markers for rapid disease progression. However, these studies did not in-
clude a comparison with healthy subjects. We found renal vascular resistance to be elevated early 
in the disease compared with healthy controls. 
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Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common hereditary kid-
ney disease is characterised by progressive cyst formation in the kidneys, leading to pain, hema-
turia and end stage renal disease. End stage renal disease usually occurs in the 4th-7th decade of 
life.1 The clinical course of ADPKD is highly variable between families, but also within families.2 
Current treatment cannot prevent renal failure.3;4 However, a better understanding of the 
pathophysiology of the disease identified promising candidate drugs for renal preservation.5 Cli-
nical trials have been initiated for vasopressin-2 receptor antagonists, long-acting somatostatin 
analogues and mTOR inhibitors.6 With these upcoming therapeutic regimens, and the existing 
variation in disease course, monitoring disease severity will become more important. 
Measurement of serum creatinine to assess estimated glomerular filtration rate (eGFR) is of 
limited use in determining disease severity in ADPKD, since it has been suggested that GFR 
remains relatively long stable due to compensatory hyperfiltration, while disease progresses.7 Ef-
fective renal blood flow (ERBF) and total kidney volume have been proposed as better markers 
for disease severity, for they predict renal decline during follow-up7-10 However, measurement of 
RBF and total kidney volume is time consuming and expensive. Therefore, interest has grown in 
urinary biomarkers. These biomarkers are relatively easy to obtain and inexpensive to mea-
sure.  In renal diseases in general, urinary Kidney Injury Molecule-1 (KIM-1) and Neutrophil 
Gelatinase-Associated Lipocalin (NGAL) for example are well described markers and predictors 
of renal disease progression11-13 and may be promising candidate markers in ADPKD. In ADPKD 
patients, a limited number of urinary biomarkers have been investigated, namely albuminuria, 
β2 microglobulin,14;15 NGAL16 and Monocyte Chemotactic Protein-1 (MCP-1).17;18 In general, 
the promising results obtained for these markers have not been corroborated by others, except 
for albuminuria. Several studies showed that in ADPKD, albuminuria is associated with incre-
ased renal volume,19;20 mean arterial blood pressure, filtration fraction,20 renal growth and slope 
of glomerular filtration rate.9 Albuminuria is therefore a valuable biomarker indicating disease 
severity and predicting outcome. As such it has become a secondary endpoint in intervention 
studies in ADPKD.21
In normal physiology, albumin passes the glomerular filtration barrier only in trace amounts, 
after which it is reabsorbed in the proximal tubule.22;23 In general, albuminuria is assumed to 
reflect predominantly glomerular endothelial damage. ADPKD however is a disease characte-
rized predominantly by structural abnormalities of especially the distal tubules and collecting 
ducts, and by interstitial inflammation and fibrosis. In ADPKD, albuminuria might therefore also 
reflect (inflammatory) tubular damage. 
Given this background, we investigated in a cross-sectional study, in a well phenotyped cohort 
of 102 ADPKD patients, (1) whether urinary biomarkers reflecting glomerular, proximal or 
distal tubular damage or inflammation are elevated when compared to healthy controls, (2) 
whether these elevated biomarkers are associated with current markers of disease severity in 
ADPKD (effective renal blood flow and glomerular filtration rate as functional measures and 




Disease monitoring of ADPKD will become more important with upcoming therapeutic 
potential interventions. Since serum creatinine is considered of limited use and measurement 
of effective renal blood flow (ERBF) and total renal volume (TRV) are time consuming and 
expensive, there is a need for other biomarkers. We aimed to investigate which urinary markers 
are elevated in ADPKD, whether these urinary markers are associated with measured glome-
rular filtration rate (mGFR), ERBF and TRV and whether these associations are independent of 
albuminuria (UAE). 
We measured 24-h urinary excretion of albumin, of glomerular- (IgG), proximal tubular- 
(KIM1, NAG, NGAL, β2 microglobulin) and distal tubular (H-FABP) damage markers and 
inflammatory markers (MCP-1 and MIF) in 102 ADPKD patients and compared these to 102 
age- and gender matched healthy controls. For ADPKD patients, disease severity was assessed 
by measures of function (mGFR and ERBF, measured by clearance of 125I-Iothalamate and 131I 
Hippuran, respectively, during continuous infusion) and structure (TRV, measured by MRI.
In 102 ADPKD patients (aged 40±11y, 58% male), all measured urinary biomarkers were 
elevated compared to healthy controls. Excretion of IgG and albumin were relatively most 
elevated. ERBF and mGFR were associated with urinary excretion of β2 microglobulin, NGAL 
and H-FABP, independent of UAE, while TRV was associated with KIM-1, NGAL and MCP-1 
independent of UAE.
Our results suggest that markers for multiple parts of the nephron are elevated in ADPKD and 
that measurement of urinary β2 microglobulin, H-FABP, MCP-1 and especially NGAL could be 
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cording to Lockwood and corrected for nonspecific conversion (HaemoScan, www.haemoscan.
com). For all urinary markers, urinary excretion was calculated by multiplication with the vo-
lume of the 24-hour urine collection, resulting in biomarker excretion expressed per 24 hours. 
Prior to renal function measurement, blood samples were drawn for determination of haemo-
globin, glucose, creatinine and urea. Concentrations of haemoglobin and glucose were measured 
in serum using standard methods. Creatinine was measured with the Roche enzymatic creati-
nine assay (IDMS traceable). Creatinine values were used to calculate an estimated glomerular 
filtration rate (eGFR), using the 4-variable MDRD formula.33 Urinary creatinine excretion was 
normalized to body weight by dividing the 24h urinary creatinine excretion by the patient’s 
weight in kilograms.
Renal function measurements were performed using the constant infusion method with 125I-
Iothalamate and 131I-hippuran.34-37 Effective renal blood flow (ERBF) was calculated as ERPF / 
(1-Hct). (Hematocrit was measured halfway during the renal function measurement.) Patients 
underwent a standardized abdominal magnetic resonance imaging protocol without the use of 
i.v. contrast.  Scanning was performed on a 1.5 Tesla MRI Magnetom Avento (Siemens, Erlan-
gen, Germany) with the use of body matrix and spine matrix coils. Renal volume was measured 
on T2 weighted coronal images38 (slice-thickness 4.0 mm) using Analyze Direct 8.0 (Analyze-
Direct, Inc., Overland Park, KS) software.
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Normally distribu-
ted variables are expressed as mean ± standard deviation (SD), whereas non-normally distribu-
ted variables are given as median (interquartile range). A two sided p < 0.05 was considered to 
indicate statistical significance.
Differences between ADPKD patients and healthy controls were tested using the two-sample 
T-test when normally distributed, or Mann-Whitney test when not normally distributed. Secon-
dary, we compared biomarker excretions for ADPKD patients with a relatively well preserved 
renal function (eGFR >60) with healthy controls.
To investigate whether biomarker excretions correlated with mGFR, ERBF and total renal vo-
lume, Spearman correlation coefficients were calculated. We also analyzed the reference test as 
dichotomous variables to calculate Reciever Operating Characteristics curves. As cut-off values 
an ERBF <500 ml/min, a mGFR <60 ml/min and a TRV > 1000 mL were used. To be able 
to adjust for potential confounders, multiple regression analysis was performed. Biomarkers 
were log base 2 transformed to fulfil the requirement of normal distribution of the residuals. 
Two models were built. First, the association between biomarkers and variables of interest was 
investigated adjusted for age and gender, and second, albuminuria was entered as an indepen-
dent variable in addition to the previous variables to investigate whether the associations were 
independent of albuminuria. To check for co-linearity, variance inflation factor diagnostic was 
used. The VIF diagnostic is the reciprocal of tolerance (1-R squared for the regression of that 
variable on all the other independents, ignoring the dependent). So when VIF is high, there 
is high multicollinearity and instability of the beta coefficients.To visualise the independency 
of albuminuria in the associations of urinary biomarkers with glomerular filtration rate, renal 
Materials and Methods
Patients and healthy controls
One hundred and eighteen consecutive patients with ADPKD visiting our out-patient clinic 
meeting our in- and exclusion criteria were asked to participate. Diagnosis of ADPKD was 
made upon Ravine criteria.24 Subjects were considered ineligible to participate if they received 
renal replacement therapy (including renal transplantation), had undergone renal surgery, were 
unable to undergo magnetic resonance imaging (as having distorting foreign bodies or aneu-
rysmal clips), had other systemic diseases potentially affecting renal function (such as diabetes 
mellitus), had other specific medical conditions such as pregnancy, lactation, or who were less 
than 6 months postpartum. After screening, subjects underwent an extensive medical history 
assessment and were scheduled for a 1-day outpatient clinic evaluation. 
For this study, healthy controls were also invited to participate. These control subjects were mat-
ched for age and gender and were considered healthy in case they had a history without cardio-
vascular and/or renal disease, used no medication, had a normal blood pressure (systolic blood 
pressure < 140 and diastolic blood pressure <90 mmHg) and a normal estimated glomerular 
filtration rate (>60 ml/min *1.73 m2). This study was performed in adherence to the declara-
tion of Helsinki. All subjects gave written informed consent.
Measurements and definitions
Measurements and storage of urinary and plasma samples
Blood pressure was assessed with an automatic device (Dinamap) for 15 minutes during the 
renal function measurement. Systolic- and diastolic blood pressure values were used to calculate 
mean arterial pressure (MAP) using the standard formula: 2/3 diastolic blood pressure + 1/3 
systolic blood pressure. Weight and height were determined. Body mass index (BMI) was calcu-
lated as weight in kilograms (kg) divided by height in square meters.
Patients collected a 24-h urine sample prior to the outpatient visit. Urinary albumin concen-
tration was determined by immunonephelometry (BNII; Dade Behring Diagnostics, www.
dadebehring.com). Urine was stored at -80°C until measurement of Immunoglobulin G 
(IgG), Kidney Injury Molecule 1 (KIM1), N-acetyl-β-D-glucosaminidase (NAG), Neutrophil 
Gelatinase-Associated Lipocalin (NGAL), β2 microglobulin, Heart-type Fatty Acid Binding 
Protein (H-FABP), macrophage migration inhibitory factor (MIF) and monocyte chemotactic 
protein-1 (MCP-1). Urinary IgG is a marker for glomerular damage, urinary β2 microglobulin, 
KIM, NAG and NGAL are markers for damage of the proximal tubule,12;25;26 whereas urinary 
H-FABP is a damage marker of the distal tubule.27;28 Urinary MIF and MCP-1 are markers for 
inflammation.29-32 Urinary IgG, HFAB-P (Hytest, www.hytest.fi), β2 microglobulin (Anogen, 
www.yesbiotech.com), KIM1, NGAL, MCP-1 and MIF (R&D systems, www.rndsystems.
com) were measured by ELISA. Before measurement, urine samples were diluted two times for 
KIM-1, β2 microglobulin, MCP1 and MIF, 5 times for H-FABP, and 100 times for NGAL and 
IgG.
Detection limit for KIM-1 was 0.087 ng/ml, for IgG 220 ng/ml, for NAG 22 ng/ml, for MCP 
0.04 ng/ml, for MIF 0.06 ng/ml, for β2 microglobulin 18 ng/ml and for H-FABP 0.38 ng/ml.  
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Association of urinary biomarkers with ADPKD
To answer our first research question, we investigated urinary biomarkers for different segments 
of the nephron in ADPKD patients and in healthy controls. Urinary creatinine excretion norma-
lized to body weight was 19.3 ± 5.6 mg/kg for the whole group. 
Table 2 shows that albuminuria, glomerular, proximal- and distal tubular damage markers, 
as well as markers reflecting inflammation, were all significantly elevated in ADPKD patients 
compared to healthy controls. IgG excretion and albuminuria were relatively more elevated 
(6-77 x) in the ADPKD patients than excretion of the other markers (1.4-7.7 x). Values of the 
urinary markers for ADPKD patients and healthy controls are depicted in box plots in Figure 
1. Although significantly different, there is some overlap in biomarker excretions between the 
ADPKD patients and healthy controls. To adjust for potential errors in 24h urine collection, also 
marker/creatinine ratios were compared. All urinary biomarker/creatinine ratio’s, except MIF, 
remained significantly higher in ADPKD patients compared to healthy controls. When patients 
with a reasonably well preserved renal function (eGFR >60 ml/min per 1.73 m2, n=60) were 
selected, all urinary markers (except for H-FABP) were still significantly elevated compared to 
healthy controls. Also, when patients were selected with a relatively well preserved renal blood 
flow (ERBF>500 ml/min, n=45) or with a relatively modest total renal volume (TRV <1000 
ml, n=30), all urinary markers (except for H-FABP and MIF) were elevated compared to heal-
thy controls. 
blood flow and total renal volume, figures were made. For these figures, the excretion of various 
biomarkers was divided into tertiles. Linear regression analysis was used to calculate adjusted 
values of measured glomerular filtration rate and effective renal blood flow and geometric mean 
total renal volume (all ± 95% CI of the mean) per tertile. Means were adjusted for age, gender 
and urinary albumin excretion. P values for the unadjusted tertiles are calculated using ANOVA. 
As sensitivity analyses, we attempted to adjust for potential errors in 24h urine collection all 
analyses by repeating all analyses using biomarker/creatinine ratios as the index test (instead 
of 24h urinary excretions). We also repeated the analyses in which we only included ADPKD 
subjects with a mGFR > 60 mL/min.
 
Results
Thirteen patients refused to participate, two patients were not eligible to participate and 1 
patient did not collect 24-h urine, leaving 102 patients for analyses. Characteristics of the parti-
cipating patients and healthy controls are presented in table 1.  A total of 102 ADPKD patients 
(58% male, aged 40±11 years) and 102 healthy controls were analysed. As shown in table 1, 
ADPKD patients had a higher body mass index, blood pressure (despite more frequent use of 
antihypertensive medication), serum creatinine, and 24-h urinary volume than age-and gender 
matched healthy controls. Haemoglobin and estimated glomerular filtration rate were lower 
than in healthy controls.
Table 1: Characteristics of 102 ADPKD patients and 102 age- and gender matched healthy 
Variable ADPKD Healthy controls p-value 
Age (y) 40 ± 11 39 ± 12   0.5 
Male, n (%) 59 (58) 59 (58)   1.0 
BMI (kg/ m2) 26±5 23±3 <0.001 
BSA (m2) 2.1±0.3 1.9 ± 0.2 <0.001 
SBP (mm Hg) 129 ± 12 122 ± 12 <0.001 
DBP (mm Hg) 80 ± 9 72 ± 8 <0.001 
Antihypertensive medication, n (%) 78 (77) 0 (0) <0.001 
Hb (g/l) 135 ± 14 140 ± 13   0.003 
Plasma creatinine (mg/dl) 1.3 ± 0.8 0.8 ± 0.1 <0.001 
24h urinary volume (l/24h) 2.3 ± 0.8 2.0 ± 0.8   0.003 
eGFR(ml/min per1.73 m2) 68 ± 27 92 ± 12 <0.001 
mGFR (ml/min) 91 ± 36 - - 
mGFR/BSA (ml/min/1.73 m2) 77 ± 31 - - 
RBF (ml/min) 498 ± 207 - - 
Total renal volume (l) 1.5 (0.9-2.2) - - 
 
Variables are presented as mean ± SD. Significance was tested using the two-sample T-test. Abbreviations are: BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb haemoglobin; eGFR, estimated 
glomerular filtration rate; mGFR, measured glomerular filtration rate; RBF, renal blood flow.
Table 2: Urinary biomarker excretions for ADPKD patients and controls
Variables are presented as median (25th percentile-75th percentile). Significance was tested using the Mann-Whitney 
U test. Abbreviations are: UAE, urinary albumin excretion; IgG, immunoglobulin G; β2 MG,  β2 microglobulin; 
KIM-1, Kidney Injury Molecule 1; NAG, N-acetyl- β-D-glucosaminidase; NGAL, Neutrophil Gelatinase-Associated 
Lipocalin; H-FABP,  Heart-type Fatty Acid Binding Protein; MIF, macrophage migration inhibitory factor; MCP-1, 
monocyte chemotactic protein-1.
Variable ADPKD Controls p-value 
• UAE (mg/24u) 41.2 (14.9-121.7) 7.8 (6.4-10.4) <0.001 
Glomerular    
• IgG (mg/24u) 15.3 (4.3-47.5) 0.2 (0.2-0.3) <0.001 
Proximal Tubular    
• !2 MG (µg/24u) 192.1 (77.6-589.1) 79.4 (49.1-121.3) <0.001 
• KIM-1 (µg/24u) 1.5 (1.0-2.2) 0.8 (0.4-1.2) <0.001 
• NAG (U/24u) 3.1 (0.8-8.1) 0.4 (0.3-2.4) <0.001 
• NGAL (µg/24u) 73.7 (29.2-158.2) 23.4 (16.5-30.8) <0.001 
Distal Tubular    
• H-FABP (µg/24u) 1.9 (1.3-3.2) 1.4 (1.0-2.2) 0.003 
Inflammatory    
• MIF (µg/24u) 0.2 (0.1-0.3) 0.1 (0.1-0.2)  0.03 
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Association of urinary biomarkers with functional measures in ADPKD
Glomerular filtration rate and effective renal blood flow correlated strongly with each other 
(R=0.94, p<0.001). The associations of urinary markers with measured glomerular filtration 
rate (mGFR) and effective renal blood flow are depicted in table 3. Figures 2 and 3 depict 
scatterplots of the associations in table 3 with a p-value below 0.05. These are scatterplots for 
excretion of IgG, β2 microglobulin, NAG, NGAL, H-FABP and MCP-1 with mGFR (Figure 
2), and IgG, β2 microglobulin, NAG, NGAL, H-FABP and MCP-1 with ERBF (Figure 3). For 
measured glomerular filtration rate and effective renal blood flow, the strongest association was 
with NGAL. Furthermore, IgG correlated strongly with UAE (R=0.70, p<0.001, not depicted 
in the table). 
Figure 1: Urinary biomar-
kers for ADPKD patients and 
healthy controls. Boxplots 
with whiskers from minimum 
to maximum.
Table 3: Crude correlation coefficients of urinary biomarkers with glomerular filtration rate, renal blood flow and 
total renal volume in ADPKD patients.
Correlations and significance were calculated using the spearman correlation coefficient. Abbreviations are: 
IgG, immunoglobulin G; β2 MG, β2 microglobulin; KIM-1, Kidney Injury Molecule 1; NAG, N-acetyl-β-D-
glucosaminidase; NGAL, Neutrophil Gelatinase-Associated Lipocalin; H-FABP,  Heart-type Fatty Acid Binding 
Protein; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemotactic protein-1.
Variable Glomerular Filtration Rate  Renal Blood Flow  Total Renal Volume 
 R p-value  R p-value  R p-value 
Glomerular         
• IgG -0.22 0.03  -0.21 0.04  0.35 <0.001 
Proximal Tubular         
• !2 MG -0.38 <0.001  -0.37 <0.001  0.14 0.2 
• KIM-1 0.09 0.4   0.05 0.6  0.23 0.02 
• NAG -0.30 0.002  -0.29 0.004  0.27 0.007 
• NGAL -0.43 <0.001  -0.45 <0.001  0.16 0.1 
Distal Tubular         
• H-FABP -0.37 <0.001  -0.36 <0.001  0.13 0.2 
Inflammatory         
• MIF 0.04 0.7   0.03 0.8  0.03 0.8 
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ROC  curves for an ERBF < 500 ml/min and a mGFR <60 ml/min are depicted in Figure 4 
for the urinary biomarkers with the highest R values. All area’s under the curves of the depicted 
urinary biomarkers are significantly different from chance. For both functional measures, NGAL 
has the largest AUC (0.74 and 0.75 respectively).
Figure 3: Associations between urinary biomarkers and Effective Renal Blood Flow (ERBF). Depicted are graphs of 
the urinary biomarkers under study that were significantly associated with ERBF (table 3).
Figure 2: Associations between urinary biomarkers and Glomerular Filtration Rate.
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Our third research question was whether these potential associations were independent of albu-
minuria (urinary albumin excretion, UAE). Table 4 shows the associations between 24h urinary 
biomarker excretions with measured glomerular filtration rate and Table 5 with effective renal 
blood flow, both adjusted for age, gender and albuminuria. The urinary biomarker excretions are 
log base 2 transformed. The beta therefore represents the change in mGFR or RBF per doubling 
of the biomarker. Of note, albuminuria (adjusted for age and gender) correlated well with both 
measured glomerular filtration rate and with effective renal blood flow. There are several as-
sociations that remained significant after adjustment for age, gender and albuminuria. For both 
measured glomerular filtration rate and for effective renal blood flow, β2 microglobulin, NGAL 
and H-FABP remained significantly associated. Figures 5 and 6 depict the associations between 
biomarkers that were associated with measured glomerular filtration rate independent of albu-
minuria (Figure 5) and effective renal blood flow independent of albuminuria (Figure 6). The 
figures show mean values of measured glomerular filtration rate and effective renal blood flow 
for tertiles of the aforementioned biomarkers, both crude and after adjustment of age, gender 
and albuminuria. 
Figure 4: Reciever Operating Characteristics curves for various urinary biomarkers for dichotomized mGFR (cut-off 




Urinary biomarkers to assess ADPKD Severity 
Table 4: Multivariable associations of various biomarkers with glomerular filtration rate after adjustment for age, 
gender (model 1) and additional adjustment for UAE (model 2).
Beta’s, confidence intervals and p-values were calculated using multivariable linear regression. Dependent variable is 
mGFR, independent variables are the log base2 transformed 24h excretions of the various urinary biomarkers.
Model 1: adjusted for age and gender
Model 2: adjusted for age, gender and albuminuria.
Abbreviations are: IgG, immunoglobulin G; β2 MG, β2 microglobulin; KIM-1, Kidney Injury Molecule 1; NAG, 
N-acetyl-β-D-glucosaminidase; NGAL, Neutrophil Gelatinase-Associated Lipocalin; H-FABP,  Heart-type Fatty Acid 
Binding Protein; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemotactic protein-1.
 model Urinary biomarker UAE 
  ! 95% CI for ! p-value ! 95% CI for ! p-value 
• UAE 1 - - - -6.1 -8.9- -3.2 <0.001 
Glomerular        
• IgG 1 -3.2 -5.0- -1.5 <0.001 - - - 
 2 -1.4 -3.7-0.9 0.22 -4.5 -8.3 - -0.8 0.02 
Proximal tubular        
• KIM-1 1 2.0 -3.6-7.6 0.48 - - - 
 2 5.2 -0.07-10.5 0.053 -6.8 -9.7—3.9 <0.001 
• "2MG 1 -6.0 -8.4 - -3.6 <0.001 - - - 
 2 -4.8 -7.2- -2.3 <0.001 -4.2 -7.1- -1.4 0.004 
• NAG 1 -3.3 -6.4- -0.2 0.04 - - - 
 2 -1.5 -4.5-1.6 0.35 -5.6 -8.6- -2.6 <0.001 
• NGAL 1 -10.6 -14.0- -7.3 <0.001 - - - 
 2 -8.9 -12.7- -5.2 <0.001 -2.8 -5.7-0.2 0.07 
Distal tubular        
• H-FABP 1 -9.3 -13.5- -5.1 <0.001 - - - 
 2 -7.3 -11.5- -3.1 0.001 -4.6 -7.6- -1.6 0.003 
Inflammatory        
• MIF 1 -0.1 -5.4-5.1 0.9 - - - 
 2 2.3 -2.6-7.3 0.4 -6.4 -9.3- -3.5 <0.001 
• MCP-1 1 -7.5 -12.6- -2.5 0.004 - - - 
 2 -2.6 -8.4-3.2 0.4 -5.2 -8.6- -1.8 0.003 
 
Table 5: Multivariable associations of various biomarkers with effective renal blood flow after adjustment for age, 
gender (model 1) and additional adjustment for UAE (model 2).
Beta’s, confidence intervals and p-values were calculated using multivariable linear regression. Dependent variable is 
ERBF, independent variables are the log base2 transformed 24h excretions of the various urinary biomarkers.
Model 1: adjusted for age and gender
Model 2: adjusted for age, gender and albuminuria.
Abbreviations are: IgG, immunoglobulin G; β2 MG, β2 microglobulin; KIM-1, Kidney Injury Molecule 1; NAG, 
N-acetyl-β-D-glucosaminidase; NGAL, Neutrophil Gelatinase-Associated Lipocalin; H-FABP,  Heart-type Fatty Acid 
Binding Protein; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemotactic protein-1.
 model Urinary biomarker UAE 
  ! 95% CI for ! p-value ! 95% CI for ! p-value 
• UAE 1 - - - -30 -47- -13 0.001 
Glomerular        
• IgG 1 -17 -27- -7 0.001 - - - 
 2 -9 -23-4 0.18 -20 -42-2 0.08 
Proximal tubular        
• KIM-1 1 4 -28-37 0.8 - - - 
 2 19 -12-51 0.2 -32 -50- -15 <0.001 
• "2MG 1 -34 -48 - -20 <0.001 - - - 
 2 -28 -43- -14 <0.001 -19 -35- -2 0.03 
• NAG 1 -21 -39- -3 0.02 - - - 
 2 -13 -31-5 0.17 -26 -43- -8 0.005 
• NGAL 1 -55 -75- -35 <0.001 - - - 
 2 -47 -70- -24 <0.001 -12 -30-6 0.18 
Distal tubular        
• H-FABP 1 -52 -77- -28 <0.001 - - - 
 2 -43 -68- -18 0.001 -22 -39- -4 0.02 
Inflammatory        
• MIF 1 -3 -33-28 0.9 - - - 
 2 9 -20-39 0.5 -31 -48- -13 0.001 
• MCP-1 1 -35 -65- -6 0.02 - - - 





Urinary biomarkers to assess ADPKD Severity 
Figure 5: The associations between  β2 microglobulin (upper panel), NGAL (middle panel) and H-FABP (lower 
panel), and mGFR are independent of albuminuria. Tertiles of the biomarkers are shown crude (light grey) and after 
adjustment of age, gender and albuminuria (dark grey).
Figure 6: The associations between β2 microglobulin (upper panel), NGAL (middle panel) and H-FABP (lower 
panel), and ERBF are independent of albuminuria. Tertiles of the biomarkers are shown crude (light grey) and after 
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Association of urinary biomarkers with structural changes in ADPKD
Effective renal blood flow (ERBF) and glomerular filtration rate (mGFR) correlated with total 
renal volume (TRV) (R=-0.20, p=0.05 and R=-0.28, p=0.004 respectively). Crude associati-
ons between the urinary biomarker excretions and total renal volume are depicted in table 3. Fi-
gure 7 consists of 4 scatterplots showing the association between IgG, KIM-1, NAG and MCP-1 
with TRV. The strongest association for total renal volume was with MCP-1 excretion. The ROC 
curve in Figure 4 for a total renal volume < 1000 mL shows that MCP-1 has the largest AUC 
(0.73). 
To investigate whether the potential associations were independent of albuminuria (urinary al-
bumin excretion, UAE), Table 6 shows the associations between 24h urinary biomarker excreti-
ons and total renal volume adjusted for age, gender and albuminuria. KIM-1, NGAL and MCP-1 
remained associated with total renal volume.
Figure 8 depicts the associations between the biomarkers that were associated with total renal 
volume independent of albuminuria. The figures show geometric mean values of total renal 
volume for tertiles of the aforementioned biomarkers, both crude and after adjustment of age, 
gender and albuminuria. Thus, NGAL remained associated with measured GFR, effective renal 
blood flow and total renal volume; all other biomarkers are associated with either mGFR / ef-
fective renal blood flow or total renal volume.
Figure 7: Associations between urinary biomarkers and Total Renal Volume.
Depicted are graphs of the urinary biomarkers under study that were significantly associated with TRV (table 3).
Table 6: Multivariable associations of various biomarkers with total renal volume after adjustment for age, gender 
(model 1) and additional adjustment for UAE (model 2).
Beta’s, confidence intervals and p-values were calculated using multivariable linear regression. Dependent variable 
is log base 2 transformed TRV, independent variables are the log base2 transformed 24h excretions of the various 
urinary biomarkers.
Model 1: adjusted for age and gender
Model 2: adjusted for age, gender and albuminuria.
Abbreviations are: IgG, immunoglobulin G; β2 MG, β2 microglobulin; KIM-1, Kidney Injury Molecule 1; NAG, 
N-acetyl-β-D-glucosaminidase; NGAL, Neutrophil Gelatinase-Associated Lipocalin; H-FABP,  Heart-type Fatty Acid 
Binding Protein; MIF, macrophage migration inhibitory factor; MCP-1, monocyte chemotactic protein-1.
 model Urinary biomarker UAE 
  ! 95% CI for ! p-value ! 95% CI for ! p-value 
• UAE 1 - - - 0.21 0.14-0.29 <0.001 
Glomerular        
• IgG 1 0.10 0.05-0.14 0.001 - - - 
 2 0.02 -0.04-0.08 0.5 0.19 0.09-0.29 <0.001 
Proximal tubular        
• KIM-1 1 0.23 0.09-0.38 0.002 - - - 
 2 0.15 0.01-0.28 0.04 0.19 0.12-0.27 <0.001 
• !2MG 1 0.05 -0.02-0.13 0.15 - - - 
 2 -0.01 -0.08-0.06 0.8 0.22 0.14-0.29 <0.001 
• NAG 1 0.09 0.01-0.18 0.04 - - - 
 2 0.03 -0.05-0.11 0.5 0.20 0.13-0.28 <0.001 
• NGAL 1 0.22 0.12-0.32 <0.001 - - - 
 2 0.12 0.02-0.23 0.03 0.17 0.09-0.25 <0.001 
Distal tubular        
• H-FABP 1 0.10 -0.02-0.23 0.11 - - - 
 2 0.01 -0.11-0.12 0.9 0.23 0.15-0.31 <0.001 
Inflammatory        
• MIF 1 0.02 -0.13-0.17 0.8 - - - 
 2 -0.07 -0.20-0.06 0.3 0.22 0.14-0.30 <0.001 
• MCP-1 1 0.40 0.27-0.52 <0.001 - - - 
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Sensitivity analyses
The associations between urinary biomarker excretions with functional and structural measures 
in ADPKD were essentially the same as the associations between urinary biomarker/creatinine 
ratios and these functional and structural measures. When all analyses were repeated including 
only ADPKD subjects with a mGFR >60 mL/min (n=79, not performed with mGFR as a 
reference test), the results of the crude associations (Table 3) remained the same, except for the 
association between H-FABP and ERBF, that now did not reach significance when only subjects 
with an mGFR > 60 mL/min were included.
 
Discussion
The most important finding of this study is that all urinary biomarkers, be it for glomerular, 
proximal tubular, distal tubular damage or for inflammation, were elevated in ADPKD patients, 
when compared to healthy controls. Furthermore, NGAL was associated with renal blood flow 
and total renal volume, independent of albuminuria and is therefore an interesting candidate 
marker to predict disease progression. In addition to that, β2 microglobulin and H-FABP were 
inversely associated with glomerular filtration rate and effective renal blood flow, independent 
of albuminuria and KIM-1, NGAL and MCP-1 were positively associated with total renal vo-
lume, independent of albuminuria. Albuminuria correlated well with glomerular filtration rate, 
effective renal blood flow and total renal volume. 
We found all urinary biomarkers to be elevated in ADPKD. According to our study, both glo-
merular, proximal- and distal tubular and the inflammatory marker MCP-1 were elevated in 
ADPKD compared to healthy controls, suggesting the disease (indirectly) affects multiple parts 
of the nephron. Glomerular markers were more markedly elevated in the ADPKD patients 
than tubular damage markers. When patients are studied with a relatively well preserved eGFR 
(>60 ml/min per 1.73 m2), a relatively well preserved renal blood flow (>500 ml/min) or a 
relatively modest total renal volume (<1000 ml) all urinary biomarkers (except H-FABP and 
MIF) were also increased, indicating that the increase in urinary biomarkers occurs early in the 
disease process. That H-FABP excretion is elevated only later in the disease process is in contrast 
with literature that suggests that the main site of cystogenesis is distal in the tubules39. Of note, 
we found a striking correlation between IgG and albuminuria, which could suggest albuminuria 
in ADPKD is predominantly glomerular in origin. Furthermore, biomarkers were associated 
with either glomerular filtration rate and renal blood flow or total renal volume. Also in the 
ROC curves, the biomarkers with highest area under the curve are different for TRV and ERBF/
mGFR.  NGAL was the only urinary biomarker that remained associated with mGFR, effective 
renal blood flow and with total renal volume. 
An increased urinary albumin excretion is a risk factor for ADPKD disease progression (renal 
growth and renal function deterioration).9 Apart from albuminuria however, the studies that 
have been published on urinary biomarkers in ADPKD, are nearly always performed in small 
sample size populations and not corroborated by others.  Urinary β2 microglobulin was eleva-
ted in 14 ADPKD patients compared to 6 healthy controls.15 KIM-1 was expressed in murine 
polycystic kidneys, but not in normal kidneys.40 To our knowledge however, urinary KIM-1 in 
human ADPKD has never been measured, nor are we aware of any studies describing urinary 
Figure 8: The associations between KIM-1 (upper panel), NGAL (middle panel), and MCP-1 (lower panel), and 
total renal volume are independent of albuminuria. Tertiles of the biomarkers are shown crude (light grey) and after 




Urinary biomarkers to assess ADPKD Severity 
Acknowledgements
We greatly acknowledge Lucia Kadijk for her assistance at the outpatient clinic and the technical 
assistance of Marian Vroom-Dallinga, Roelie Karsten-Barelds and Dirkina Hesseling for renal 
function measurements. Furthermore, we acknowledge Peter Kappert, Annemarie Tienhoven 
and Irene Willeboordse for their technical expertise with the magnetic resonance images. Fi-
nally, we thank Gerwin Engels for his help in determination of the urinary biomarkers.
NAG levels in ADPKD. For NGAL, serum and urinary levels were higher in 26 ADPKD patients 
compared to 26 healthy volunteers.16 Urinary fatty acid binding protein excretion is previously 
described to be elevated in ADPKD.41 However, in this study liver-fatty acid binding protein 
was measured and not heart fatty acid binding protein, as in our study.  Increased levels of 
MCP-1 in cyst mural cells and in urine was associated with monocyte accumulation within the 
renal interstitium in a rat model of ADPKD.42 Also, in ADPKD patients, an increased urinary ex-
cretion of MCP-1 has been described.17;18 MCP-1 is thought to play a critical role in the respon-
ses of macrophage migration inhibition factor (MIF). No studies so far have described urinary 
MIF excretion in ADPKD as yet. In one study, in polycystic kidney disease, multiple urinary 
biomarker tests were compared, namely albuminuria and urinary β-N-acetlyhexosaminidase and 
its isoenzymes.43
The question arises whether the markers we measured are only markers of disease activity, or 
whether they are also involved in the pathophysiologic process of cyst formation. Experimen-
tal studies suggest that KIM-1 is probably involved in phagocytosis.44 It is also an endogenous 
ciliary protein45 and could be involved in regulating flow-induced calcium signalling.46 NGAL 
suppressed cyst growth by PKD1 null cells in vitro and in mice.47 Because of the observational 
nature of our study, we can only speculate whether the markers we found are indeed involved in 
the pathophysiology of ADPKD. 
We acknowledge that our study has limitations. First, our study is cross-sectional, which could 
induce selection bias and makes that we are not able to look at associations between the markers 
and prediction of disease progression. Future studies will have to establish the clinical utility of 
these urinary biomarkers in predicting prognosis or response to therapy. Second, being a single 
centre study, our study needs of course external validation. Third, we do not know whether 
the found elevation of urinary biomarkers is specific for ADPKD or could also occur in non-
ADPKD patients with chronic kidney disease. The increased urinary biomarker excretion could 
be caused by non-specific injury rather than the cystogenic process.  Of note, we investigated 
whether urinary biomarkers can improve the assessment of disease severity in clinical practice. 
Therefore we did not take serum levels into account. Assessment of albuminuria is often perfor-
med in clinical practice, we attempted to identify urinary biomarkers that are of additional value 
to albuminuria. Strengths of our study are that we measured multiple markers in a relatively 
large cohort, consisting of 102 ADPKD patients, at different stages of the disease, and associated 
these biomarkers with gold standard measurements of renal blood flow and total renal volume, 
enabling a comparison between these biomarkers.
In summary, we found urinary biomarkers from all segments of the nephron to be elevated in 
ADPKD patients compared to healthy controls. NGAL was associated with both renal blood 
flow, as well as total with renal volume, independent of albuminuria. We found associations that 
were independent of albuminuria between β2 microglubulin and H-FABP versus effective renal 
blood flow and of KIM-1, NGAL and MCP-1 and total renal volume. Based on these cross-sec-
tional data, we hypothesize that determination of β2 microglobulin, KIM-1, H-FABP, MCP-1, 
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Vasopressin and UAE in healthy subjects
Introduction
Urinary albumin excretion (UAE) is a powerful predictor of cardiovascular mortality and pro-
gressive renal function deterioration, not only in diabetics, but also in the general population.1;2 
It is assumed that UAE not only reflects glomerular damage, but is also related to systemic 
endothelial dysfunction. Lowering albuminuria is associated with a better renal3 and cardiovas-
cular4 outcome. Identifying modifiable factors that cause a rise in UAE is, therefore, important, 
since intervention directed to these factors might be expected to result in a better renal and 
cardiovascular prognosis. 
Vasopressin has been hypothesized to be one of these modifiable factors. Vasopressin is also 
known as antidiuretic hormone since it binds to the V2 receptors in the collecting ducts, in-
ducing the insertion of the molecular water channel aquaporin-2 in the luminal membrane of 
principal cells. This mediates water reabsorption, thereby reducing water excretion5. Despite 
its importance for normal water regulation in the body, vasopressin also has been reported to 
exert deleterious effects on the kidney. Administration of 1-desamino-8-D-arginine vasopres-
sin (a vasopressin receptor agonist) to rats and humans induces albuminuria6;7 and inhibition of 
vasopressin by drinking water or V2 antagonism, reduces proteinuria in rats with renal failure8;9 
and diabetes.10
Interest in pleiotropic effects of vasopressin has risen because vasopressin antagonists are expec-
ted to become available for clinical use within the next years. Human studies investigating the 
influences of endogenous vasopressin on albuminuria are, however, lacking. Presumably this is 
caused by the fact that direct measurement of vasopressin in humans is problematic. More than 
90% of vasopressin in the circulation is bound to platelets,11 vasopressin is unstable in isolated 
plasma11 and most vasopressin assays have relatively limited sensitivity. Recently, an assay has 
been developed to measure copeptin, the C-terminal portion of the precursor of vasopressin. 
Copeptin has been proven to be a reliable marker of vasopressin secretion and a useful substitute 
for circulating vasopressin concentration in clinical routine.12;13 These characteristics make co-
peptin a promising marker, which allows for the first time (indirect) measurement of vasopres-
sin in epidemiological studies.
Given the aforementioned, we hypothesized that in the general population copeptin (a surrogate 




Study Design and Population
This study is part of the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study, 
a cohort study that investigates the predictive value of UAE for renal and cardiovascular disease 
progression. All inhabitants of the city of Groningen between the ages 28 and 75 years (85,421 
subjects) were asked to send in a morning urine sample and to fill a short questionnaire on 
demographics and cardiovascular history. A total of 40,856 subjects (47.8%) responded. After 
exclusion of insulin dependent diabetes mellitus and pregnant women, all others with urinary 
albumin concentration ≥ 10 mg /l, together with a randomly selected control group, were 
invited. Finally, 8592 subjects completed the total screening program, rendering the actual 
Abstract
Urinary albumin excretion is a powerful predictor of progressive cardiovascular and renal 
disease. In rats and humans, administration of a synthetic vasopressin analogue, 1-desamino-
8-D-vasopressin, increases urinary albumin excretion; however, it is unknown if endogenous 
vasopressin levels influence albumin excretion. 
To determine this, we measured copeptin, a marker of endogenous vasopressin levels, and its 
association with urinary albumin excretion in 7,593 subjects who participated in the PREVEND 
study, a prospective population based, observational cohort. Urinary albumin excretion was 
measured in two consecutive 24h urine samples by nephelometry while copeptin was measured 
by an immuno-assay.
Median copeptin concentrations were significantly higher in males than females and high levels 
were associated with significantly lower 24h urine volumes of high osmolarity. With increasing 
quintiles of copeptin levels, the percentage of microalbuminuric subjects increased from 13 to 
25 for males and from 8 to15 for females. This association was independent of age and other 
potential confounders; however, we found an interaction between age and copeptin in their as-
sociation with urinary albumin excretion. 
Our study shows that plasma copeptin levels are associated with microalbuminuria, consistent 
with the hypothesis that vasopressin is involved in causing urinary albumin excretion. If future 
studies show that this relation is causal, then drinking more water or pharmacological interven-
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time, creatinine is always provided as non-IDMS traceable values. We have, however, validated 
creatinine against IDMS and used this as an additional sensitivity analysis. Microalbuminuria was 
defined as an UAE > 30 mg/24h. Urinary osmolarity was calculated as 2 * (Urinary sodium 
concentration +Urinary potassium concentration) + Urinary urea concentration. This formula 
is not validated in our cohort, but extracted from literature.19-21
Statistical Analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Parametric 
variables are expressed as mean ± s.d., whereas non-parametric variables are given as median 
(interquartile range). Skewed data, such as C-reactive protein (CRP), were normalized by loga-
rithmic transformation in analyses. A two sided p < 0.05 was considered to indicate statistical 
significance.
To visualize associations with copeptin, the study population is subdivided into quintiles of 
copeptin concentration. Since males have a significantly higher copeptin concentration than 
females,13 when depicted not specifically separately, these quintiles were stratified for gender. 
P-values for differences between these quintiles were obtained using ANOVA or Kruskal-Wallis 
test.
Gender-stratified quintiles were also made for BMI, blood pressure, cholesterol, fasting glucose 
and CRP (other modifiable factors that are known to be associated with an increase in UAE in 
the non-diabetic population22) . This was done to compare the association between copeptin 
concentration and UAE with the association between these other modifiable factors and UAE.
To investigate whether copeptin concentration is associated with other variables, multiple 
regression analysis was performed. Logarithmic transformation of copeptin was applied to fulfill 
the requirement of equal distribution of the residuals.  This was performed for the whole group 
and for males and females separately, both crude and adjusted for age. 
To investigate the association between copeptin and UAE, logarithmic transformation of UAE 
was applied and linear regression was performed. Stepwise, various models were built to 
adjust for possible confounding variables for males and females separately. First, the association 
between log copeptin and log UAE was investigated crude; second, it was 
adjusted for age and gender; third, adjusted for potential cardiovascular confounders (MAP, 
BMI, smoking, glucose, cholesterol, CRP, eGFR); and, finally, adjusted for medication that could 
potentially influence both vasopressin secretion as well as UAE (diuretics and ACEi/ARB). The 
same models were used to investigate the association between urinary osmolarity and UAE in 
multiple regression analyses. Interactions between baseline characteristics and log copeptin 
were tested in the multivariate model with UAE being the dependent variable.
Various sensitivity analyses were performed. To test whether use of diuretics would not only 
influence copeptin concentration, but also influence UAE, the analyses were also performed 
separately for subjects with and without diuretic use. Analyses were also performed stratified for 
medication influencing the renin-angiotensin system (ACEi and ARB’s, yes/no) and for diabetic 
status (yes/no). All analyses were repeated, first, without outliers for copeptin (defined as a 
measurement which falls more than 1.5 times the interquartile range above the third quartile 
or below the first quartile;23 second, we repeated the analyses with creatinine values that were 
screening cohort. Details of this study have been published elsewhere.14;15 For this study, subjects 
with a missing copeptin value (n=888, missing samples), missing 24h urine collections (n=8) or 
non-fasting blood sample (n=103) were excluded, leaving 7593 subjects for analysis. The PRE-
VEND study is approved by the medical ethics committee of our institution and was conducted 
in accordance with the guidelines of the Declaration of Helsinki. All participants gave written 
informed consent.
Measurements and definitions
Participants completed two visits at our outpatient unit. Height and weight were measured. 
Information on drug use was given by data from community pharmacies. During the first and 
the second visit, blood pressure was measured on the right arm, in supine position, every mi-
nute for 10 and 8 minutes, respectively, with an automatic device (Dinamap XL Model 9300; 
Johnson-Johnson Medical, Tampa, FL). Two 24h urine samples were collected after thorough 
oral and written instructions on how to perform urine collection, and fasting blood sample was 
drawn.
Urinary albumin concentration was determined by nephelometry (BNII; Dade Behring Diag-
nostics, Marburg, Germany). Concentrations of sodium and potassium were measured in urine, 
and cholesterol and glucose levels were measured in serum using standard methods. Creatinine 
concentration was measured using Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, 
NY, USA). Copeptin was measured using a new sandwich immunoassay (B.R.A.H.M.S. AG, 
Hennigsdorf / Berlin, Germany), which was based on the assay described previously.12 
The assay was modified as follows: the capture antibody was replaced by a murine monoclonal 
antibody directed to amino acids 137-144 of proAVP. This modification improved the sensitivity 
of the assay. The lower detection limit was 0.4 pmol/L and the functional assay sensitivity (20% 
interassay coefficient of variation) was less than 1 pmol.16
BMI was calculated as weight in kilograms (kg) divided by height in square meters (measured 
to the nearest 0.5 kg and 0.5 cm, respectively). History of coronary heart disease was defined 
as self-reported myocardial infarctions, cardiac operations, percutaneous transluminal coronary 
angioplasty or cerebrovascular accident. This definition of coronary heart disease would proba-
bly misclassify subjects with unrecognized or silent coronary heart disease.17
Systolic and diastolic blood pressure were measured as mean of the last two measurements of 
the two visits. These blood pressure values were used to calculate a mean arterial pressure using 
the standard formula 2/3 diastolic blood pressure + 1/3 systolic blood pressure. UAE was 
calculated as the mean of the two 24h urine excretions. Included in our definition of diuretic use 
are all agents mentioned under C03 of the Anatomical Therapeutic Chemical (ATC) classifica-
tion system (low-ceiling diuretics, thiazides, low-ceiling diuretics, excl thiazides, high-ceiling 
diuretics, potassium-sparing agents, diuretics and potassium sparing agents in combination and 
combinations including these agents). Diabetes was defined as use of oral antidiabetic medica-
tion, or a fasting glucose >7.0 mmol/l. Sodium excretion was used as a surrogate for sodium 
intake. Creatinine values were used to calculate an eGFR, using the modification of diet in 
renal disease formula.18 In early PREVEND papres, creatinine has not been reported as IDMS-
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IDMS traceable. Finally, all analyses were repeated excluding subjects with >20% difference in 
creatinine excretion in two consecutive 24h urine collections as this may indicate incomplete-
ness of urine collection.
Results
Characteristics of participating subjects are presented for quintiles of copeptin in Table 1 sepa-
rately for gender. A total of 7,593 subjects (47.2% male, aged 49 ±13 years) were analyzed. 
Median copeptin concentration in these subjects was 4.7 (2.9-7.5) pmol/l, with significantly hi-
gher concentration in males (6.2 (4.1-9.5) pmol/l) than in females (3.6 (2.4-5.5) pmol/l, p < 
0.001). Table 2 depicts associations between copeptin and these variables for males and females. 
As copeptin concentration is significantly associated with age, an additional column is included 
to represent the association adjusted for age. When adjusted for age, copeptin concentration was 
positively associated with serum creatinine, blood pressure, body mass index (BMI) and sodium 
intake in males and females, whereas the association with eGFR was negative. Associations 
between copeptin and smoking and use of angiotensin-converting enzyme inhibitors/ angioten-
sin-II-recepor blockers (ACEi/ARBs) are significant in females and not in males, while plasma 
glucose and plasma cholesterol levels are significant in males but not in females. The associa-
tion between copeptin and blood pressure is presented in the table for the whole group. For 
subjects on antihypertensive medication (males n=494, females n=510) this association is not 
significant. For those who do not receive antihypertensive treatment, the associations between 
copeptin and blood pressure are approximately similar to that of the whole group (depicted in 
Table 2).
Table 1: Characteristics of participating subjects (N = 7,593) per quintile of copeptin for males (M) and females (F). 
Parametric variables are expressed as mean ± SD, whereas non-parametric variables are given as median (interquar-
tile range).
Quintile  1 2 3 4 5 
copeptin (pmol/l) M 0.6-3.7 3.8-5.3 5.4-7.3 7.4-10.4 10.5-632 
 F 0.1-2.1 2.2-3.0 3.1-4.2 4.3-6.2 6.3-131 
n M 730 726 696 716 715 
 F 772 829 809 803 797 
Age (y) M 49 ± 13 48 ± 13 50 ± 13 49 ± 12 52 ± 13 
 F 47 ± 12 47 ± 12 48 ± 12 48 ± 12 50 ± 12 
History of CHD, n (%) M 58 (8) 43 (6) 55 (8) 63 (9) 69 (10) 
 F 21 (3) 15 (2) 20 (3) 21 (3) 25 (3) 
Smoking, n (%) M 113 (15) 123 (17) 118 (17) 126 (18) 95 (13) 
 F 98 (13) 94 (11) 136 (17) 157 (20) 165 (21) 
BMI, kg/m2 M 25.7 ± 3.3 25.9 ± 3.3 26.4 ± 3.6 26.5 ± 3.7 26.7 ± 4.0 
 F 25.4 ± 4.1 25.6 ± 4.5 25.8 ± 4.7 26.3 ± 4.9 26.2 ± 5.4 
MAP, mm Hg M 93.4 ± 11.3 94.3 ± 10.5 95.2 ± 11.6 95.6 ± 11.1 98.5 ± 12.3 
 F 87.9 ± 11.8 88.5 ± 11.8 88.2 ± 11.4 88.9 ± 12.4 90.0 ± 12.6 
Use of diuretics, n (%) M 19 (3) 21 (3) 21 (3) 20 (3) 39 (5) 
 F 40 (5) 39 (5) 28 (3) 42 (5) 48 (6) 
Use of ACEi / ARB, n (%) M 42 (6) 35 (5) 34 (5) 33 (5) 52 (7) 
 F 27 (3) 28 (3) 22 (3) 34 (4) 44 (6) 
Sodium intake, mmol/day M 154 ± 51 161 ± 53 163 ± 54 163 ± 57 156 ± 54 
 F 123 ± 42 126 ± 41 127 ± 42 125 ± 42 127 ± 47 
Plasma glucose, mmol/l M 4.9 ± 0.9 4.9 ± 0.9 4.9 ± 0.9 5.1 ± 1.3 5.3 ± 1.8 
 F 4.7 ± 0.8 4.8 ± 1.3 4.7 ± 0.9 4.7 ± 0.9 4.8 ± 1.3 
Diabetes, n (%) M 26 (4) 26 (4) 18 (3) 26 (4) 50 (7) 
 F 18 (2) 28 (4) 23 (3) 18 (2) 28 (4) 
Plasma cholesterol, mmol/l M 5.6 ± 1.1 5.6 ± 1.1 5.6 ± 1.1 5.7 ± 1.1 5.8 ± 1.2 
 F 5.6 ± 1.2 5.5 ± 1.1 5.6 ± 1.2 5.6 ± 1.1 5.8 ± 1.2 
Serum CRP, mg/l M 1.0 (0.5-2.3) 1.0 (0.5-2.4) 1.2 (0.6-2.7) 1.3 (0.6-3.0) 1.4 (0.7-3.0) 
 F 1.2 (0.5-3.2) 1.2 (0.5-3.0) 1.4 (0.6-3.2) 1.4 (0.6-3.3) 1.5 (0.6-3.6) 
Serum creatinine, umol/l M 89 ± 11 90 ± 13 91 ± 13 92 ± 13 98 ± 41 
 F 74 ± 9 75 ± 10 76 ± 10 77 ± 10 78 ± 17 
eGFR, ml/min*1.73m2 M 87 ± 14 86 ± 15 84 ± 14 83 ± 14 80 ± 16 
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To investigate whether vasopressin concentration is consistent with normal physiology, we 
tested the associations between copeptin and 24h urinary volume and 24h urinary osmolarity. 
A high concentration of copeptin was associated with a low 24h urinary volume (in males R= 
-0.27 and in females R = -0.23, both p <0.001) and high urinary osmolarity (in males R=0.27 
and in females R=0.23, both p<0.001). The correlation of copeptin with overall calculated uri-
nary osmolarity was stronger than with the single determinants of the calculated osmolarity (for 
copeptin and urinary sodium concentration R-value was 0.25 in males and 0.22 in females; for 
urinary potassium concentration this was 0.16 for males and 0.15 for females; and for urinary 
urea concentration, R-value was 0.25 and 0.21, respectively). The associations of copeptin with 
24h urinary volume and 24h urinary osmolarity are presented in Figure 1. Twenty-four-hour 
urinary volume is highest in quintile 1 and lowest in quintile 5 (1.74 ± 0.51 versus 1.36 ± 0.44 
L for males and 1.82 ± 0.60 versus 1.43 ± 0.52 L for females) whereas urinary osmolarity 
varies in an opposite manner (533 ± 155 versus 667 ± 183 mOsm/L for males and 418 ± 133 
versus 530 ± 170 mOsm/L for females). The osmolar load is not different between quintile 1 
and quintile 5 for each gender (for males 876 mOsmol in quintile 1, versus 841 osmol in quintle 
5, p =0.06 and for females 707 versus 698 mOsmol, p=0.3).
Figure 1: Associations between quintiles 
of copeptin and 24h urinary volume (upper 
panel) and 24h urinary osmolarity (lower 
panel) for males and females. Depicted are 
mean values (± 95% confidence interval of 
the mean). Differences between the quintiles 
were tested by analysis of variance.
















































































































































































































































































































































































































































































































































































Vasopressin and UAE in healthy subjects
Median UAE for the whole group was 9.3 (6.4-16.8) mg per 24 hour and 986 (13%) of the 
subjects had micro-albuminuria (micro-albuminuria is defined as a UAE ≥30 mg per 24h). 
Copeptin level was significantly associated with UAE (R = 0.20, p <0.001). This association is 
depicted in Figure 2. UAE is higher in the quintile with higher copeptin values: in quintile 1: 9.4 
(6.5-17.2) mg/24h for males and 7.3 (5.5-11.7) mg/24h for females and in quintile 5: 13.4 
(8.1-29.8) mg/24h for males and 10.0 (6.6-18.3) for females. Also depicted in Figure 2 is the 
percentage of microalbuminuric subjects per quintile of copeptin. The percentage of microalbu-
minuric subjects is highest in the highest quintile of copeptin.
In Figure 3, the association between copeptin and UAE is shown in addition to that of modi-
fiable factors that are known to influence UAE (mean arterial blood pressure (MAP), BMI, 
fasting plasma glucose and cholesterol). For this purpose gender-stratified quintiles were made 
for every factor specifically. This figure shows that the association between MAP and UAE is the 
strongest and that the association between copeptin and UAE is comparable to that between 
glucose, BMI or cholesterol and UAE. R-values for the association between MAP, glucose, BMI 
and cholesterol versus UAE are respectively 0.36, 0.25, 0.21 and 0.12.
The association between copeptin and UAE was also investigated using copeptin as a continuous 
variable in multivariate regression analyses. We adjusted this association in a multivariate model 
for several potential confounders. Despite the fact that our regression model did not show indi-
cations for an interaction with gender and that the regression coefficients for males and females 
were not different (p=0.11 for the crude model and 0.37 for the fully adjusted model), results 
are depicted for males and females separately in Table 3. The association was significant with a 
beta-value of 0.25 for males and 0.19 for females, both p < 0.001 (Table 3, model 1). Adjusted 
for gender, the association remained significant. Further adjustment for potential cardiovascular 
confounders (model 3), and for medication that could potentially influence both vasopressin 
(and thus copeptin concentration) and UAE (model 4), did not materially influence the associa-
tion between copeptin and UAE.
Urinary osmolarity was also associated with UAE with a standardized beta-value of -0.05 for 
males and 0.07 for females, both p <0.001. This association was independent of age, gender, 
potential cardiovascular confounders and use of diuretics and/or ACEis/ARBs.
Figure 2: Association between quintiles of 
copeptin and median 24h urinary albumin 
excretion (UAE, upper panel) and prevalence of 
micro-albuminuria (lower panel) for males and 
females. Differences between the quintiles were 
tested by Kruskal Wallis test.
Figure 3: Association between copeptin and UAE (upper 
panel) and copeptin and micro-albuminuria (lower panel) 
compared with known modifiable factors influencing UAE. 
Depicted are gender-stratified quintiles of copeptin con-
centration / Mean Arterial Pressure (MAP) / body mass 
index (BMI) / fasting plasma glucose and plasma cholesterol. 




Vasopressin and UAE in healthy subjects
Of note, apart from the interaction of age and log copeptin on UAE, we did not find any other 
interactions between baseline characteristics and log copeptin on UAE. The results we obtained 
in the various sensitivity analyses (stratified for ACEi/ARB and diuretics use (yes / no), with or 
without outliers of copeptin, with or without diabetic subjects and without subjects with a non-
fasting blood sample and without subjects with >20% difference in creatinine excretion in two 
consecutive 24h urine collections and repeated with IDMS traceable creatinine values), were 
essentially similar to those from our primary analyses.
Discussion
In the present study, we found copeptin values to be higher in males than in females, correspon-
ding with lower urine volumes and higher urinary osmolarity in males versus females. In both 
males and females, high copeptin concentration (a surrogate for vasopressin) is associated with 
low 24h urinary volume and high 24h urinary osmolarity. Furthermore, our study shows that 
copeptin is associated with UAE: the higher copeptin, the higher UAE and the more microalbu-
minuric subjects, again, both in males and in females. This association remained significant after 
adjustment for age, potential cardiovascular confounders and medication that could potentially 
influence both vasopressin (and thus copeptin) secretion and UAE. The association between co-
peptin and UAE was found to be most pronounced for older subjects. The observed association 
between vasopressin and UAE is consistent with our hypothesis that vasopressin induces albu-
minuria. Animal studies showed that administration of 1-desamino-8-D-arginine-vasopressin (a 
V2-receptor agonist) induced an increase in urinary protein excretion and a more rapid decline 
of renal function.24 Also in humans, short-term 1-desamino-8-D-arginine-vasopressin adminis-
tration has been shown to result in an increase in UAE. 6 In contrast, vasopressin inhibition by 
drinking water8 or by V2 antagonism25 led to a decrease in proteinuria in rats with renal failure. 
In the crude and the full corrected model, an interaction was found between age and log co-
peptin on UAE (p <0.001). In Figure 4, the association between copeptin and UAE is depicted 
stratified for quintiles of age. Copeptin was associated with UAE in all age groups, but this 
association is the strongest when subjects are older. In the youngest age quintile (age 28-36y), 
copeptin concentration rose from 1.9 (1.6-2.7) to 11.2 (8.3-14.4) pmol/l from the first to the 
fifth quintile of copeptin, with median UAE rising from 7.5 (5.8-10.4) to 8.5 (6.2-13.6) mg 
/24h. In the oldest age quintile of our study (age 62-75y), copeptin concentration rose from 
2.0 (1.5-2.8) to 11.9 (9.3-15.8) pmol/l while median UAE rose from 11.1 (7.0-23.5) to 18.2 
(9.4-40.8) mg/24h. Twenty-four-hour urinary volume and 24h urinary osmolarity were signifi-
cantly different, with 24h urinary volume being higher and 24h urinary osmolarity being lower 
in the oldest age group when compared to the youngest age group (in the highest quintile of 
copeptin, 1434 ± 465 ml and 543 ± 163 mOsm/l for the oldest quintile versus1259 ± 485 ml 
and 673 ± 202 mOsm/l in the youngest quintile).
Figure 4: Interaction between age and 
copeptin in the association with urinary 
albumin excretion (UAE). Depicted are 
median UAE values according to gender-
stratified quintiles of copeptin for the 
various age groups.
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Table 3 Associations between log copeptin concentration and log UAE in univariate (model 1) and multivariate 







Vasopressin and UAE in healthy subjects
by Figure 3 and the R-values of these associations). It is furthermore important to note that the 
association between copeptin and UAE was independent of these potential confounders (Table 
2).
Copeptin levels are likely to fluctuate day by day according to changes in volume or plasma 
osmolarity. This questions whether the found association will be of relevance for renal function 
or albuminuria in the long run. There is, however, evidence that copeptin levels are not only 
dependent on volume status and plasma osmolarity, but also to a certain extent are genetically 
determined. Subjects who have higher thirst and vasopressin threshold as genetic trait,29-31 could, 
therefore, be at greater renal risk. These subjects with higher vasopressin level as a genetic trait 
and / or elderly subjects are most likely to profit from intervention (as drinking water or admi-
nistration of a vasopressin-receptor antagonist).
  
We acknowledge that this study has limitations. First, it is a cross-sectional epidemiologic study. 
Therefore no certain causal relationship can be proven. A third factor could underlie both co-
peptin level and albuminuria. For instance, subjects with higher UAE have more risk factors and 
a greater extent of subclinical interstitial injury and subsequent reduction of urine-concentrati-
on capacity. The observation that the association remains significant in the multivariate regres-
sion analysis suggests that this association is independent of possible confounding factors. It is, 
however, possible that residual confounding remained even in multivariate-analysis, because it is 
hard to adjust completely for the duration or severity of each risk factor, for extent of tubulo-
interstitial injury and impairment of water-concentration capacity. Additional research is needed 
to point out a mechanism underlying the observed association. Furthermore, our study consis-
ted of predominantly Caucasian people, making extrapolation of our results to other ethnicities 
difficult. 
   
Strengths of our study, as far as we know, are that, this is the first study to investigate the as-
sociation between endogenous vasopressin and UAE. It confirms the results obtained with 
1-desamino-8-D-arginine-vasopressin administration in animals and humans. Furthermore, this 
study has been performed in a large number of subjects with extensive information on a large 
number of covariates. 
In conclusion, our study shows that copeptin (a reliable substitute for vasopressin) is associated 
with UAE and microalbuminuria, consistent with the hypothesis that vasopressin induces UAE. 
If it is true that vasopressin induces albuminuria, suppressing vasopressin by administration of 
a vasopressin-receptor antagonist or simply by drinking more water might be beneficial for the 
kidney, especially in the elderly.
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In a rat model of diabetes mellitus, chronic treatment with a vasopressin V2 antagonist pre-
vented the rise in albuminuria seen in untreated rats.10 In these untreated rats with diabetes 
mellitus, albuminuria was significantly correlated with free-water reabsorption, suggesting an 
association between albuminuria and vasopressin.
The unfavorable renal effects of vasopressin have been argued to be partly due to an effect on 
blood pressure. Vasopressin may contribute to hypertension either by a direct effect on vascular 
smooth muscle through activation of the V1a receptor,26 or by V2 receptor-dependent tubular 
effects. The latter includes an enhancement of sodium reabsorption in the collecting duct,27 and 
an increase in intrarenal urea recycling which participates in the urine-concentrating mecha-
nism. The latter may, indirectly modify NaCl concentration at the macula densa, thereby influ-
encing tubuloglomerular feedback, leading to renin release, hypertension, glomerular hyper-
filtration, and proteinuria.6;28 In our study however, the association between copeptin and UAE 
was independent of systemic blood pressure, indicating that other mechanisms of action may be 
important. Furthermore, urinary osmolarity was independently associated with UAE, but less 
strong that the association between copeptin and UAE, suggesting that besides the antidiuretic 
effect of vasopressin, also other effects (e.g. pressor effects) might be involved in the relationship 
of copeptin with UAE. Induction of specific glomerular hyperfiltration or decreased tubular 
albumin reabsorption might be mechanisms underlying this relationship.
We also found copeptin to be associated with renal function. Subjects with higher levels of 
copeptin had lower renal function. Reasons for this phenomenon could be that copeptin causes 
renal function decline or that subjects with low renal function are less sensitive to the actions 
of copeptin / vasopressin. The fact that copeptin is partly cleared by the kidney19 is not likely 
to be an explanation, because negative feedback loops will downregulate copeptin/ vasopressin 
secretion. 
We investigated potential interactions between log copeptin on the one hand and gender, age 
and baseline renal function on the other hand, because we wanted to investigate whether there 
are certain subgroups of subjects that are more susceptible to copeptin’s influences. We found 
no interaction between copeptin and gender or renal function, suggesting that the association 
between log copeptin and UAE is essentially similar in men and women and independent of 
renal function. The interaction between age and copeptin was, however, significant, suggesting 
that the association between log copeptin and UAE is most pronounced in older subjects (Figure 
4). This could be explained because they might be more vulnerable to the influence of vasopres-
sin or because they have been longer exposed to high vasopressin levels. Another explanation 
for this interaction could be that older subjects might have decreased tubular reabsorption. 
This could result in both an increased UAE and decreased concentration capacity (24h urinary 
volume is higher and 24h urinary osmolarity is also lower in the oldest quintile) or become 
resistant to vasopressin with age. 
The association between copeptin and UAE has an R-value of 0.20. This relatively low R-value 
indicates that other factors also contribute to UAE. Compared with well acknowledged modifi-
able risk factors for UAE, the association between copeptin and UAE is less strong than between 
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Chapter 4.1 Vasopressin  or sodium and UAE
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To the Editor: 
In his commentary,1 dr Cirillo focuses on the Prevention of Renal and Vascular Endstage Disease 
(study) data showing that copeptin plasma levels are associated with albuminuria.2 He empha-
sizes that vasopressin needs to be paid more attention when analyzing kidney dysfunction. He 
also raises two questions, which we would like to answer.
First, he points out that the inverse association between vasopressin and glomerular filtration 
rate (GFR) that we found22 seems in contradiction to the increase in GFR that Bankir and col-
leagues reported after vasopressin administration in short-term intervention studies.3 A possible 
explanation could well be that exposure to vasopressin in the short-term induces glomerular 
hyperfiltration, and that this hyperfiltration will in the long-term be detrimental. Indeed, Bankir 
et al showed in an animal model that long-term administration of a vasopressin V2 receptor 
agonist caused an increase in proteinuria and a more rapid decline in renal function.4 In analogy, 
we described recently that higher baseline endogenous vasopressin levels were associated with 
a more rapid decline in renal function decline during follow-up in a cohort of renal transplant 
recipients.5 In our opinion, our data and those of Bankir et al are therefore not contradictory, 
but in line.
Second, dr. Cirillo raises the suspicion that the association between vasopressin and albuminuria 
might not be due to the effects of vasopressin per se, but may be the result of another variable 
that determines vasopressin release, such as salt intake. He argues that a high salt intake could 
induce a higher plasma osmolarity and thus vasopressin release, and that a high sodium intake 
is also associated with albuminuria, but through another mechanism. Of note, we previously 
indeed described an association between sodium intake and albuminuria in the Prevention of 
Renal and Vascular Endstage Disease (study) cohort.6 In response to this question, we added so-
dium intake (assessed as 24-h urinary sodium excretion) to our multivariate model. The addition 
of sodium intake did not change the beta value in males (0.09 (P=0.001) vs 0.09 (p=0.001), 
respectively) and only marginally changed the value in females (from 0.17 (p<0.001) to 0.15 
(p<0.001)). This observation makes it less likely that high salt intake is the common factor that 
induces an increase in albuminuria as well as in vasopressin, and pleads for the option that vaso-
pressin per se is detrimental. 
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Vasopressin and renal graft deterioration
Introduction
The antidiuretic hormone vasopressin (VP) is crucial for water regulation in the body. Its secre-
tion is stimulated in response to an increase in plasma osmolarity or a decrease in
blood volume. VP binds to the V2 receptors in the collecting ducts, inducing the insertion of the 
molecular water channel aquaporin-2 in the luminal membrane of principal cells. This mediates 
water reabsorption, thereby reducing water excretion.1;2 
Despite its relevance for normal physiology, several unfavorable effects of VP have been re-
ported on the kidney by affecting renal hemodynamics. Experimental studies have shown that 
a sustained V2 receptor stimulation results in increased renal plasma flow and particularly in 
increased Glomerular Filtration Rate.3 This hyperfiltration may have deleterious consequences, 
in particular in diseased kidneys, resulting in renal hypertrophy,4 proteinuria,5 and accelerated 
renal function decline.6-8 This proposed mechanism is supported by studies in rats with chronic 
renal failure, showing that increased water intake or chronic infusion of a VP V2-receptor anta-
gonist reduced proteinuria and prevented glomerulosclerosis6;9 and tubulo-interstitial fibrosis.10 
Similarly, chronic infusion of a V2-receptor antagonist reduced albuminuria and kidney weight 
in diabetic rats.11 
Interest in pleiotropic effects of VP has risen because VP antagonists are expected to become 
available for clinical use within the next years. Human studies showing deleterious effects of 
VP on renal function are, however, lacking. Presumably, this is caused by the fact that direct 
measurement of VP in human is problematic. More than 90% of VP in the circulation is bound 
to platelets, VP is unstable in isolated plasma,12 and most VP assays have relatively limited sensi-
tivity. Recently, an assay has been developed to measure copeptin, the C-terminal portion of the 
precursor of VP. Copeptin has been shown to be a reliable marker of VP secretion and a useful 
substitute for circulating VP concentration in clinical routine.13-15 These characteristics make 
copeptin a promising marker, which allows for the first time (indirect) measurement of VP in a 
large population. 
Renal transplant recipients often exhibit renal function deterioration and have a higher VP 
concentration than healthy controls.16 Because of the aforementioned hypothetical deleterious 
effects of VP, we hypothesized that a high concentration of copeptin is associated with renal 
function decline during follow- up in renal transplant recipients and investigated this hypothesis 
in a prospective observational study.
Materials and Methods
Study Design and Patients
In this prospective observational study, all renal transplant recipients who visited our outpatient 
clinic between August 2001 and July 2003 and had a functioning graft for at
least 1 year were eligible to participate at their next visit to the outpatient clinic (baseline). 
Baseline visits were postponed until symptoms had resolved in patients with fever or other
signs of infection (e.g. complaints of upper respiratory tract infection or urinary tract infection). 
Patients with overt heart failure and patients diagnosed with cancer other than cured skin cancer 
were not considered eligible for the study. A total of 606 of 847 (72%) eligible renal transplant 
recipients signed written informed consent. The group that did not sign informed consent was 
Abstract
Chronically elevated vasopressin (VP) plasma levels have been shown to induce accelerated renal 
function decline in rats with chronic renal failure. Whether endogenous VP is a renal risk factor 
in humans has not been investigated yet. We aimed to investigate whether, in renal transplant 
recipients, VP concentration is associated with change in renal function during follow-up.
In this prospective study, all consecutive patients visiting our kidney transplant outpatient clinic 
between August 2001 and July 2003 were asked to participate. Serum creatinine was assessed at 
baseline and at follow-up. Copeptin, the C terminal portion of the precursor of VP was deter-
mined at baseline (immunoassay). Univariate and multivariate regression analyses were perfor-
med to investigate the association between copeptin and renal function decline.
Overall, 548 patients were included 6.0 (2.8-11.6) years after transplantation (men 54%, age 
52 (43-60) years). Median follow-up was 3.2 (2.7-3.7) years. Median copeptin level was 9.1 
(5.0-18.6) pmol/L at baseline. Copeptin was significantly associated with change in estimated 
glomerular filtration rate (eGFR; MDRD) during follow up. When our study population was 
subdivided according to gender-stratified tertiles of increasing copeptin concentration, mean 
changes in eGFR during follow-up were -0.03, -0.44 and -1.06 mL/min*1.73m2 per year. In 
multivariate regression analysis, the association of copeptin at baseline with change in eGFR 
during follow-up remained significant after adjustment for age, gender, baseline eGFR and 
known risk factors for renal function decline.
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rity and not total osmolarity. Effective plasma osmolarity was calculated as plasma osmolarity=2 
x concentration sodium + concentration glucose.19 Fractional urea excretion was calculated as 
FE urea= ([urinary urea concentration/plasma urea concentration]/[urinary creatinine concen-
tration/ plasma creatinine concentration]) x100. Total protein concentration was analyzed using 
the Biuret reaction (MEGAAU 510; Merck Diagnostica, Darmstadt, Germany). 
N-terminal pro brain natriuretic peptide (NTproBNP) measurements were performed in 
plasma on an Elecsys 2010 analyzer, a commercially available electrochemiluminescent sandwich 
immunoassay (Elecsys proBNP; Roche Diagnostics, Mannheim, Germany). Creatinine values 
were used to calculate estimated Glomerular Filtration Rate (eGFR) at baseline and at follow-
up, using the Modification of Diet in Renal Disease (MDRD) formula.20 The assay of human leu-
kocyte antigen classes I and II antibodies was performed by ELISA (LATM20X5, One Lambda, 
Canoga Park, CA); positive and negative samples were identified according to the instructions of 
the manufacturer. 
The eGFR at follow-up was subtracted from that of baseline, and this value was divided by time 
from baseline to follow-up, to obtain a delta eGFR in mL/min/1.73 m2 per year. This delta 
eGFR (change in renal function over time) is our outcome variable for the longitudinal analyses. 
Our main study variable, copeptin was measured in samples stored at -80°C, that were trans-
ported in frozen condition to the laboratory of Brahms Berlin, using a new sandwich immunoas-
say (B.R.A.H.M.S. AG, Hennigsdorf/Berlin, Germany), as described
previously.13 Briefly, this sandwich immunoluminometric assay uses two polyclonal antibodies to 
the C-terminal region (acid sequence 132–164) of prepro-AVP. One antibody is bound to poly-
styrene tubes and the other is labeled with acridinium ester. The assay requires 50μL of plasma 
and no extraction steps or other preanalytical procedures.
Statistical Analysis
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Normality was 
tested with the Kolmogorov-Smirnov test. Parametric variables are expressed as mean±SD, 
whereas nonparametric variables are given as median (interquartile range). A two-sided P value 
less than 0.05 was considered to indicate statistical significance. 
To investigate potential associations with copeptin and other variables (plasma osmolarity, 24 
hr urinary volume, urinary sodium concentration, and fractional urea excretion) at baseline, 
univariate linear regression analyses were performed. To visualize these associations, we divided 
copeptin in tertiles of increasing copeptin concentration. Because men have a significant higher 
copeptin concentration than women,14 these tertiles were stratified for gender. Statistical testing 
of differences between the tertiles was performed with ANOVA (when the variable was nor-
mally distributed) and Kruskal-Wallis (in case of skewed distribution). 
For the analyses of copeptin as predictor of change in renal function during follow-up, we 
performed continuous analyses by performing univariate regression analyses with baseline log 
copeptin as independent variable and change in renal function as the dependent variable (Table 
2, model 1). To visualize this association, we compared rate of renal function decline for gender-
stratified tertiles of copeptin. Subsequently, we used univariate regression analysis, to investigate 
the association between copeptin and change in renal function, using copeptin as a continuous 
comparable with the group that signed informed consent concerning age, gender, body mass 
index (BMI), baseline serum creatinine, creatinine clearance, and proteinuria. All participating 
subjects visited the outpatient clinic at least once a year, and serum creatinine was assessed at 
every visit. To assess change in renal function over time, baseline renal function was related to 
information on renal function obtained at the last known visit to the outpatient clinic. Follow-
up date for patients who died with a functioning graft (n=32) was defined as renal function at 
the last visit to the outpatient clinic before death, and follow-up for patients with graft failure 
(n=17) was defined as renal function at the last visit to the outpatient clinic before starting 
dialysis. Details of this study have been published previously.17;18 Excluded from our study were 
recipients without copeptin value at baseline (n=28, 4.6%, because of missing samples) and re-
cipients with a follow-up of less than 1 year (n=30), leaving a total of 548 recipients for analysis. 
The institutional review board approved the study protocol (METc 01/039), which was in ad-
herence to the declaration of Helsinki. Funding sources had neither a role in the collection and 
analysis of data, nor in the submission and publication of the manuscript.
Immunosuppressive Medication
Standard immunosuppression consisted of the following: from 1968 until 1989, prednisolone 
(10 mg/day) and azathioprine (100 mg/day). From 1989 until 1993, cyclosporine standard 
formulation (Sandimmune; Novartis, Huningue, France; 10 mg/kg; trough concentrations of 
175–200 μg/L in first 3 months, 150 μg/L between 3 and 12 months post transplant and 100 
μg/L thereafter) combined with prednisolone (starting with 20 mg/day, rapidly tapered to 10 
mg/day). From 1993 until 1996, cyclosporine micro emulsion (Neoral; Novartis Pharma b.v. 
Arnhem, The Netherlands; 10 mg/kg; trough concentrations idem) and prednisolone. From 
May 1996 until present, mycophenolate mofetil (Cellcept; Roche b.v., Woerden, The Nether-
lands; 2 g/day) was added to the latter regimen. Current medication was extracted from the 
medical record of individual patients.
Baseline Measurements and Definitions
The BMI was calculated as weight in kilograms (kg) divided by height in square meters (measu-
red to the nearest 0.5 kg and 0.5 cm, respectively). Blood pressure was measured as the average 
of three automated measurements (Omron M4;Omron Europe B.V. The Netherlands) with 
1-min interval after a 6-min rest in supine position. Mean arterial pressure (MAP) was calcu-
lated using the standard formula: 2/3 diastolic blood pressure +1/3 systolic blood pressure. 
Plasma glucose was determined by the glucose-oxidase method (YSI 2300 Stat plus, Yellow 
Springs, OH). Diabetes mellitus was diagnosed if fasting plasma glucose concentration was 
more than or equal to 7.0 mmol/L and antidiabetic medication was used. Serum sodium, potas-
sium, urea, uric acid, and urinary urea were determined with dry chemistry, using a standard 
auto-analyzer (Kodak Ektachem; Eastman Kodak, Rochester, New York). Serum creatinine and 
urinary creatinine concentration were determined using the Jaffe´ method (MEGA AU 510; 
Merck Diagnostica, Darmstadt, Germany). Because urea is an ineffective osmole that readily 
crosses cell membranes, it will not induce water movement out of the osmoreceptor cells,19 and 
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Results
Patient characteristics are presented in Table 1. A total of 548 patients (54% men, aged 52±12 
years at baseline) were analyzed. Median time between transplantation and baseline
measurements was 6.0 (2.7–11.6) years. Median copeptin concentration for the whole group 
at baseline was 9.1 (5.0– 18.5) pmol/L. Median copeptin concentration was 12.2 pmol/L 
(interquartile range 6.3–23.3) for men and 6.6 pmol/L (4.1–12.7) for women (P=0.001). The 
distribution of copeptin values ranged from 1.4 to 102.0 pmol/L. 
To investigate whether copeptin concentration, as measure of VP, is consistent with normal phy-
siological regulation, we tested the association between plasma osmolarity, one of the causes of 
VP secretion and copeptin. We found that plasma osmolarity was positively associated with log 
copeptin (R=0.13, P=0.003). Figure 1 shows that from tertile 1 to tertile 3 effective plasma 
osmolarity is increasing, indicating that indeed a higher plasma osmolarity is associated with a 
higher copeptin concentration.
variable. Using a multivariate regression model, this association was adjusted for several factors 
that could potentially be confounders in this association. We built multivariate models stepwise. 
First, our association was adjusted for gender and age (model 2). Second, baseline eGFR was 
entered into the model (model 3). In addition to that, factors known from literature that could 
possibly influence VP (and thus copeptin) secretion (osmolarity, BMI, Diabetes, and use of diu-
retics and of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers) were 
added into the model (model 4).19 Because heart failure and inflammation could underlie both 
elevated copeptin concentration and renal function decline, the model was also adjusted for 
C-reactive Protein (CRP) and NTproBNP (model 5). Finally, in addition to the previous steps, 
we also adjusted for other known determinants of renal function decline (time on dialysis before 
kidney transplantation
(ntx, time from ntx until baseline, living related ntx, donor age, immunosuppressive medica-
tion, antidonor antibody status, current smoking, MAP, and proteinuria) (Model 6). Because 
borderline positive antidonor antibodies seem to have protective value, we added the antibody 
status as categorical variable in the model. For analyses, immunosuppressive medication was 
subdivided into three groups: prednisolone, calcineurin inhibitors (tacrolimus/cyclosporin), and 
proliferation inhibitors (azathioprine/mycophenolate mofetil). Because all subjects use pred-
nisolone, daily dose was entered as a continuous variable. We tested for significant interactions 
between patient characteristics and baseline log copeptin in predicting change in renal function 
during follow-up. 
Various sensitivity analyses were performed. Because use of diuretics influences copeptin con-
centration and possibly also are associated with renal function decline, the longitudinal analyses 
were also performed separately for subjects with and without diuretics use. Despite the fact 
that no significant interaction was found, we also repeated the analyses stratified for BMI (in 
tertiles), gender, renal function (increments of 10 mL/min), diabetes mellitus status (yes/no), 
and with and without outliers of copeptin concentration (copeptin >21.8 pmol/L for women, 
n=30 and copeptin>39.5 pmol/L for men, n=21). To investigate possible survivor bias, we 
added year of transplantation as an interaction term in the multivariate analysis and performed 
a sub analysis in patients who were between 1 and 3 years after donation (n=143). Our primary 
outcome variable is the difference between initial eGFR and last recorded eGFR. We also repea-
ted our analyses using slopes through the four eGFR values over time that are available in our 
database (baseline, and at 2.4, 2.8, and 3.1 years after baseline). 
Figure 1: Physiologic regulation of vasopressin: 
Mean (± SE) effective plasma osmolarity per gender-
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To investigate whether the effects of VP are consistent with normal physiology, we tested the 
associations between copeptin and 24-hr urinary volume, urinary sodium concentration and 
fractional urea excretion. A high concentration of copeptin was found to be associated with 
a low 24-hr urinary volume (R=-0.22, P =0.001), low fractional urea excretion(R= -0.28, 
P=0.001), and a high urine (sodium) concentration (R=0.33, P=0.001). Figure 2 visualizes 
these associations.
Table 1. Patient characteristics at baseline 
N = 548. Parametric variables are expressed as mean ± SD, whereas non-parametric variables are given as median 
(interquartile range).  Abbreviations are: BMI, body mass index; ACEi, angiotensin converting enzyme inhibitors; 
ARB, angiotensin II receptor blockers; ntx, kidney transplantation;  NT pro BNP, N-Terminal pro Brain Natriuretic 
Peptide; eGFR, estimated Glomerular Filtration Rate.
 
Variable Value 
Age (years) 52 ±12 
Male gender n (%) 296 (54) 
Prior history of cardiovascular disease n (%) 68 (12) 
Current Smoking n (%) 117 (21) 
BMI (kg/m2)  26.2 ± 4.3 
Mean arterial pressure recipient (mm Hg) 111 ± 13 
Blood pressure lowering drugs  
  - Diuretics n (%) 238 (43) 
  - ACEi / ARB n (%)  186 (34) 
Diabetes at baseline n (%) 111 (20) 
Time from ntx until baseline (years) 6.0 (2.7-11.6) 
Time on dialysis prior to ntx (months) 27 (14-48) 
Living related donation n (%) 49 (9) 
Donor age (years) 37 ± 16 
Immunosuppressive regimen  
 - Calcineurin inhibitor (tacrolimus/ciclosporin) n (%) 433 (79) 
 - Proliferation Inhibitor (azathioprine / MMF) n (%)  406 (74) 
- Prednisolone n (%) 548 (100) 
Anti-donor antibody status  
- Negative, class I n (%) / class II n (%) 480 (88) / 481 (88) 
- Borderline, class I n (%) / class II n (%) 20 (4) / 11 (2) 
- Positive, class I n (%) / class II n (%) 48 (9) / 56 (10) 
Serum potassium (mmol/l) 4.5 ± 0.5 
Serum sodium (mmol/l) 139 ± 3 
Effective plasma osmolarity (mOsm/l) 283 ± 6 
Serum uric acid (mmol/l) 0.45 ± 0.12 
NT pro-BNP (pg/ml) 285 (129-622) 
Urinary volume (l/24h) 2.5 ± 0.8 
Sodium excretion (mmol/24h) 139 ± 62 
Urea excretion (mmol/24h) 381± 113 
Fractional urea excretion (%) 45 ± 11 
Proteinuria (g/24h) 0.2 (0.0-0.5) 
eGFR (ml/min/1,73m2) 47 ± 14 
Copeptin (pmol/l) 9.1 (5.0-18.5) 
Figure 2. Physiologic effects of vasopressin: Mean 
(± SE) 24h urinary volume, urinary sodium excre-
tion, and fractional urea excretion per gender-
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Because it has been hypothesized that VP is involved in causing hypertension,21 a regression ana-
lysis with mean arterial pressure as the dependent variable and log copeptin as the independent 
variable was performed. This association was not significant when analyzed univariate (P=0.22), 
or when corrected for the use of antihypertensive medication (P=0.33), or when corrected 
for use of such medication and age and gender (P=0.35). Of note, the results we obtained in 
the various sensitivity analyses were essentially similar to those from our primary analyses. No 
significant interaction was found between gender and baseline log copeptin in predicting change 
in renal function during follow-up, meaning that the association between baseline log copeptin 
and change in renal function is not different for men or women. Also no interaction was found 
between renal function at baseline and log copeptin in predicting renal function decline. When 
analyses were stratified for BMI (tertiles), gender, renal function (increments of 10 mL/min), 
or diabetes mellitus (yes vs. no), the main results were similar to those of our primary analysis. 
The same holds true when the analyses were repeated with and without outliers with respect 
to copeptin concentration, when a subgroup analysis was performed in patients only between 
1 and 3 years after donation (indicating that survivor bias does not play an important role), or 
when slope of renal function was used as the primary outcome.
Median (interquartile range) follow-up after baseline was 3.2 (2.7–3.7) years. Mean change 
in renal function over this period was -0.52 mL/min/1.73 m2 per year. During follow-up, a 
significant association was found between baseline log copeptin and change in renal function 
(R= -0.14, P=0.001). This inverse association indicates that a high log copeptin concentration 
at baseline was associated with more renal function decline during follow-up.
In Figure 3, mean change in renal function during follow-up is depicted per gender-stratified 
tertile of copeptin. Duration of follow-up was the same for the three tertiles; 3.2 (2.6 –3.6) 
years, 3.3 (2.9 –3.7) years, and 3.2 (2.7– 6.6) years, respectively (P=0.99). Mean change in 
renal function over time in tertiles 1, 2, and 3, respectively, was -0.03(±3.20), -0.44 (±3.01), 
and -1.06 (±3.00) mL/min/1.73 m2 per year. 
The association between baseline log copeptin and change in renal function during follow-up 
was also investigated using copeptin as a continuous variable in multivariate regression analyses. 
We adjusted this association in a multivariate model for several potential confounders. Results 
are listed in Table 2. The association was significant (with β=-1.2, P=0.001, Table 2, model 1). 
This indicates that an increase of logcopeptin with 1 unit, parallels with a renal function decline 
of 1.2 mL/min/yr). Adjusted for age and gender, the association remained significant. Further 
adjustment for baseline eGFR (model 3), for factors that might influence VP and thus copeptin 
concentration (model 4), and for factors influencing renal function decline (model 6) did not 
materially influence the association between log copeptin and change in renal function during 
follow-up. The r value for the association of log copeptin with renal function is -0.14. This is, in 
this population, at least comparable with other acknowledged factors of renal function decline, 
as for instance for the association between baseline mean arterial pressure and delta renal func-
tion, for baseline glucose, for age, and for baseline renal function. 
Figure 3. Mean (± SE) change in renal function accor-
ding to gender-stratified tertiles of copeptin
Table 2. Associations between baseline log copeptin concentration and change in renal function during follow-up.
A negative beta indicates that a high baseline copeptin concentration is associated with more renal function decline 
during follow-up.
model corrected for     !  P 
1 - (crude)    -1.2   0.001 
2 As 1 + age and gender    -1.2   0.001 
3 As 2 + baseline eGFR    -1.8 <0.001 
4 As 3 + BMI, plasma osmolarity, diabetes, use of diuretics and ACEi / 
ARB 
   -1.9 <0.001 
5 As 4 + NT pro BNP and CRP    -1.7 <0.001  
6 As 5 + time on dialysis before ntx, time from ntx until baseline, living 
related ntx, donor age, immunosuppressive medication, anti-donor 
antibody status, current smoking, MAP and proteinuria. 
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Because we wanted to investigate whether there are certain subgroups that are more suscep-
tible to copeptin’s influences, we investigated potential interactions between log copeptin on 
one hand and on the other gender, age, or baseline renal function. These interactions were not 
significant, suggesting that the association between log copeptin and rate of renal function loss 
during follow-up is essentially similar in men and women, in various age groups and indepen-
dent of renal function. The observation that a high concentration of copeptin is associated with 
accelerated renal function decline gives rise to the hypothesis that a high-VP concentration is 
related to rate of renal function decline in these patients.
Animal experiments indeed suggest that a high concentration of VP causes accelerated renal 
function decline. A chronic reduction in plasma VP concentration slowed the progression of 
renal failure in Sprague-Dawley rats with impaired renal function,6 whereas infusion of 1-Des-
amino 8-D-arginine Vasopressin (dDAVP) induced a rise in serum creatinine and in proteinuria 
in Brattleboro rats.7
Human studies on the association between VP concentration and rate of renal function decline 
are scarce. To our knowledge only one study indirectly addressed this issue. A retrospective 
analysis of the MDRD study showed that, in patients with chronic kidney disease, higher urinary 
volume and lower estimated urinary osmolarity were associated with faster eGFR decline.25 The 
authors offered two possible explanations for this relationship. The first is that excessive fluid 
intake may cause faster renal disease progression. This would be in contrast to our findings, be-
cause high fluid intake is probably associated with low concentration of VP. The other proposed 
possibility is that, instead of the cause, a high urinary volume with a low urinary osmolarity is 
the result of faster renal disease progression. This explanation might be more likely because one 
of the clinical manifestations of chronic renal failure is a defect in urinary concentrating abili-
ty.26 Unfortunately, VP (or copeptin) concentration is not determined in this study, and definite 
conclusions could, therefore, not be drawn.
The unfavorable renal effects of VP have been argued to be partly due to an effect on blood pres-
sure. VP may contribute to hypertension by a direct effect on vascular smooth muscle through 
activation of the V1a receptor27 or by V2 receptor-dependent tubular effects. The latter includes 
an enhancement of sodium reabsorption in the collecting duct,28 and an increase in intrarenal 
urea recycling that participates in the urine concentrating mechanism. The latter may indirectly 
modify NaCl concentration at the macula densa, thereby influencing tubuloglomerular feed-
back, leading to renin release, hypertension, glomerular hyperfiltration, proteinuria, and, if 
sustained, renal hypertrophy and tubulointerstitial disease.8;10
Discussion
In this study, we aimed to investigate the possible association between copeptin concentration at 
baseline and change in renal function during follow-up in a cohort of renal
transplant recipients. Regulation and action of copeptin in this study seemed to be consistent 
with normal physiology because we found, at baseline, a positive association between plasma os-
molarity and copeptin concentration, a negative association between copeptin and 24 hr urinary 
volume and fractional urea excretion, and a positive association between
copeptin and urinary sodium concentration.
With respect to our primary study question, we found that an elevated concentration of copep-
tin was associated with accelerated renal function decline in these renal transplant recipients. 
This association seemed to be independent of baseline eGFR, proteinuria, and of other known 
risk factors for renal function decline in renal transplant recipients. As far as we know, this is the 
first human study to investigate the association between VP concentration (measured as copep-
tin) and changes in renal function during follow-up. It confirms the results obtained so far in 
animal experiments. Furthermore, this study has been performed in a large number of subjects 
and had sufficient duration of follow-up (more than 3 years). 
This study found copeptin concentration in renal transplant recipients to be approximately 
twofold higher in men (median concentration 12.2 pmol/L) than in women (6.6 pmol/L), in 
agreement with previous reports,14;22 and consistent with a gender difference in plasma VP and 
in urinary osmolarity.23 This copeptin concentration is higher than the values of 5.2 and 3.7 
pmol/L, for men and women, respectively, that have been reported in healthy controls.14 In 
renal transplant patients, VP concentration is previously been described to be higher than in 
healthy controls.16 A reason for this difference could be that renal transplant recipients have 
lower renal function than healthy controls (mean eGFR in this study is 47±14 mL/min/1.73 
m2). Renal function has previously been described to be associated with copeptin concentra-
tion.22 The reason for this phenomenon is not known. It could be hypothesized that copeptin 
concentration is a consequence of less renal clearance because VP (and also copeptin) is cleared 
for about 25% by the kidneys.24 This hypothesis is, however, less likely because negative feedback 
mechanisms should reduce the rate of secretion of the hormone and bring it back to normal 
concentration (assumed that the effect on the target organ is not impaired). 
Because of the cross-sectional association between copeptin and renal function, renal function 
could be a confounder for the association between copeptin and change in renal function. There-
fore, we corrected for baseline eGFR in our multivariate regression analysis. After this adjust-
ment, copeptin remained significantly associated with the rate of renal function decline during 
follow-up (Table 2, model 3, etc.). Furthermore, we repeated multivariate analysis stratified for 
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In our study, however, no association was found between copeptin concentration and blood 
pressure, and the association between baseline copeptin and rate of renal function loss during 
follow-up was independent of blood pressure, indicating that a rise in blood pressure by VP is 
not likely in our patients and that other mechanisms of action may be important. Also, unidenti-
fied factors could contribute simultaneously to a rise in VP secretion and to an accelerated renal 
function decline. Examples of such factors could be inflammation and heart failure. The patholo-
gic condition of chronic transplant dysfunction probably includes inflammation.29 Several studies 
have shown that proinflammatory cytokines can activate VP secretion.30 Therefore, inflammation 
could induce both VP secretion and accelerated decline in renal function. Another factor could 
be cardiac failure, which might result in both high VP concentration31 and accelerated renal 
function decline. However, in the previously mentioned animal experiments where VP adminis-
tration led to renal function deterioration, and intervention with VP antagonists led to renop-
rotection, strongly suggest a causal role for VP and make the possibility of an underlying factor 
leading to both a rise in VP and accelerated renal function decline, less likely. Furthermore, the 
association between copeptin concentration and renal function decline also remained significant 
after adjustment for CRP and NT-proBNP (Table 2, model 5), markers of inflammation and 
severity of heart failure. Definite proof for a causal role of VP in inducing renal function decline 
should come from randomized intervention studies. At the moment, several selective (V1a or 
V2) and combined V1/V2 receptor antagonists are being developed for clinical use.32 Use of 
these drugs may provide a valuable tool to determine whether VP is related to renal function 
decline, and whether the V1a and/or the V2 receptor are involved.
The association between copeptin and renal function decline has an r value of -0.14. This rela-
tively low r value indicates that other factors also contribute to rate of renal function decline. 
We included several of the known risk factors for renal function decline in transplant recipients 
in our multivariate model (Table 2), for example, age, gender, baseline eGFR, diabetes, BMI, 
NT-proBNP (a surrogate for cardiac failure), CRP (a surrogate for subclinical infection), time 
on dialysis before ntx, time from ntx until baseline, living related ntx, donor age, immunosup-
pressive medication, antidonor antibody status, current smoking, MAP, and proteinuria, and the 
association between copeptin and renal function decline was still significant after adjustment for 
all these factors. Furthermore, it appeared that the r value of copeptin was one of the stron-
gest and that the association between well acknowledged renal risk factors (e.g. blood pressure 
and fasting glucose) and the rate of renal function decline is of approximately similar or lower 
strength (r value is of similar strength). 
We acknowledge that the present study has limitations. Because of the observational nature of 
our study, it is impossible to draw a definite conclusion about causality. We cannot exclude that 
other, yet unidentified factors, led to an elevated copeptin concentration and accelerated renal 
function decline. Furthermore, renal function is estimated using the MDRD formula, which is 
less precise than for instance iothalamate clearance, but more frequently used. 
Our creatinine measurement method (Jaffe´) is not calibrated against IDMS traceable standards. 
However, because we calculated changes in eGFR, instead of only one value (and for all eGFR 
values of a given subject the same correction factor would have to be used), we expect that this 
would minimally influence our results. We measured copeptin at the beginning of the study 
once, instead of as average of three measurements this will probably have led to an underesti-
mation of the effect size, given the widening of confidence intervals that would have occurred. 
Finally, the study population consisted of renal transplant recipients who were almost all of 
white ethnicity. Whether our results can be extrapolated to other populations, such as subjects 
with impaired renal function without transplantation or subjects of other ethnicity, is therefore 
unknown. 
In conclusion, copeptin (a surrogate marker of VP) is independently associated with rate of renal 
function decline during follow-up in renal transplant recipients. This finding suggests that VP 
may play a role in renal function decline. This alludes to the intriguing possibility that interventi-
ons leading to lower VP activity, as drinking more water or using the newly developed VP recep-
tor antagonists, may be beneficial for the prevention of renal function decline in these patients.
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Vasopressin and ADPKD severity
Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common renal heredita-
ry disease (caused in most cases by a mutation in the PKD1 or PKD2 gene1;2) with an incidence 
of 1 in 400 to 1,000 live births.3;4 The disease is characterized by progressive cyst formation in 
both kidneys, often leading to end stage renal disease. Current treatment is not able to inhibit 
cyst formation or to prevent renal failure.
Vasopressin, also known as antidiuretic hormone, is essential for regulation of water homeostasis 
and osmoregulation in the body. Its secretion is stimulated in response to an increase in plasma 
osmolarity or a decrease in blood volume. Vasopressin binds to the V2 receptors in the collecting 
duct, which induces the insertion of the molecular water channel aquaporin-2 in the luminal 
membrane of principal cells. This mediates water resorption, thereby reducing water excretion.5 
Despite its role for normal physiology, vasopressin has also been mentioned to be involved in 
pathophysiological processes, among others in ADPKD. Vasopressin promotes cAMP production 
by acting on vasopressin-2 receptors in the distal nephron and collecting ducts. Experimen-
tal studies have implicated a central role for 3-5-cyclic adenosine monophosphate (cAMP) in 
promoting cyst growth.6 cAMP stimulates cyst formation by promoting chloride-driven fluid 
secretion and by stimulating activation and proliferation of cyst-derived cells.7 In line with this 
potential detrimental role of vasopressin are the findings in animal models of  polycystic kidney 
disease, where blocking the effect of vasopressin (and consequently decreasing cAMP levels) by 
either a pharmacological agent8-10 or by drinking more water11 led to reduction of cyst formation 
and renal function preservation.  
So far, no studies have looked at the association between endogenous vasopressin levels and 
disease severity in subjects with ADPKD. The paucity of data on this issue may be caused by the 
fact that measurement of vasopressin is problematic. More than 90% of VP in the circulation is 
bound to platelets, VP is unstable in isolated plasma,12 and most VP assays have relatively limited 
sensitivity. Recently, an assay has been developed to measure copeptin, the C-terminal portion 
of the precursor of VP. Copeptin has been shown to be a reliable marker of VP secretion and a 
useful substitute for circulating VP concentration in clinical routine.13-15
Because of the potential detrimental role of vasopressin in the pathogenesis of ADPKD, we ai-
med to investigate whether endogenous copeptin levels (a surrogate marker of vasopressin) are 
associated with disease severity in subjects with ADPKD. As markers of disease severity we stu-
died glomerular filtration rate, effective renal blood flow, total renal volume and albuminuria. To 
investigate whether copeptin concentration is consistent with normal physiological regulation 
and has its normal physiologic effects, we also studied associations with plasma osmolarity, 24h 




One hundred and twenty consecutive patients with ADPKD visiting our out-patient clinic 
meeting our in- and exclusion criteria were asked to participate. Diagnosis of ADPKD was made 
upon Ravine criteria.16 Subjects were considered ineligible to participate if they received renal 
replacement therapy, had undergone renal surgery, were unable to undergo magnetic resonance 
Abstract
Experimental studies suggest a detrimental role for vasopressin in the pathogenesis of Autoso-
mal Dominant Polycystic Kidney Disease (ADPKD). It is, however, unknown whether endoge-
nous vasopressin concentration is associated with disease severity in patients with ADPKD.
We measured plasma copeptin concentration (a marker of endogenous vasopressin levels) in 102 
ADPKD patients (diagnosis based on Ravine criteria) by an immunoassay. Plasma- and urinary 
osmolarity were also measured. To assess disease severity, we measured glomerular filtration 
rate and effective renal blood flow by continuous infusion of 125I-Iothalamate and 131I-Hippu-
ran, total renal volume by MRI and 24h urinary albumin excretion by nephelometry. 
In these ADPKD patients (age 40±11y, 56% male, GFR 77±31 ml/min per 1.73 m2, total 
renal volume 1.5 (0.9-2.2)L), copeptin was associated with the various markers of disease 
severity in ADPKD (positively with total renal volume (R=0.47) and albuminuria (R=0.39) and 
negatively with glomerular filtration rate (R=-0.58) and effective renal blood flow (R=-0.52), 
all p<0.001). These associations were independent of age, gender and use of diuretics.  Copep-
tin was furthermore associated with plasma osmolarity (p<0.001), but not with 24h urinary vo-
lume, 24h urinary osmolarity or fractional urea excretion (p=0.7, p=0.9, p=0.3, respectively). 
On cross-sectional analysis, copeptin is associated with disease severity in ADPKD patients, sup-
porting the results of experimental studies that suggest that vasopressin antagonist have a renop-
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Direct 8.0 (AnalyzeDirect, Inc., Overland Park, KS) software.
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Parametric variables 
are expressed as mean ± standard deviation (SD), whereas non-parametric variables are given 
as median (interquartile range). A two sided p < 0.05 was considered to indicate statistical 
significance.
Regression analysis was performed to investigate whether plasma copeptin concentration was 
correlated with plasma osmolarity, physiologic variables and variables representing disease 
severity. In case of non-normal distribution, variables were log transformed, and R and p values 
are given. GFR and ERBF were normalized for body surface area. To visualize the associations, 
scatter plots (with males and females depicted separately) were made showing the associations 
between copeptin and plasma osmolarity and markers of disease severity (TRV, GFR, ERBF and 
albuminuria).
To further investigate whether plasma copeptin concentration was associated with markers of 
disease severity, multivariable regression analysis was performed. Logarithmic transformation 
of copeptin (and of urinary albumin excretion and total renal volume) was applied to fulfil the 
requirement of equal distribution of the residuals. Associations were investigated crude and after 
adjustment for age, gender, use of diuretics and GFR. 
Interactions between log copeptin concentration and age and gender were tested for GFR, 
ERBF, log total renal volume and log UAE as the dependent variables.
 
Results
Characteristics of participating 
patients are depicted in Table 1. A 
total of 102 patients (56% male, 
aged 40± 11 years) were analyzed. 
Median copeptin concentration for 
the whole group was 7.0 (3.1-
15.7) pmol/L. Median copeptin 
concentration was higher in men 
than in women (10.1 (4.7-19.8) vs. 
3.2 (2.4-8.3) pmol/L, p<0.001).
imaging (as having distorting foreign bodies or aneurysmal clips), had other systemic diseases 
potentially affecting renal function (as diabetes mellitus and malignancies), or had other medical 
conditions that included pregnancy, lactation, or who were less than 6 months postpartum. 
After screening, subjects underwent an extensive medical history. Subjects were scheduled for a 
1-day outpatient clinic evaluation. Thirteen patients refused to participate and two patients were 
not eligible. Three patients had a copeptin concentration more than 10 times the interquartile 
range above the third quartile, although their plasma osmolarity was within normal limits. These 
subjects were considered outliers17 and their data were not taken into consideration, leaving 102 
patients for analyses.
This study was performed in adherence to the declaration of Helsinki. All subjects gave written 
informed consent.
Measurements and definitions
Blood pressure was assessed with an automatic device (Dinamap) for 15 minutes during the 
renal function measurement. Systolic- and diastolic blood pressure values were used to calcu-
late mean arterial pressure (MAP) using the standard formula: 2/3 diastolic blood pressure + 
1/3 systolic blood pressure. Weight and height were determined. Body mass index (BMI) was 
calculated as weight in kilograms (kg) divided by height in square meters. Patients collected a 
24h urine sample prior to the outpatient visit. Urinary albumin concentration was determined 
by immuno nephelometry (BNII; Dade Behring Diagnostics, Marburg, Germany). Prior to renal 
function measurement, blood samples were drawn for determination of haemoglobin, sodium, 
creatinine, urea, plasma osmolarity and copeptin. Concentrations of haemoglobin, sodium and 
urea were measured using standard methods. Creatinine was measured with the Roche enzyma-
tic creatinine assay. Plasma- and urine osmolarity was measured using freezing point depression. 
Fractional urea excretion was calculated as FE Urea = ((urinary urea concentration / plasma 
urea concentration) / (urinary creatinine concentration / plasma creatinine concentration)) * 
100.  
Copeptin was measured using a new sandwich immunoassay (B.R.A.H.M.S. AG, Hennigsdorf / 
Berlin, Germany), which was based on the assay described previously13. The assay was modi-
fied as follows: the capture antibody was replaced by a murine monoclonal antibody directed 
to amino acids 137-144 of proAVP. This modification improved the sensitivity of the assay. The 
lower detection limit was 0.4 pmol/L and the functional assay sensitivity (20% interassay coef-
ficient of variation) was less than 1 pmol.18
Renal function measurements were performed using the constant infusion method with 125I-
Iothalamate to measure glomerular filtration rate (GFR) and with 131I-Hippuran to measure ef-
fective renal plasma flow (ERPF).19-22 Effective renal blood flow (ERBF) was calculated as ERPF 
/ (1-Hematocrit). Hematocrit was measured halfway during the renal function measurement.) 
Patients underwent a standardized abdominal magnetic resonance imaging protocol without the 
use of i.v. contrast.  Scanning was performed on a 1.5 Tesla MRI Magnetom Avento (Siemens, 
Erlangen, Germany) with the use of body matrix and spine matrix coils. Total renal volume 
(TRV) was measured on T2 weighted coronal images23 (slice-thickness 4.0 mm) using Analyze Table 1: Patient characteristics (n=102)
Variable  
Men, n (%) 57 (56) 
Age (y) 40 ± 11 
Body mass index (kg/m2) 26 ± 5 
Mean arterial pressure (mm Hg) 96 ± 10 
Use of antihypertensive medication, n (%) 79 (78) 
Use of diuretics, n (%) 23 (23) 
Haemoglobin (mmol/l) 8.3 ± 0.8 
Serum sodium (mmol/L) 140 ± 2 
Plasma osmolarity (mOsm/L) 290 ± 8 
Copeptin (pmol/L) 7.0 (3.1-15.7) 
Serum creatinine (µmol/L) 115 ± 70 
Serum urea (mmol/L) 8 ± 4 
24h urinary volume (L) 2.3 ± 0.8 
24h urinary osmolarity (mOsm/L) 425 ± 148 
24h urinary albumin excretion (mg/24h) 41 (15-122) 
Fractional urea excretion (%) 42 ± 10 
Glomerular filtration rate (ml/min/1.73 m2) 77 ± 31 
Effective renal blood flow (ml/min/1.73 m2) 421 ± 170 
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These associations remained significant after adjustment for age, gender and use of diuretics, 
and after adjustment of GFR (Table 3).  In Figure 2, these associations are shown. Copeptin was 
furthermore inversely associated with effective renal blood flow (overall R= -0.52, p<0.001, 
males R= -0.57, p<0.001, females R= -0.61, p<0.001) and with glomerular filtration rate 
(overall R= -0.58, p<0.001, males R= -0.58, p<0.001, females R= -0.61, p<0.001). These 
associations remained significant after adjustment for age, gender and use of diuretics (Table 
4). Correlation between effective renal blood flow and glomerular filtration rate was very high 
(R=0.94, p<0.001), therefore adjustment of the association between copeptin and ERBF for 
GFR was not possible.  Figure 2 shows the associations between copeptin and GFR and ERBF. 
That females have a lower ERBF than males is at least partly caused by the known gender dif-
ference in hematocrit (also found in these patients, Ht was 0.41±0.03 for males vs. 0.38±0.03 
for females, p<0.001) for estimated renal plasma flow is not different between males and fema-
les (253±106 vs. 256±97 ml/min per 1.73 m2 respectively, p=0.9).
Plasma copeptin concentration, as a surrogate of vasopressin, was significantly correlated with 
plasma osmolarity (figure 1, R=0.53, p<0.001). This correlation is not different for males 
when compared to females. No association was found between copeptin and urinary osmolarity 
(R= 0.01, p=0.9), copeptin and urinary volume (R= -0.04, p=0.7) or copeptin and fractional 
urea excretion (R= -0.10, p=0.3).
In general, the different markers of disease severity correlated well with each other. Correlation 
coefficients are depicted in Table 2. Looking into the association between copeptin and markers 
of disease severity, copeptin was positively associated with total renal volume (overall R=0.47, 
p<0.001, males R=0.47, p<0.001, females R=0.37, p=0.01) and 24h urinary albumin excre-
tion (overall R=0.39, p<0.001, males R=0.30, p=0.03, females R=0.29, p=0.07 for females).
Figure 2: Vasopressin in association with markers of disease severity in ADPKD (Males ▲ and  ▬ . Females o and 
- -). On the left: associations between copeptin and total renal volume (TRV, upper panel, overall: R=0.47, p<0.001, 
males: R=0.37, p=0.006, females: R=0.37, p=0.01) and 24h urinary albumin excretion (UAE, lower panel, overall: 
R=0.39, p<0.001, males: R=0.30, p=0.03, females: R=0.29, p=0.07). On the right: associations between log 
copeptin and effective renal blood flow (ERBF, upper panel, overall R=-0.52, p<0.001, males: R=-0.57, p<0.001, 
females: R=-0.61, p<0.001) and glomerular filtration rate (GFR, lower panel, overall R=-0.58, p<0.001, males: 
R=-0.58, p<0.001, females: R=-0.61, p<0.001).
Figure 1: Association between plasma osmolarity and copeptin (overall R=0.53, p<0.001. Males ▲ and  ▬ ,  
R=0.40, p=0.003, and females o and - -, R=0.46, p=0.002).
Table 2: Associations between the different markers of disease severity
Abbreviations are: GFR, glomerular filtration rate; BSA, body surface area; ERBF, effective renal blood flow; TRV, 
total renal volume; UAE, 24h urinary albumin excretion. Depicted values are Pearson correlation coefficients and 
p-values. Variables are log transformed in case of non-normal distribution (total renal volume, urinary albumin 
excretion).
 GFR ERBF TRV 
 R p-value R p-value R p-value 
ERBF 0.94 <0.001 - -   
TRV -0.42 <0.001 -0.30 0.002 - - 
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Discussion
In this study, we found that in ADPKD patients, plasma osmolarity was associated with copeptin 
concentration. Copeptin concentration however was not associated with 24h urinary volume, 
24h urinary osmolarity or fractional urea excretion. Most importantly, we found that copeptin 
levels were associated with disease severity; higher copeptin levels were associated with lower 
renal function, lower effective renal blood flow, larger kidneys and more albuminuria. These as-
sociations were the same for males and females, and independent of age, and use of diuretics.
The markers of disease severity that we studied are acknowledged in literature. Total renal 
volume is considered a good measure for disease severity because kidney enlargement results 
from the expansion of cysts in patients with ADPKD. Higher total renal volume is associated 
with a more rapid decrease in renal function.24;25 In a large number of animal studies, treatments 
that inhibited renal enlargement, also ameliorated renal function. 25 Renal blood flow is also an 
accepted measure of disease severity. A reduction of renal blood flow parallels the increase in 
total renal volume, and importantly, precedes GFR decline and predicts structural and functi-
onal disease progression.26 Several studies show that in ADPKD, albuminuria is associated with 
renal volume,27;28 mean arterial blood pressure, filtration fraction,28 renal growth and slope of 
glomerular filtration rate.29 In our study, the different markers for disease severity correlated 
reasonably well with each other.
Only two studies that we know of, both performed more than 10 years ago, measured vasopres-
sin in ADPKD patients. One study described that vasopressin was increased ADPKD patients,30 
the other that vasopressin was increased in hypertensive ADPKD patients compared to non-
hypertensive ADPKD patients and healthy controls.31 These studies did not look into potential 
physiologic regulation and effects of vasopressin. In normal physiology, vasopressin is secreted 
in response to an increase in plasma osmolarity. We found that also in these ADPKD patients 
plasma osmolarity was associated with copeptin (as reliable and stable surrogate of vasopressin). 
Vasopressin mediates urea recirculation and water reabsorption and is therefore under normal 
circumstances positively associated with urinary osmolarity and inversely with urinary volume 
and fractional urea excretion. In these ADPKD patients however, we did not find significant 
associations between copeptin and 24h urinary volume, 24h urinary osmolarity or fractional 
urea excretion. This is in contrast to what is described in healthy subjects32 and renal transplant 
recipients33 and suggests that ADPKD patients do not respond effectively to vasopressin.  In line 
with this assumption is the observation that ADPKD patients have an impaired urinary concen-
trating capacity, already present when GFR is still normal.34
We found that copeptin is associated with the various markers of disease severity in ADPKD.  
This association is consistent with the hypothesis that vasopressin is involved in disease progres-
sion in subjects with ADPKD. This hypothesis is supported by several experimental studies. 
Vasopressin, acting on V2 receptors, is described to increase cAMP in the distal nephron and 
collecting duct. This promotes chloride driven fluid secretion and, in polycystic kidney cells, 
stimulation of the B-RAF/MEK/extracellular signal-regulated pathway for mitogenesis and 
epithelial cell proliferation.35;36 In line, we found an association between plasma copeptin 
 
Of note, we found no interactions between age and log copeptin concentration, or gender and 
log copeptin concentration on any of the aforementioned markers for disease severity (GFR, 
ERBF, total renal volume and albuminuria). The lack of interaction between gender and copep-
tin concentration on these markers is also shown in figures 1 and 2, where the regression lines 
for males and females all have the same slopes.
Table 3: Associations between copeptin and total renal volume (TRV) and 24h urinary albumin excretion (UAE) as 
markers of disease severity in ADPKD.
Independent variable is log copeptin. Dependent variables are log total renal volume and log albuminuria. A positive 
standardized beta indicates that a high copeptin concentration is associated with a high TRV or UAE, respectively. 
Abbreviations are: TRV total renal volume; UAE 24h urinary albumin excretion.
Model Adjusted for TRV UAE 
  Standardized  ! p-value Standardized  ! p-value 
1 crude 0.47 <0.001 0.39 <0.001 
2 As 1 + age and gender 0.34 0.001 0.42 <0.001 
3 As 2+ use of diuretics 0.33 0.001 0.44 <0.001 
4 As 2 + GFR 0.23 0.05 0.26 0.04 
 
Table 4: Associations between copeptin and glomerular filtration rate (GFR) and effective renal blood flow (ERBF) 
as markers of disease severity in ADPKD.
Independent variable is log copeptin. Dependent variables are GFR and ERBF (both in ml/min per 1.73 m2). A nega-
tive standardized beta indicates that a high copeptin concentration is associated with a low GFR or ERBF.
Abbreviations are: GFR, glomerular filtration rate; BSA, body surface area; ERBF, effective renal blood flow.
Model Adjusted for GFR ERBF 
  Standardized ! p-value Standardized ! p-value 
1 crude -0.58 <0.001 -0.52 <0.001 
2 As 1 + age and gender -0.55 <0.001 -0.55 <0.001 
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allowed to use their own medication, including diuretics. These drugs may influence plasma os-
molarity and consequently copeptin concentration. However, adjustment for diuretic use in our 
multivariate models did not change our results. Third, we did not perform a water deprivation 
test, so are unable to draw firm conclusions whether ADPKD patients indeed do not respond 
effectively to vasopressin and have an impaired urinary concentrating capacity.
Strengths of our study are that, as far as we know, this is the first clinical study looking into 
the association between endogenous vasopressin and disease severity in ADPKD. It provides a 
rationale for the intervention studies with vasopressin receptor antagonists that are being con-
ducted at this moment in subjects with this disease. Furthermore, we measured various indices 
of disease severity in ADPKD patients using the gold standards, being clearance of iothalamate 
for glomerular filtration rate, clearance of hippuran for effective renal blood flow, MRI for total 
renal volume and 24hr urinary excretion of albumin for albuminuria. 
What may be the consequences of our findings? First, they may help shed light on the pathop-
hysiology of ADPKD. Second, there may be clinical implications. At the moment, a large scale 
randomized clinical trial is being conducted to investigate efficacy of a vasopressin-2 receptor 
antagonist in ADPKD (TEMPO ¾ study, NCT00428948). This study is performed in patients 
with still relatively well preserved renal function (eGFR at baseline >60 mL/min), but large re-
nal volume (total renal volume >750 ml). Our finding that patients with more severe ADPKD, 
as assessed by lower GFR, higher total renal volume and/or higher albuminuria, have higher 
copeptin levels suggests that patients with these characteristics may need higher dosages of a va-
sopressin receptor antagonist to effectively block the hormonal activity of the higher vasopressin 
levels. Although not studied yet, it is expected that tolvaptan treatment increases copeptin levels 
by feed-back mechanisms and that the increase in copeptin with tolvaptan will reflect adequacy 
of vasopressin suppression. If so, it is tempting to hypothesize that in patients with ADPKD 
the increase in copeptin due to tolvaptan could be used as a short-term marker for long-term 
therapy effectiveness of this drug with respect to renoprotection and that the level of copeptin 
could be used to determine the effective treatment dose of this drug .
In conclusion, our study shows that in ADPKD, copeptin, a surrogate for vasopressin, is as-
sociated with disease severity. This finding supports the results of animal models for ADPKD, 
in which vasopressin-2 antagonists resulted in renoprotection and offers a good prospect for 
clinical intervention studies that are currently being conducted with these agents.
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concentration and urinary cAMP excretion. Furthermore, a vasopressin V2 receptor antagonist 
inhibited cyst formation in models for ADPKD.8;9 Moreover, genetic elimination of AVP in a rat 
model of ADPKD yielded animals born with normal kidneys that remained relative free of cysts 
unless an exogenous vasopressin V2 receptor agonist was administered.37 We found copeptin 
to be higher in males than in females which is also consistent with the hypothesis that copeptin 
is involved in disease progression, for it is known that male gender is a risk factor for disease 
progression in ADPKD.38-40
Also in other renal conditions than ADPKD, vasopressin is thought to have a potential detrimen-
tal role. In non-ADPKD animal models, sustained vasopressin V2 receptor stimulation results 
in hyperfiltration,41 which may have deleterious consequences, in particular in diseased kidneys, 
resulting in renal hypertrophy,42 proteinuria,43 and accelerated renal function decline.44-46 In 
contrast, in rats with chronic renal failure, increased water intake (resulting in lower vasopressin 
concentration) or chronic infusion of a vasopressin V2-receptor antagonist reduced proteinuria 
and prevented glomerulosclerosis44;47 and tubulo-interstitial fibrosis.48 In humans, we have des-
cribed previously that higher copeptin levels are associated with micro albuminuria in a popula-
tion based cohort32 and that higher copeptin levels at baseline predict renal function decline in 
renal transplant recipients.33  
In our ADPKD patients, but also in non-ADPKD subjects,32;49 copeptin concentration was found 
to be associated with renal function. The fact that copeptin is partly cleared by the kidney50 is not 
likely to be an explanation for higher copeptin concentrations in subjects with lower GFR, be-
cause increased copeptin levels, would induce lowering of plasma osmolarity, which would lead 
to a reduced copeptin concentration. These mechanisms are difficult to dissect in a cross-secti-
onal study. Alternatively, in subjects with lower GFR, the medullary urea gradient will be im-
paired due to loss of functioning nephrons and interstitial fibrosis. Subjects with impaired GFR 
have therefore lower urinary osmolarity and higher urinary volume than subjects with normal 
renal function51;52 Consequently, fluid reabsorption will be more difficult and higher vasopressin 
levels will be necessary to maintain fluid balance. Furthermore, patients with ADPKD have an 
additional anatomical disruption of the medullary architecture induced by cyst formation, which 
will also diminish urinary concentrating capacity. Indeed, in a study including 177 ADPKD 
patients the observed renal concentrating defect paralleled the severity of anatomical changes 
caused by renal cysts.34 Thus, according to this hypothesis, genetically determined progressive 
cyst formation will lead to higher vasopressin concentration. At the same time these higher va-
sopressin levels will lead to disease progression, as reasoned in the aforementioned paragraphs. 
These two processes are therefore expected to induce a vicious circle in ADPKD, predisposing 
to cyst growth, distortion of renal anatomy and renal function decline. This hypothesis may form 
an explanation why in subjects with ADPKD GFR remains relatively stable for a long period, 
while cyst formation progresses, then entering a phase with accelerated GFR decline.25;53
We acknowledge that this study has limitations. First, the cross-sectional observational design 
and the lack of data in non-cystic chronic kidney disease do not allow firm conclusions on the 
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Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common renal heredi-
tary disease (caused in most cases by a mutation in the PKD1 or PKD2 gene1;2) . The disease is 
a systemic disorder characterised by progressive cyst formation in both kidneys, with progres-
sive renal enlargement often leading to end stage renal disease. Other renal symptoms include 
pain, hypertension, gross haematuria, nephrolithiasis and mild albuminuria. Current therapies 
are directed towards limiting morbidity and mortality from complications of ADPKD,3 but not 
specifically targeting the inhibition of cyst formation. 
Although renal failure is the most feared consequence of the disease, measurement of glomeru-
lar filtration rate (GFR) is a poor marker of disease severity and progression in early phases of 
the disease. GFR remains intact during a prolonged period (typically decades) through compen-
satory hyperfiltration, but ultimately declines sharply thereafter. Gradual anatomical distortion, 
however, likely parallels the actual loss of functioning glomeruli.4 The Consortium for Radio-
logic Imaging Studies of Polycystic kidney disease (CRISP) showed that total kidney volume at 
entry into the study predicted future renal function deterioration.5 Therefore, in early ADPKD, 
total kidney volume (TKV) is likely to be a more sensitive marker of disease progression than 
kidney function.
Improved knowledge of genetic, molecular, and cellular mechanisms underlying cyst formation 
in ADPKD has resulted in the discovery of potentially effective therapeutic targets.6 Vasopressin, 
acting on Vasopressin 2 (V2) receptors, increases intracellular cAMP in distal nephron seg-
ments including the collecting ducts, promoting chloride driven fluid secretion apically. Cyclic 
AMP also stimulates B-RAF/MEK/extracellular signal-regulated signalling, mitogenesis and 
proliferation of polycystic kidney epithelial cells or of wild-type kidney epithelial cells under 
experimental conditions of calcium deprivation.7;8 Localization of the V2 receptors in the distal 
nephron and collecting duct,9 corresponds to the main site of cystogenesis in Autosomal Reces-
sive Polycystic Kidney Disease (ARPKD) and arguably in ADPKD,10 and increased circulating 
levels of vasopressin in animal models11;12 and in patients with ADPKD13;14 provided the rationale 
for experimental studies with vasopressin V2 receptor antagonists. The vasopressin V2 receptor 
antagonist OPC-31260 indeed inhibited cyst formation in animal models for ARPKD, nephro-
nophthisis 11 and ADPKD.12 Tolvaptan, another vasopressin V2 receptor antagonist, with high 
potency and selectivity for human vasopressin V2 receptor, proved effective in a rat model for 
ARPKD.15 Moreover, genetic elimination of arginine vasopressin (AVP) in this model yielded 
animals born with normal kidneys that remained relative free of cysts unless an exogenous V2R 
agonist was administered.16
Because tolvaptan (Samsca®) induces free water clearance, it is approved by the US Food 
and Drug Administration (FDA) for “the treatment of clinically significant hypervolemic and 
euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is 
symptomatic and has resisted correction with fluid restriction), including patients with heart 
failure, cirrhosis, and the Syndrome of Inappropriate Antidiuretic Hormone (SIADH)” with 
“Important limitations: Patient requiring intervention to raise serum sodium urgently to prevent 
or to treat serious neurological symptoms should not be treated with SAMSCA” and “It has not 
been established that raising serum sodium with SAMSCA provides a symptomatic benefit to 
Abstract
Current clinical management of ADPKD is mainly focused on managing complications of the 
disease, not on therapeutic targeting of cyst development or prevention of renal failure. Re-
cently, tolvaptan, a selective vasopressin V2 receptor antagonist, was proven to inhibit renal cyst 
growth and preserve renal function in animal models of polycystic kidney disease. The TEMPO 
¾ study is the first phase 3 clinical trial to examine the long-term effectiveness and safety of 
tolvaptan in patients with ADPKD.
This multicenter, double-blind, placebo controlled trial includes patients with ADPKD who 
have a relatively preserved renal function (baseline eCrCl ≥ 60 mL/min) and are anticipated to 
have progressive renal disease (age ≤50 years and total kidney volume (TKV) measured with 
MRI ≥750 mL). Primary outcome is rate of TKV percent change from baseline for tolvaptan 
relative to placebo. Secondary outcome parameters include time to multiple ADPKD progres-
sion events, among others time to a 33% increase in serum creatinine.
From March 2007 through January 2009, 1445 ADPKD subjects were enrolled. Preliminary 
baseline median TKV was 1.46 L and eCrCl was 105 ± 34 mL/min. A pre-specified, blinded, 
sample size re-calculation at 2/3 enrollment confirmed the likely power of the study to detect 
20% differences from placebo in the primary and key secondary endpoints at p<0.05.
Results from this randomized clinical trial will show whether treatment with a vasopressin 2 
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patients”  The European Medicines Agency (EMA) has also approved the drug for “Treatment 
of adult patients with hyponatremia secondary to the syndrome of inappropriate antidiuretic 
hormone secretion.” These approvals were based on studies of efficacy and safety in hyponatre-
mia17 and safety in patients with congestive heart failure, with or without hyponatraemia.18;19  
Phase 2 studies  in ADPKD patients showed that split-dose administration of tolvaptan was more 
effective than a single dose in achieving sustained suppression of vasopressin action, as evidenced 
by a 24 hour urine osmolality reduced below 300 mOsm/L.20 A phase 2 open-label trial in 46 
and 17 ADPKD patients investigating the long-term safety, tolerability and efficacy of split-dose 
regimens has completed 3 years of treatment and is ongoing in the US21 and Japan22 respectively. 
Based on promising results in animal models and early clinical studies with respect to efficacy 
and safety, we have designed and initiated the first large clinical trial to examine the effective-
ness (rate of TKV change and time to multiple ADPKD progression events) of a selective vaso-
pressin V2 receptor antagonist (tolvaptan) in young patients at relatively early stages of ADPKD.
Materials and Methods
Study population
ADPKD patients (diagnosis based upon Ravine criteria23) between 18 and 50 years were eligible 
for study-participation. Patients furthermore had an estimated creatinine clearance by the 
Cockcroft-Gault equation24 (eCrCl) above 60 mL/min and a measured TKV (sum of right and 
left kidney volumes) by magnetic resonance imaging (MRI) larger than 750 mL. Detailed study 
inclusion and exclusion criteria are presented in Table 1. 
Study design and setting
The TEMPO ¾ study was designed as a multi-center, double-blind, placebo-controlled, 
parallel-arm trial in subjects with ADPKD. Subjects were enrolled worldwide (North and South 
America, Europe, Japan, Russia and Australia). After determining eligibility (Table 1), patients 
were randomized with stratification to one of the two treatment groups (2:1 ratio, tolvaptan: 
placebo). Stratification factors include baseline hypertension (present or absent), eCrCl (≥ 80 
mL/min or <80 mL/min), and TKV (≥1000 mL or <1000 mL).) Hypertension is defined as 
a systolic blood pressure >139 and/ or diastolic blood pressure >89 mm Hg or use of anti-
hypertensive treatment. 
Figure 1 schematically represents the trial design. Three split-dose regimens of tolvaptan and 
matching placebo are tested: low (45/15 mg), medium (60/30 mg) and high (90/30 mg). 
Subjects begin treatment with the lowest dose and after each 1-week safety assessment, are ti-
trated to the next higher dose treatment group, until a level of intolerability or the highest dose 
of treatment is reached. After the titration phase, participating subjects remain on the highest 
tolerable dose until 36 months of treatment is completed. Patients are evaluated every 4 months 
during treatment and twice for 2-6 weeks after treatment concludes. 
Figure 1: schematic trial design of the TEMPO ¾ study
Table 1: Eligibility criteria of the TEMPO ¾ study
Inclusion Criteria: 
• Adult subjects providing informed consent  
[Defined as men or women !18 years and ! regional legal age of maturity to 
age 50 years.] 
• Adult subjects with a diagnosis of ADPKD  
• Willingness to comply with reproductive precautions 
Women who are capable of becoming pregnant must be willing to comply with 
approved birth control from two-weeks prior to, and for 60 days after taking 
investigational product.  
• Estmated creatinine clearance (eCrCl) !60 mL/ min within -31 days of 
randomization  
[Established using Cockcroft Gault.33] 
• Rapid estimated rate of kidney volume increase based on total kidney volume 
!750 mL by MRI at randomization 




• Subjects who, in the opinion of the study investigator or sponsor may present 
a safety risk  
• Subjects who are unlikely to adequately comply with the trial’s procedures 
[Due to medical conditions likely to require an extended interruption or 
discontinuation, history of substance abuse or non-compliance) 
• Subjects having contraindications to, or interference with MRI assessments 
• Subjects taking medications or having concomitant illnesses likely to 
confound endpoint assessments  
• Subjects taking other experimental (i.e., non marketed) therapies, or taking 
approved therapies for the purpose of affecting ADPKD cysts, or those taking 





Rationale and design of the TEMPO ¾ study
Trial treatments
Tolvaptan or placebo tablets are given orally, twice daily for three years. Dosing occurs on 
waking and approximately 9 hours later, irrespective of meals. Exact timing is adjusted based on 
wake/sleep habits. However, dosing times are consistent for each individual’s daily dose to avoid 
breakthrough. After titration to tolerability, the maintenance phase starts, during which subjects 
may down-titrate at any time. Subjects unable to tolerate the lowest dose are discontinued from 
investigational product use, yet are asked to continue participation in study exploratory ADPKD 
outcomes assessment (Table 2) in the trial. Subject compliance is monitored by pill counts as 
drug is returned. Non-compliant subjects (defined as discontinuation of investigational product 
for 30 consecutive days or >30% missed dosages intended for a period, without investigator and 
medical monitor approval) are deemed non-compliant and withdrawn from the trial.
Safety of subjects and optimal testing of tolvaptan efficacy requires standardization of back-
ground clinical care. Therefore, this trial includes a requirement for antihypertensive therapy in 
subjects with hypertension (SBP > 139 mm Hg and/or DBP > 89 mm Hg). Since deterioration 
of renal function in ADPKD is likely to be accelerated by hypertension, treatment is also re-
quired (unless otherwise contraindicated) in subjects with reproducible systolic blood pressure 
of 130-139 mm Hg and / or a diastolic blood pressure of 85-89. The protocol recommends 
first-line use of an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor 
blocker (ARB). Chronic use of diuretics is not allowed as they may impact certain assessments 
(as urine sodium or osmolality). In addition, recommendation for dietary restrictions (such as 
restrictions for salt, protein and caffeine) is left to the discretion of the principle investigator 
and therefore site specific. Additional site-specific or region-specific additions to the visit sche-
dule have been allowed where requested by local regulatory authorities or ethics committees.
Subjects are given standard fluid ingestion recommendations, to help avoid dehydration and 
reflex vasopressin increases. They are asked to drink enough water to prevent thirst throughout 
the daytime period and an additional 1-2 cups of water before bedtime. During the titration 
phase, subjects were asked to self monitor changes in body weight, reporting changes of greater 
than 3% in body weight over any 7-day period to the trial physician.
Primary outcome
The primary outcome of the TEMPO ¾ trial is to determine the effect of tolvaptan on TKV in 
ADPKD. Primary efficacy endpoint is the rate of TKV change (normalized as percentage) for 
tolvaptan (combining all doses) relative to placebo.
Secondary outcomes
Secondary outcomes involve a composite secondary efficacy endpoint and non-composite secon-
dary efficacy endpoints. Additional safety, pharmacokinetic-, pharmacodynamic and exploratory 
endpoints have been formulated.
The composite secondary efficacy endpoint is the time to multiple investigator-reported ADP-
KD clinical progression events (changes in blood pressure category, or the onset or worsening 
of hypertension requiring adjustment to hypertensive treatment), severe renal pain (requiring 
medical intervention), worsening albuminuria (by category), worsening renal function (33% 
Table 2: Primary and secondary endpoints of the TEMPO ¾ study
Primary outcome endpoint: 
Primary efficacy endpoint:  
Rate of total renal volume change (normalized as percentage) for tolvaptan (combining all doses) 
relative to placebo. 
 
Secondary outcome endpoints: 
Composite secondary efficacy endpoint:  
Time to investigator-reported multiple ADPKD clinical progression events (i.e. onset or progression of 
hypertension (need for hypertensive treatment), severe renal pain (requiring medical intervention), 
worsening albuminuria (by category), worsening renal function (25% change in reciprocal serum 
creatinine) for tolvaptan (combining all doses) relative to placebo while on treatment.  
Non-composite secondary efficacy endpoints: 
For tolvaptan compared to placebo: 
1. Rate of eGFR change from post-dose baseline (end of titration) to last on-drug trial visit (using 
1/serum creatinine as primary measure). 
2. For subjects who are non-hypertensive at baseline, change from baseline for resting mean 
arterial pressure at scheduled clinic visits up to point of exposure to anti-hypertensive therapy 
for any reason  
3. Change from baseline in kidney pain as assessed by 0-10 pain scale as average area under the 
concentration-time curve between baseline and last trial visit or last visit prior to initiating 
medical or surgical therapy for pain. 
4. For subjects who are non-hypertensive at baseline, time to progress to any of: 
a) high-pre-hypertension (SBP >129 and/or DBP >84 mm Hg) 
b) hypertension (SBP>139 and/or DBP > 89 mm Hg) 
c) requiring anti-hypertensive therapy 
5. For subjects who are taking anti-hypertensive therapy at baseline, percentage with clinically 
sustained decreases of blood pressure leading to a sustained reduction in antihypertensive 
therapy compared to baseline (while taking investigational product) at visits months 12, 24 and 
36. 
Safety endpoints: 
Safety endpoints to be analyzed will include a descriptive summary of: 
1. Reported adverse events 
2. Vital signs 
3. Clinical laboratory tests 
4. ECG data 
Pharmacokinetic endpoint: 
1. Determination of tolvaptan and metabolite plasma concentrations  
Pharmacodynamic endpoints: 
For tolvaptan compared to placebo: 
1. For urine, through spot osmolality and MCP1/creatinine ratios 
2. For blood, cystatin C and BUN concentrations 
Exploratory endpoint: 
1. Fasting urine osmolality (at randomization and follow-up visit #2 only) 
2. ADPKD outcomes and medical resource utilization. Analysis of additional events attributed to 
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MRI for determination of kidney volume
Patients undergo a standardized abdominal MRI protocol without use of intravenous contrast, at 
baseline, month 12, 24 and 36. In case of early termination, MRI is obtained when the last MRI 
was more than 6 months ago. MRI acquisition protocol includes T2-weighted single-shot fast 
spin-echo (SSFSE/HASTE) images with fat saturation and three-dimensional spoiled gradient 
interpolated T1-weighted images without fat saturation. At some sites, T2/T1 weighted fast 
imaging (true FISP/FIESTA) series are added to improve the delineation of kidney borders. All 
MR images are acquired in the coronal plane at 4 mm slice thickness covering the entire kidneys 
during breath-hold(s). 
MRI images are sent to the central reading facility for quality control and measurement of renal 
volume using T1 and T2 weighted MR images as defined in a study specific imaging charter. 
Alice™ software (Perceptive Informatics) is used to measure TKV by calculating the volume of 
serial renal outlines which have been verified by independent radiologists familiar with ADPKD. 
To maintain objectivity in the evaluations, the radiology reviewers will be blinded to patient 
name and sequence of acquisition. Any investigator site identifiers, assessments, and determina-
tions will also be masked. 
increase in serum creatinine) for tolvaptan (combining all doses) relative to placebo while on 
treatment. A detailed description of those secondary endpoints is depicted in Table 2. An inde-
pendent clinical events committee will adjudicate events contributing to the secondary compo-
site endpoint for sensitivity analysis. 
Data collection
Data as outlined in Table 3 is obtained. Patients are seen every 4 months. During each visit, 
medical history, concomitant medication, adverse events and tolerability are assessed. Blood is 
drawn and a spot urine sample is obtained to assess safety endpoints. In addition, a pregnancy 
test is performed (for women with childbearing potential). Subjects return used packages and 
receive new blinded study drug. Subjects are asked about investigational product tolerability and 
pain attributed to their kidneys (on a 0-10 scale).
Annually, a renal magnetic resonance imaging (MRI), using standardized procedures (see below) 
is obtained. An electrocardiogram (ECG) is performed at the beginning (baseline and end of 
titration) and end of the study (month 36 or early termination and second follow up visit). All 
blood and urine chemistry, ECG and MRI endpoint data are analyzed and read centrally. Data 
on PKD outcome assessments are collected through use of standardized case report forms 
and entered into a central database. Monitoring and auditing of the participating centers takes 
place to ensure data are correctly obtained. After 36 months (or an early termination visit), 
two follow-up visits are planned, one after 7-21 days and one 7-21 days after the previous visit. 
These visits are performed to assess potential persistence or rebound of effects as well as safety 
of the subjects upon study treatment withdrawal. 
Table 3: Ongoing data collection of the TEMPO ¾ study
Abbreviations are: MRI, magnetic resonance imaging; ADPKD, autosomal dominant polycystic kidney disease; ECG, 
electrocardiogram; M, month; ET, early termination; FU, follow up.
* for all other visits, a directed exam should be conducted at the investigators discretion if deemed necessary to assess 
changes in medical history, adverse events or other medically indicated parameters.
Assessment Number of times 
performed 
Visit 
• MRI 4 Baseline, M12, 24, 36/ET 
• ADPKD outcomes: composite endpoint 
components, in-clinic blood pressure, 
serum creatinine, albumin, renal pain 
score, origin of renal pain via exam or 
history, review of disease burden and 
health care utilization attributable to 
ADPKD 
12 All visits 
• Tolerability 12 All visits 
• Pharmacokinetics (determination of 
tolvaptan and metabolite (DM-4103 and 
DM-4107) plasma concentrations 
5 Baseline, week 3, M12,24, 
36/ET 
• Lab (hematology, serum chemistry, 
urinalysis and urine pregnancy)  
12 All visits 
• Physical exam 2* Baseline and M36/ET* 
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All subjects have the right to withdraw from the study at any time during the trial. Safety of trial 
subjects is monitored by an unblinded independent data monitoring committee (IDMC).
Study Organization
The design and conduct of the study are overseen by a Steering Committee.  An independent 
data monitoring committee (IDMC) has been established to monitor the safety and efficacy of 
the trial.  The IDMC is managed by an independent statistical data analysis center.  A Clinical 
Events Committee (CEC) was formed to independently adjudicate events contributing to the 
secondary composite endpoint for inclusion in a sensitivity analysis.  All study committees are 
guided by charters defining their roles and responsibilities and methods specific to the commit-
tee. 
Results
This study has been submitted to clinicaltrials.gov. Identifier of this trial is NCT00428948. 
Included are 1445 adult men and women (aged 18-50 years) in a relative early stage of ADPKD. 
Subjects were screened and enrolled at 132 sites worldwide; 38 sites in the Americas, 56 sites in 
Europe, 30 in Japan and 8 sites in Australia. Recruitment started in January 2007 and closed in 
January 2009. The final patient is expected to complete the trial in February 2012.
Preliminary baseline characteristics of the study population are described in Table 4 for the 
group as a whole and for women and men separately. These preliminary data approximate the 
final results for the study, but are still in the process of quality-control auditing. In total, 1445 
subjects are randomized in the TEMPO ¾ study (52% men, aged 39±7 years). Median TKV is 
almost 1.5 L, approximately twice the minimum TKV needed to meet the inclusion criteria. 
Estimated kidney function is on average relatively well preserved at baseline (eCrCl 105 mL/
min), with approximately 30% of subjects having an eCrCl between 60 and 80 mL/min. More 
then 75% of the subjects use at least 1 antihypertensive drug to control their blood pressure. 
Median urinary albumin/creatinine ratio is 3 mg/mmol for the whole group, over 50% subjects 
having micro-albuminuria (cut-off values defined as 2.8-28 mg/mmol for women and 2.0-20 
mg/mmol for men) and 5% having overt proteinuria (>28 or 20 mg/mmol, respectively). 
Medication interfering with the renin-angiotensin-aldosterone system is used by nearly half of 
the subjects. The percentage of men treated with antihypertensive drugs is slightly higher than 
in women. Men furthermore have larger kidneys and a significantly higher eCrCl (all p<0.001), 
although the eGFR (MDRD) is approximately the same, which is explained by a higher body 
surface area for men. 
Estimation of power and sample size
In a large cohort of ADPKD patients, mean annual total kidney volume growth rate was ap-
proximately 5%5. Growth rate in the TEMPO ¾ study is expected to be higher since only 
subjects with large kidneys (baseline TKV ≥750 mL) are included. Assuming an average untre-
ated growth rate of 7%, an average 20% reduction in growth rate deemed clinically significant, 
85% power to detect this difference and a two-sided alpha of 0.045, then approximately 504 
subjects (split 2 tolvaptan : 1 placebo) are needed. This sample size calculation uses the sample 
size formula for longitudinal trial provided by J. Lefante25 and assumes (in 10 log scale) the total 
noise standard deviation and the standard deviation of the slope across subjects to be 0.017 and 
0.0184, respectively. Taking into consideration a possible 20% withdrawal rate for the trial, 
about 600 subjects need to be enrolled in the trial. By doubling this, an enrolment of 1,200-
1,500 subjects was targeted so the study is powered to provide a higher than usual degree of 
statistical significance for the primary endpoint and a reasonable ability to evaluate the secon-
dary composite endpoint. 
Statistical analyses
Analysis will take place after completion of the study. The analysis of the primary endpoint is to 
fit the log10 transformed TKV data to a linear mixed-effect Laird-Ware model, with a p-value 
derived by applying the ‘sandwich’ estimator of the covariance matrix to the Wald test of the 
treatment-time interaction of the model, using observed cases of all intent to treat subjects. 
In addition to the primary analysis provided above, mixed model repeated measures (MMRM) 
analysis will be applied to the repeated measures of change from baseline in TKV (based on lo-
garithm transformed data) as a sensitivity analysis. Mean difference of the two treatment groups 
at year 3 under the MMRM will be used to estimate the treatment effect at year 3. The MMRM 
includes stratification factors (hypertensive status, kidney volume status and creatinine clearance 
status at baseline and geographic region), visit, treatment, and treatment visit interaction as 
class variables and baseline TKV as covariate. Observed cases dataset will be used in this MMRM 
analysis.
Secondary composite efficacy will be analyzed using the Andersen-Gill approach of the exten-
ded Cox model for analysis of time to multiple events with p-value provided by the robust Wald 
test using ‘sandwich’ estimate for the covariance matrix26;27. No interim analysis will be perfor-
med for this study. The independent data monitoring committee will monitor the study safety as 
well as efficacy.
Ethical considerations
Institutional review boards / independent ethics committees approved the protocol and infor-
med consent forms (ICF) in all participating centers according to regional requirements. The 
trial is conducted according to the International Conference of Harmonization (ICH) Good 
Clinical Practice Guidelines and all other applicable regulatory requirements and adheres to the 
ethical principles that have their origin in the Declaration of Helsinki. Subject privacy is ensured 
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Discussion
The TEMPO ¾ study seeks to determine if tolvaptan inhibits TKV growth in patients with 
ADPKD and whether such changes might meaningfully impact the clinical course of the disease. 
The approach of study designers to achieving these goals followed these principles:
• The primary endpoint should focus on the established mechanism of action of   
 tolvaptan by studying its effects on the cystic expansion as measured by TKV.
• Treatment effects can most readily be measured in a population where cystic kidneys  
 are rapidly growing.
• Secondary endpoints will confirm the medical impact of these effects by measuring  
 meaningful consequences of the disease i.e., direct clinical outcomes.
• If renal structure and function correlate with clinical outcomes, an intervention should  
 begin while the kidney remains largely intact or early in disease.
• Outcomes must be expected to measurably worsen over a reasonable observation  
 period.
• Where endpoints are particularly clinically important and extraneous influences can be  
 measured or controlled; stratification and standardization across treatment groups can  
 help control confounders.
The primary endpoint of the trial is change in TKV. The Consortium for Renal Imaging Studies 
in Polycystic Kidney Disease showed that kidney enlargement results from the expansion of cys-
ts in patients with ADPKD. This growth is continuous and quantifiable (as shown by MRI) and 
is associated with decline of renal function. Higher rates of kidney enlargement are associated 
with a more rapid decrease in renal function.4;5 In a large number of animal studies, treatments 
that inhibited renal enlargement, also protected renal function.4 Furthermore, several studies 
show that the rate of increase of renal volume can reliably be measured.28-30 These data provide 
support for the assumption that a change in rate of renal volume growth is a valid endpoint to 
assess the efficacy of drugs in ameliorating rate of disease progression in ADPKD. Based on the 
principles outlined above, patients were selected if they had a relatively rapid course of disease, 
as evidenced by a large TKV with a relatively young age but with relatively preserved renal func-
tion. Nevertheless, as renal function is such an important clinical consideration, it is included 
both as a component of the composite secondary endpoint and as a separate endpoint defined as 
a rate of decline over time as compared to placebo/standard care. 
The subjects included in this study are ADPKD subjects with an age ≤ 50 years, an eCrCl ≥60 
mL/min and a TKV ≥ 750 mL. These criteria were formulated to include subjects at a relatively 
early stage of their disease, but with a high likelihood of disease progression. This was done for 
several reasons. First tolvaptan is believed likely to delay disease progression, not restore renal 
function. Second, given that ADPKD is a progressive condition, intervention as early in life as 
possible to delay or prevent long-term consequences (including renal failure) seems most ap-
propriate. Third, young patients with high TKV are likely to have a more difficult course than 
patients of the same age with smaller kidneys, since larger kidneys appear to be associated with 
hypertension, pain, haematuria, albuminuria, and renal function decline.5 Assessment of a treat-
ment effect on the secondary outcomes as defined in the TEMPO ¾ study will therefore
A blinded sample size re-estimation was pre-specified in the protocol to be conducted either 
after 1000 subjects had been enrolled or at least 200 subjects have completed their 12 month 
visit, which ever came first.  The blinded sample size re-estimation was conducted on Oct. 20, 
2008, when more than 1000 subjects had been enrolled.  The sample size re-estimation sugge-
sted that a sample size of 1400 subjects would be expected to provide at least 80% power to the 
key composite secondary endpoint of the study.
Table 4: Preliminary baseline characteristics of participating subjects in the TEMPO ¾ study
Values are depicted as mean± standard deviation or median (25th-75th percentile) in case of skewed distribution. 
Gross proteinuria is defined as an ACR>28 mg/mmol for women and >20 mg/mmol for men. Abbreviations are: 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ACR, albumin creatinine ratio; 
eCrCl estimated creatinine clearance. 
 All (n=1445) Women (n=699) Men (n=746) 
Age (yr) 39± 7.1 39±7.1 387.1 
Body mass index (kg/m2) 26±5.1 26±5.5 27±4.6 
Systolic blood pressure 126±14 126±13 131±14 
Diastolic blood pressure 82±10 81±9 84±10 
MAP (mm Hg) 98±11 96±10 99±11 
Subjects taking ! 1 antihypertensive, n (%) 1108 (77) 495 (71) 613 (82) 
Subjects taking ACEi and / or ARB, n(%) 696 (48) 313 (45) 383 (51) 
Total kidney volume (l) 1.46 (1.07-2.01) 1.30 (0.98-1.73) 1.64 (1.19-2.23) 
Serum creatinine (mg/dl) 1.0±0.3 0.9±0.2 1.2±0.3 
Urinary osmolarity (mOsm/l) 502±179 477±177 525±177 
Urinary ACR (mg/mmol) 3.2 (1.7-7.0) 3.5 (2.0-7.1) 2.8 (1.5-6.7) 
Gross proteinuria, n(%) 75 (5.5) 50 (7.0) 25 (3.8) 
eGFR (MDRD, ml/min/1.73 m2) 79±23 79±21 78±24 
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 be feasible. Fourth, these patients, who have at baseline a reasonably preserved renal function, 
but already a large renal volume, are likely to be rapid progressors and prone to develop renal 
failure.5 This specific subgroup would benefit most from a potential effective treatment.
For the secondary endpoint analysis, two analyses will be performed. The first one includes all 
the events observed during the double blind treatment period starting from the date of first 
dose of study medication. The second one includes all the events observed during the double 
blind treatment period from week 3 / end of titration to the end of the double blind treatment 
period, using week 3 / end of titration as new baseline. This last analysis will be a sensitivity 
analysis. Rationale for this sensitivity analysis is that there may be instability of fluid-related 
variables during the protocol-mandated switch of concurrent hypertensive medication in the 
titration period. Furthermore, vasopressin antagonists may, due to their aquaretic effect, have 
reversible, short-term hemodynamic effects on systemic blood pressure, GFR and urinary 
albumin excretion.31 Such short-term reversible effects may obscure the efficacy of these drugs 
on long-term disease outcome. By adopting week 3 / end of titration values as baseline for as-
sessment of long-term efficacy this potential source of bias is circumvented.    
Phase 1 and 2 studies showed that the time to reach peak concentration (Tmax) of tolvaptan 
ranges from 1 to 4 hours32 and mean half-life of tolvaptan ranged from 3 to 20 hours (data on 
file). Subjects with ADPKD respond similarly to oral doses of tolvaptan as healthy subjects, in-
cluding a decrease in urine osmolality and an increase in 24h urinary volume. Because successful 
treatment of ADPKD is presumed to require constant inhibition of the vasopressin V2 receptor, 
dose regimens have been selected to provide as constant and complete an inhibition as would 
likely be tolerated by individuals taking tolvaptan chronically. A twice-daily regimen is designed 
to produce a maximal inhibition during waking with a gradual fall-off effect during sleep. This 
dosing scheme has been chosen to prevent intolerable polyuria and nycturia. Urine osmolality 
has been used as a surrogate of vasopressin V2 receptor inhibition. Normally, urine osmolality 
only increases above plasma osmolality (approximately 290 mOsm/l) when vasopressin is acting 
at the kidney’s distal collecting ducts. When spot urine osmolality remains below 300 mOsm, 
effective vasopressin V2 receptor inhibition can be assumed. To induce the highest tolerable effi-
cacy, a titration strategy with split-dosing regimens of 45/15, 60/30 and 90/30 mg was chosen 
for the TEMPO ¾ study. 
In conclusion, the TEMPO ¾ Study is the first clinical study investigating the efficacy of a selec-
tive vasopressin V2 receptor antagonist (tolvaptan) in ADPKD. Baseline data show that we were 
able to include a large number of ADPKD patients relatively early in their disease, with a high 
likelihood of disease progression, as suggested by their relatively young age, relatively preserved 
renal function, but large kidneys. A blinded sample size re-calculation performed after 1000 
subjects were enrolled, confirms that the trial has appropriate power to address the primary and 
secondary outcomes of this study. We hypothesize that tolvaptan will be able to inhibit or reduce 
renal volume growth and improve clinical outcomes in these ADPKD patients and might be an 
effective therapeutic option for ADPKD patients in an early phase of the disease.
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Importance of dose and stage of disease
Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common renal heredi-
tary disease, characterized by progressive cyst formation in both kidneys, often leading to end 
stage renal disease.1;2 The majority of patients (85%) have a mutation in the PKD1 gene.3;4 Cur-
rent clinical management of ADPKD is mainly focused on managing complications of ADPKD, 
because as yet no proven renoprotective treatments exist that are able to inhibit cyst formation 
and thus to prevent renal failure. 
Over the past 5 years, experimental studies have suggested a central role for vasopressin and 
3’-5’-cyclic adenosine monophosphate (cAMP) in promoting cyst growth, kidney enlargement 
and renal function decline in ADPKD5-8. Inhibition of vasopressin by either a pharmacological 
agent such as a Vasopressin V2 receptor antagonist (V2RA)9-11 or by drinking more water12 
led to reduced growth of cysts and renal function preservation in animal models of polycystic 
kidney disease. 
At the moment, a large scale, randomized controlled trial is being conducted with a V2RA at 
high dosage for ADPKD patients early in the disease course.13 If proven efficacious, impor-
tant questions will, however, remain after completion of this clinical study. First, it will not be 
known whether the V2RA will be effective in ADPKD patients when started later in the disease. 
Because ADPKD is a progressive condition,14 it seems rational to start an intervention as early 
in the disease process as possible to delay or prevent long-term consequences as renal failure. 
Second, it will not be known whether low dosages of the V2RA will be renoprotective. When 
given to healthy, normally hydrated volunteers, or ADPKD patients, a V2RA causes an incre-
ase in urinary volume, which is dose dependent up to 4 times compared with placebo.15  As a 
consequence polyuria, and especially nycturia causing disturbed night rest, may have a negative 
influence on quality of life. Given this side effect profile and the fact that potentially life long 
treatment is warranted, it could be an option to use lower dosages of V2RA. Third, since 24h 
urinary volume decreases in ADPKD patients after multiple doses of a V2RA,16 the adverse 
effects may diminish after prolonged administration. Because of this, we were interested in the 
time course of the effects. 
We therefore investigated the effect of different dosages of a V2RA in a Pkd1- deletion mouse 
model for ADPKD at different stages of the disease with 3 main study questions: first, whether 
treatment with a V2RA is equally effective when initiated later in the disease course as com-
pared with early administration, second, whether lower dosages result in less polyuria and are 




In this study a tamoxifen-inducible, kidney epithelium-specific Pkd1-deletion mouse model is 
used. Upon administration of tamoxifen to these mice, a genomic fragment containing exons 
2-11 of the Pkd1 gene is specifically deleted in renal epithelial cells and cysts are formed. The 
inducible Pkd1-deletion mice (tam-KspCad-CreERT2;Pkd1lox2-1l/lox2-11) have been des-
cribed previously.17 We administered tamoxifen (Sigma-Aldrich, St. Louis, MO, USA, 0.5 mg 
Abstract
The renoprotective effect of a vasopressin V2 receptor antagonist (V2RA) is currently tested in 
a clinical trial in early ADPKD. If efficacious, this warrants life long treatment with V2RA, ho-
wever with associated side effects as polydipsia and polyuria. We questioned whether we could 
modify the side effects without influencing the renoprotective effect by starting the treatment 
later in the disease, or by lowering drug dosage.     
To investigate this, we administered the V2RA OPC-31260 at high (0.1%) and low (0.05%) 
dose to a tamoxifen-inducible kidney epithelium-specific Pkd1-deletion mouse model starting 
treatment at day 21 (early) or 42 (advanced). After 3 and 6 weeks of treatment, we monitored 
physiologic effects, e.g. water intake and potential renoprotective effects, e.g. kidney weight and 
cystogenesis.
Initiation of V2RA treatment at advanced stage of the disease lacked renoprotective effects and 
had less pronounced physiologic effects than early initiation. When started early, both after 3 
and 6 weeks of treatment, the V2RA caused dose-dependent physiologic effects. On high dose, 
water intake at both time points was 2-fold higher than on low dose (p<0.001). After 3 weeks 
on high dose, cyst ratio and kidney weight were reduced vs. untreated controls (18 vs. 25%, 
p=0.05 and 0.33 vs. 0.45g, p=0.03, resp.). After 6 weeks of treatment however, no significant 
renoprotective effect was noted, even at a high dose (cyst ratio 24 vs. 27%, p=0.12 and kidney 
weight 0.55 vs. 0.66g, p=0.38). After 6 weeks of treatment, mice receiving high dose also had 
lower water intake than after 3 weeks (2-fold vs. 4-fold increase resp. compared with untreated 
controls, p=0.001).
Our results suggest that intervention with a V2RA should be instituted early in ADPKD, pre-
ferably at high dose, and that it might be necessary to either further increase the dosage of this 
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Experimental protocol
Twenty-four-hour urine outputs in individual metabolic cages were obtained before mice were 
sacrificed. The animals were weighed and anesthetized with isoflurane gas (0.5% isoflurane 
with a flow of 0.6 l/min). Blood was obtained by cardiac puncture for determination of plasma 
electrolytes, creatinine and urea. Both kidneys were removed and weight was measured on a 
precision scale. Half of the right kidney was placed into formaldehyde. The tissues were embed-
ded in paraffin for histomorphometry and immunohistochemistry. The other half of the right 
kidney and the left kidney were frozen immediately in liquid nitrogen for mRNA isolation. 
Plasma- and urine analysis
Creatinine, urea, potassium and sodium were measured in plasma and urine, using Kodak 
Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA). Copeptin was measured using 
a new sandwich immunoassay (B.R.A.H.M.S. AG, Hennigsdorf / Berlin, Germany), which was 
based on the assay described previously19 To detect murine copeptin, the capture and detection 
antibodies were made in sheep and directed to amino acids 139-148 and 156 to 168 of proAVP. 
Urinary osmolarity was calculated as 2 * (Urinary sodium concentration +Urinary potassium 
concentration) + Urinary urea concentration.20 Creatinine clearance in ml/min was calcula-
ted as (the urinary excretion of creatinine in 24h / plasma creatinine concentration) / 1440. 
Fractional urea excretion (FE Urea) was calculated as ((Plasmacreatinine * Uurea)/ (Plasmaurea * 
Ucreatinine))* 100.
Immunohistochemistry and histomorphometric analysis
Transverse tissue sections (4 μm), including cortex, medulla and papilla, were stained for PAS 
and hematoxylin-eosin (HE) to measure total area of cysts,9 and with Sirius red collagen stain to 
measure fibrosis.21 The total area of the cysts and of fibrosis was quantified using Aperio Image 
Scope software (version 9.1.772.1570, Aperio Technologies Inc, Vista, CA, USA). Total area of 
cysts (corrected for tubular lumina) was divided by total area of the tissue and multiplied by 
100% to obtain a cyst ratio, expressed as percentage. Total intensity of fibrosis staining was divi-
ded by total intensity on the slide (both positive and negative) and multiplied by 100% to obtain 
a percentage of fibrosis.
Tubular segment identity was characterized using antibodies against megalin22 to identify proxi-
mal tubules, against Tamm Horsfall protein (uromodulin, Cappel-Organon Teknika, Durham, 
NC, USA) to identify the thick ascending limb of Henle and distal convoluted tubules, against 
Aquaporin-2 (Calbiochem La Jolla, CA) to identify principal cells of the late distal tubule and 
antibodies against Dolichos biflorus agglutinin (DBA, Sigma-Aldrich, Zwijndrecht, The Nether-
lands) to identify the collecting duct. Stainings were performed as described previously.17;18;23
dissolved in ethanol in 0.25 μl sunflower oil) for 3 consecutive days to mice at Post Natal day 
11 (PN11) per gavage. This young age was chosen because most cysts will arise from the distal 
tubules as well as in collecting ducts when the gene is knocked out at an early age.18 Tam-Ksp-
Cad-CreERT2;Pkd1lox2-1l/lox2-11mice that received tamoxifen are indicated as iKsp-Pkd1del 
mice or ADPKD. Nine tam-KspCad-CreERT2;Pkd1lox2-1l/lox2-11mice did not receive tam-
oxifen and served as healthy controls (indicated as wild-types).
Study design
At 3 weeks of age, tamoxifen-treated male and female mice were divided into control groups 
and 3 treatment groups (Table 1). This time point serves as week 0 of the experiment. Figure 
1 illustrates the time course of the experiment. The vasopressin V2 receptor antagonist OPC 
31260 (V2RA, Otsuka Pharmaceutical Co, Tokushima, Japan) was added to ground rodent chow 
(AB Diets BV, RMH-B starch, 2103) at 0.05% (low dose, LD) and 0.1% (high dose, HD). 
Animals, water and food were weighed every week. Mice were housed with on average 4 mice 
per cage. Water intake and food intake was divided by the number of mice per cage to obtain an 
average intake per animal. V2RA intake per body weight was calculated by dividing the percen-
tage in food intake by body weight of the mice. Animals were sacrificed at week 0, week 3 and 
week 6 of the experiment (Table 1 and Figure 1). All experiments were approved by the local 
animal experimental committees of the Leiden and Groningen University Medical Centers and 
by the Commission Biotechnology in Animals of the Dutch Ministry of Agriculture.
Figure 1: Study design
Table 1: Experimental groups. Early treatment was initiated at week 0, late treatment started at week 3 (see also Fi-
gure 1). Abbrevations are: V2RA, vasopressin V2 receptor antagonist; HD, high dose (0.1%); LD, low dose (0.05%). 
 Groups n Sacrificed at 
   week 0 week 3 week 6 
1 Wild-type 9 3 3 3 
2 ADPKD, untreated 26 6 9 11 
3 ADPKD, V2RA early, LD 15 . . 15 
4 ADPKD, V2RA early, HD 21 . 7 14 
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Week 3
Non-treated ADPKD versus wild-type mice
After 3 weeks of the experiment, iKsp-Pkd1del mice had higher 24h urinary volumes and lower 
24h urinary osmolarity than wild-type mice (p=0.02), suggesting a decreased urinary concen-
trating capacity (Figure 3). IKsp-Pkd1del mice had significantly higher cyst ratios and larger 
kidneys than wild-type mice (p<0.001; Figure 5). Cysts were never megalin positive, suggesting 
that the cysts did not derive from proximal tubules (Figure 4). Most cysts were uromodulin 
positive; indicating the majority of cysts arose from distal parts of the nephron. Approximately 
20% of the cysts, generally smaller cysts, were positive for aquaporin-2, indicating cysts derived 
from principal cells of the collecting ducts in a minority of cases. Sixty percent of the cysts 
were positive for lectin Dolichos biflorus agglutinin (DBA), identifying cysts derived from the 
collecting duct and late distal tubules. A large proportion of the cysts stained for uromodulin as 
well as DBA, which is in agreement with a previous published expression pattern for DBA and 
Uromodulin in mouse kidneys.25 Creatinine clearance was not different between iKsp-Pkd1del 
mice and wild-type mice (150 vs.139 μl/min, p=0.6).
mRNA expression analysis
Kidneys snap frozen in liquid nitrogen were stored at -80°C until further processing. Renal 
tissues were homogenized in PBS containing 1% 2-mercapto-ethanol using a MagNa Lyser 
Instrument (Roche). Total RNA was isolated from renal tissue homogenates using TRI-Reagent 
(Sigma-Aldrich) according to the manufacturers’ protocol. cDNA was synthesized with Super-
script III (Invitrogen). Quantitative gene expression analysis of Avpr2 and Aqp2 was performed 
on a Light Cycler 480 (Roche Applied Science) using 2x Sybr-Green master (ROX) (Roche 
Applied Science) according to manufacturers’ protocol. Hprt (Hypoxanthine phosphoribosyl 
transferase) was used as a housekeeping gene. Primer sequences are available upon request.
Data were analyzed according to the Pfaffl ΔΔCT method, taking PCR efficiencies into ac-
count.24 Expression was calculated relative to the median of untreated iKsp-Pkd1del mice.
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL). Differences between 
the groups were tested using a non parametric independent sample test (Mann Whitney).
Results
Week 0
Non-treated ADPKD versus wild-type mice
At the start of the experiment (week 0), iKsp-Pkd1del mice were not different from wild-type 
mice regarding cyst ratio. Total renal weight (iKsp-Pkd1del mice 0.18g vs. wild-types 0.19g, 
p=0.7), plasma creatinine (13 μmol/l vs.15 μmol/l in wild-types, p=0.3) and urea (11 vs. 12 
mmol/l, p=0.7) were also not different.
The iKsp-Pkd1del mice were divided into controls and different treatment groups (Table 1), i.e. 
a non-treated control group, a group treated with low dose V2RA early start, a group treated 
with high dose V2RA early start and a group treated with high dose V2RA late start. Formation 
of these groups and start of the experiment took place at day 21 after birth. Figure 1 depicts the 
time course of the experiment. 
Body weight, food intake and water intake for the different groups throughout the 6 week 
experiment are presented in Figure 2. Wild-type mice had larger bodyweight and ate more 
compared with iKsp-Pkd1del mice. There were no differences between the different groups of 
iKsp-Pkd1del mice regarding body weight and food intake. 
Figure 2: Body weight (upper panel), 
food intake (middle panel) and water 
intake (lower panel) for the different 
experimental groups. Data are presented 
as means and standard errors of the mean. 
Abbreviations are ADPKD, autosomal 
dominant polycystic kidney disease; V2RA 
vasopressin V2 receptor antagonist; LD, 
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were significantly lower compared with the non-treated iKsp-Pkd1del mice (Figure 5). After 
treatment, cysts were still positive for uromodulin and aquaporin-2 and negative for megalin 
(Figure 4). There were no differences (p=0.49) in fibrosis between the treated (median1%) 
and the untreated iKsp-Pkd1del mice (median 0.7%). Creatinine clearance was not changed 
by V2RA administration. Median creatinine clearance was 119 μl/min in the treated animals 
and150 μl/min in the untreated animals (p=0.6). 
Week 6
Non-treated ADPKD versus wild-type mice
After 6 weeks of the experiment, untreated iKsp-Pkd1del mice had a higher 24h urinary volume 
and a lower 24h urinary osmolarity (p=0.05) compared with wild-types (Figure 3) suggesting 
a decreased concentrating capacity. Untreated iKsp-Pkd1del mice also had cysts (difference in 
cyst ratios p=0.007) and larger kidneys (p=0.03) than wild-types (Figure 5). Creatinine clea-
rance was not different between iKsp-Pkd1del mice (141 μl/min) and wild-types (179 μl/min), 
p=0.37.
Early start, high dose V2RA versus non-treated ADPKD
Treatment with the vasopressin V2 receptor antagonist (V2RA) at high dose induced more 
diuresis compared with the non-treated iKsp-Pkd1del mice, as shown by a higher 24h urinary 
volume (almost 7 times increased, p<0.001), a lower 24h urinary osmolarity (approximately 
4 times decreased, p<0.001) and a higher fractional urea excretion (approximately 2 times in-
creased, p<0.001, Figure 3). This was accompanied by increased water intake (p<0.001, Figure 
2). After 3 weeks high dose V2RA treatment, cyst ratios (p=0.05) and kidney weight (p=0.03) 
Figure 4: Tubular segment identity of cysts. Panels A-D show kidney sections from an untreated iKsp-Pkd1del 
mouse, sacrificed at 3 weeks. Panels E-H show kidney sections from a mouse treated with a high dose V2RA for 3 
weeks. Sections are stained for the proximal marker Megalin (A&E), the distal markers Tamm Horsfall Protein (THP, 
B&F), Aquaporin-2 (AQ2, C&G), and lectin Dolichos biflorus agglutinin (DBA, D&H). * indicates positive staining of 
the cyst.
Figure 3: Physiologic effects of the vasopres-
sin V2 receptor antagonist  (V2RA) at week 
3 and week 6 of the experiment: 24h urinary 
volume (upper panel), 24h urinary osmolarity 
(middle panel) and fractional urea excretion 
(lower panel) for experimental groups.  Data 
are presented as means and standard errors of 
the mean. LD, low dose (0.05%); HD, high 
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Early start, low dose versus early start high dose versus non-treated ADPKD mice
Treatment with the V2RA for 6 weeks resulted in larger 24h urinary volume (p=0.04) and 
lower 24h urinary osmolarity (p=0.003) with the higher dose inducing more effects than the 
lower dose (Figure 3). Fractional urea excretion was not different between the high and low 
dose group (p=0.16, Figure 3). 
No significant renoprotective effects of the V2RA were observed at this time point. Although 
cyst ratios and kidney weights were slightly different between the treated and non-treated iKsp-
Pkd1del mice the differences were not statistically significant (p=0.4 and p=0.3, resp. low-dose 
vs. untreated, Figure 5). Also the amount of fibrosis (median fibrosis on high dose was 3%, on 
low dose 5% vs. 6% in untreated animals) and creatinine clearance (median 192 μl/min on high 
dose, 246 μl/min on low dose and 141 μl/min in the group without treatment) were not dif-
ferent (p=0.7 and p-0.8, resp.) between the treated (either with high dosage or with low dosage 
of V2RA) and non-treated iKsp-Pkd1del mice. 
Later start, high dose versus early start, high dose and non-treated ADPKD
Later initiation of treatment with high dose V2RA, started in week 3 of the experiment, induced 
less diuresis compared with early treatment with high dose V2RA (p=0.01, Figure 3). Although 
there was a trend towards a higher urinary osmolarity when treatment was initiated later in the 
disease course, this was not significant (p=0.16). There was no renoprotective effect of V2RA 
treatment when initiated later in the disease course: both cyst ratios and kidney weights were 
not different (p=0.9 and p=0.8, resp.) from non-treated iKsp-Pkd1del mice (Figure 5).
Comparison of high dose V2RA effects at week 3 and at week 6
Intake of the V2RA per gram body weight was not different for iKsp-Pkd1del mice receiving 
the high dose of V2RA after three weeks of treatment compared with iKsp-Pkd1del mice after 
six weeks of treatment (Figure 6). At week 3 as well as at week 6 of the experiment treatment 
with the V2RA resulted in significant physiologic effects (figure 6). Treated animals showed a 
higher water intake, lower urine osmolarity and a higher fractional urea excretion compared to 
untreated iKsp-Pkd1del mice. Mice at 6 weeks of treatment had less physiologic effects of the 
V2RA when compared to mice at 3 weeks of treatment: twenty-four hour urinary osmolarity 
was higher (321 vs. 450 mOsm/l, p<0.001), whereas water intake (14 ml vs.18 ml, p=0.005) 
and fractional urea excretion (39 vs. 67%, p<0.001) were lower (Figure 6). 
Since the physiologic effects were lower after 6 compared to 3 weeks of treatment, we analysed 
serum levels of copeptin, a stable precursor of and a marker for endogenous vasopressin, as well 
as renal mRNA levels of the Vasopressin V2 receptor and aquaporin 2.
There was no difference in copeptin concentration between mice treated for 6 weeks when 
compared to mice treated for 3 weeks (p=0.7; Figure 6). Expression of both the vasopressin V2 
receptor and aquaporin-2 was lower in mice after 6 weeks of treatment compared with mice at 
3 weeks of treatment  (p=0.004 and p=0.006 respectively).
Figure 5: Renoprotective effects of the vasopres-
sin V2 receptor antagonist  (V2RA) at week 3 
and week 6 of the experiment. Cyst ratio (upper 
panel) and kidney weight (middle panel) for expe-
rimental groups. Data are presented as means and 
standard errors of the mean. No statistically sig-
nificant differences between the various ADPKD 
groups at week 6 were found. * indicates p<0.05 
compared with wild-type. HD, high dose (0.1%). 
The lower panel shows representative kidney 
sections of an untreated iKsp-Pkd1del mouse and 
iKsp-Pkd1del mouse treated with high dose V2RA 
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Discussion
Vasopressin V2 receptor antagonist, when given at high dose early in the disease, reduced cyst 
formation and kidney weight in a Pkd1-deletion mouse model for ADPKD. When the same 
dosage was administered for a longer period of time, cyst ratio and kidney weight were lower, 
but this difference did not reach statistical significance anymore. The direct physiologic effects 
of vasopressin V2 receptor inhibition decreased after prolonged administration of the vasopres-
sin V2 receptor antagonist (i.e. urinary osmolarity was higher and water intake was lower after 
prolonged administration compared with the earlier time point). Initiation of V2RA treatment 
at a more advanced stage in the disease had less pronounced physiologic effects compared with 
early start of treatment with the same dosage, and lacked renoprotective effects. 
The beneficial effect of the vasopressin V2 receptor antagonist at week 3 of the experiment is 
in line with literature. Also in other models for polycystic kidney disease (autosomal recessive 
polycystic kidney disease, nephronophthisis and a Pkd2-model of ADPKD) this beneficial effect 
has been described.9-11 Of note, the effects of vasopressin V2 receptor antagonists (V2RA) has, as 
far as we know, never been investigated in a Pkd1- model for ADPKD, although the majority of 
ADPKD patients (85%) have a mutation in the PKD1 gene.3;26 Because of this high face validity 
with the human situation, the beneficial effect of the V2RA that we observed in this Pkd1-deleti-
on mouse is of clinical relevance.
Aims of this study were to investigate whether we could modify the physiologic side effects 
without influencing the renoprotective effect of the V2RA by lowering drug dose or by starting 
treatment later in the disease. In normal physiology, vasopressin binds to the V2 receptors in 
the collecting ducts, increasing the water permeability along the entire collecting duct (through 
aquaporin-2), and increasing the urea permeability in the terminal inner medullary collecting 
duct.27 Both processes result in water reabsorption, thereby reducing water excretion. After 
administration of the V2RA, water excretion (and consequently water intake) and fractional 
urea excretion indeed increased, whereas urinary osmolarity decreased. Of note, the obser-
vation that administration of a V2RA results in an increased fractional urea excretion, makes 
measurement of plasma urea as a measure of renoprotective effect of the V2RA less feasible. The 
observed physiologic effects of the medicament were dose-dependent. Lower dosage of V2RA 
resulted in less diuresis compared with the higher dosage in this animal model of ADPKD. This 
is consistent with the observed dose-dependent polyuria seen in healthy volunteers.15 Initiation 
of V2RA treatment at high dose in a more advanced disease stage unexpectedly induced also less 
pronounced physiologic effects when compared with high dose treatment earlier initiated in the 
disease. Both lower dosage and initiation later in the disease could therefore partly overcome 
the physiologic side effects. In this study however, treatment with a low dosage as well as later 
initiation of treatment lacked renoprotection. 
After 6 weeks of treatment the V2RA exerted physiologic and renoprotective effects when 
compared to untreated animals. However, when compared to 3 weeks of treatment these effects 
were diminished and did not reach statistical significance in all cases. The decreased efficacy 
Figure 6: Comparison of V2RA intake (top left panel), physiologic effects of V2RA (24h water intake (upper right 
panel), 24h urinary osmolarity (middle left panel), and fractional urea excretion (middle right panel) and mRNA ex-
pression of the vasopressin V2 receptor (lower left panel) and of aquaporin-2 (lower right panel) between week 3 and 
week 6 of the experiment in untreated animals and in animals treated with high dose (0.1%) of the V2RA. * indicates 
p<0.05 for treated vs. untreated animals for that same time point. # indicates p<0.05 for week 6 compared to week 
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In conclusion, the V2RA has beneficial effects on cyst growth in a Pkd1 deletion mouse model 
when initiated at high dose early in the disease on short term. Initiation of V2RA treatment at 
lower dose or at high dose later in the disease had less pronounced physiologic effects, but also 
lacked renoprotection. After prolonged administration, the V2RA induced lower cyst ratio and 
kidney weight compared to untreated animals, but this did not reach statistical significance. Phy-
siologic side effects, though still significant, were also less pronounced at this later time point. 
This decreased responsiveness to the V2RA could be due to incomplete V2R antagonism or 
increased importance of other non-vasopressin related cystogenic pathways. Our results suggest 
that intervention with a V2RA should be instituted early in the disease course of ADPKD and at 
high dose, and that it might be necessary to either increase the dosage of this drug later in the 
disease to reach renoprotection, or to switch to combinational treatment with other drugs.
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of the drug after prolonged administration could be caused by inadequate intake of the V2RA. 
Mice almost doubled in bodyweight throughout the experiment. However, study drug was 
administered as a percentage of food, and food intake also increased throughout the experiment. 
Consequently, the intake of the V2RA per gram bodyweight was not different at 6 weeks of tre-
atment when compared with the earlier time point (Figure 6).  This does, however, not exclude 
the possibility that there are differences in pharmacokinetic parameters of the V2RA at week 6 
compared to week 3 of treatment. For instance, it could be that in these growing mice metabo-
lism of the V2RA increases, thereby decreasing the serum concentration of the V2RA at the later 
time point, despite an equal intake of the drug. Unfortunately, the low blood volume obtained 
after sacrificing the animals did not allow to measure drug concentration. Another cause for 
the decreased efficacy of the V2RA could be the result of incomplete vasopressin V2 receptor 
antagonism. This could be caused by an increase in vasopressin levels or changes in vasopressin 
V2 receptor expression. Copeptin, the stable precursor of vasopressin,28;29 was however not 
increased after prolonged administration. Vasopressin V2 receptor mRNA expression was decre-
ased at 6 weeks of the experiment compared to the situation at 3 weeks. This means that there 
is more vasopressin per receptor present, which may lead to decreased efficacy of the V2RA 
and may explain the observation that physiologic effects decreased in the mice after prolonged 
administration of the drug. The phenomenon of decreased diuresis after multiple dosages of a 
V2RA is also observed in humans with ADPKD.16 If this is indeed due to incomplete vasopressin 
V2 receptor blockade, this line of reasoning leads to the hypothesis that the dosage of vasopres-
sin V2 receptor antagonist should be increased as the disease progresses to effectively block the 
hormonal activity of vasopressin. 
An alternative explanation for the decreased sensitivity to V2RA after prolonged administra-
tion could be that vasopressin is effectively blocked, but other processes driving cyst formation 
become more important. It has been described that many signaling pathways are altered in 
cystic epithelial cells, directly or indirectly regulated by the PKD-proteins, and V2RA treatment 
may not block all of these pathways.2 In our model, approximately 20% of cysts are positive 
for aquaporin-2 (AQP2). These AQP2 positive cysts are the cysts that will be targeted by a 
vasopressin V2 receptor antagonist. Of note, the percentage of AQP2 positive cysts seems to 
be less than in the Pkd2 model that has been described in literature, where AQP2 expression is 
massively increased in the kidney.10 The majority of cysts in our model appears to derive from 
other tubular segments that most likely are not inhibited by the V2RA. In case this hypothesis 
is true, this might implicate that institution of combination therapy, targeting inhibition of cyst 
formation via various signaling pathways may overcome the decreased efficacy of the V2RA after 
prolonged administration. Examples of such medicaments could be somatostatin analogues30-32 
and mTOR inhibitors33, although two recent clinical trials did not show a clear beneficial effect 
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Summary and future perspectives
is misleading in reporting the progression of ADPKD,23 for GFR is believed to be stable in the 
beginning of the disease. This supposed stability of GFR, despite progression of renal anatomical 
abnormalities, is thought to occur because of compensatory hyperfiltration (see also Figure 3 of 
the introduction). GFR is thus assumed not to be representative of disease severity early in the 
disease.23;24 However, clinical data supporting this hypothesis are lacking. 
We therefore investigated renal parameters in ADPKD patients at different ages in comparison 
to healthy subjects (chapter 2). In this study, we found that already at young adult age, ADPKD 
patients have marked renal abnormalities, despite only modestly enlarged kidneys and a near 
normal glomerular filtration rate. These abnormalities include a renal hemodynamic profile 
characterized by decreased effective renal plasma flow and increased filtration fraction. This 
hemodynamic profile could indicate hyperfiltration. The phenomenon of hyperfiltration could 
explain why glomerular filtration rate stays stable for a number of years and then rapidly decli-
nes, as described in literature.23;24 This suggests that glomerular filtration rate is indeed not an 
appropriate marker for disease severity. This finding emphasizes the importance of a search for 
better markers to assess disease severity. We found in these ADPKD patients that effective renal 
plasma flow, as well as total renal volume could be examples of these markers (chapter 2). These 
findings are in accordance with studies of the CRISP consortium,25 showing that renal blood 
flow26 and total renal volume27 predict renal function decline.
Measurement of effective renal plasma flow and total renal volume are however time consuming 
and expensive. Because ADPKD is a disease characterized by structural abnormalities of renal 
tubuli, interstitial inflammation and fibrosis, we hypothesized that urinary biomarkers reflecting 
tubular damage and inflammation could be promising candidate markers to assess disease seve-
rity (chapter 3). Furthermore, urinary biomarkers are relatively easy to obtain and inexpensive 
to measure, making them favorable candidate markers. In ADPKD patients, a limited number 
of urinary biomarkers have been investigated so far, namely albuminuria, β2 microglobulin,28;29 
NGAL30 and Monocyte Chemotactic Protein-1 (MCP-1).31;32 In general, these studies investi-
gated only one biomarker and the promising results obtained for these markers have not been 
corroborated by others, except for albuminuria. Several studies showed that in ADPKD, albu-
minuria is associated with increased renal volume,25;33 mean arterial blood pressure, filtration 
fraction,33 renal growth and slope of glomerular filtration rate.26 Albuminuria is therefore a 
valuable biomarker indicating disease severity and predicting outcome. In general, albuminuria 
is assumed to reflect predominantly glomerular endothelial damage. In ADPKD however, albu-
minuria might also reflect (inflammatory) tubular damage. 
We therefore measured urinary biomarkers in ADPKD patients and in healthy controls and 
associated these markers with effective renal blood flow and total renal volume (chapter 3). We 
wanted to investigate whether these associations were independent of albuminuria for two rea-
sons. First, albuminuria is already an established marker to assess disease severity in ADPKD.33 
The newly found urinary biomarker should therefore add to albuminuria with respect to as-
sessment of disease severity. Second, such an analysis can provide insight into the issue whether 
Summary
ADPKD is the most frequent hereditary kidney disease characterized by massive cyst formation 
in the kidneys, leading to end stage renal disease.1 Presently it is not known whether clinical 
management of ADPKD is able to prevent or postpone renal failure. There is not much evidence 
to support dietary protein restriction,2 strict blood pressure regulation3 or treatment with 
angiotensin converting enzyme inhibitors4;5 in prevention of renal function deterioration for 
these patients. It has to be noted though, that most of the studies with these regimens had too 
short follow-up, too small patient groups or included a control group that had almost no renal 
function deterioration to allow firm conclusions. The question whether these regimens really 
lack beneficial effect on renal function preservation remains therefore unanswered. 
In the past decade, a better understanding of the pathogenesis of ADPKD6 has led to potential 
new treatment options for this chronic condition.7 Examples of these treatment options are 
triptolide,8 roscovitine,9 mammalian Target Of Rapamycin (mTOR) inhibitors,10 somatostatin 
analogues11-13 and vasopressin V2 receptor antagonists. A recent clinical trial showed that in 
early ADPKD, sirolimus did not slow kidney growth in 100 ADPKD patients, and there was a 
trend towards a better GFR.14 In late ADPKD (433 ADPKD patients with a renal volume above 
1500 ml at baseline) however, everolimus did not result in renal function preservation although 
it appeared to slow the increase of total kidney volume.15 So far, a clear beneficial effect of 
mTOR inhibitors in ADPKD is therefore lacking. Regarding vasopressin V2 receptor antago-
nists, a selective vasopressin V2 receptor antagonist called tolvaptan was proven to inhibit renal 
cyst growth and preserve renal function in animal models of polycystic kidney disease.16-18 This 
medicament is approved by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for treatment of hypervolemic and euvolemic hyponatraemia. These 
approvals were based on studies of efficacy and safety in patients with hyponatremia19 and safety 
in patients with congestive heart failure, with or without hyponatraemia.20;21  
This thesis focuses on the role of vasopressin in renal disease progression in ADPKD. It is 
divided into three parts. Part I describes our search for markers to assess disease severity in 
ADPKD. Part II investigates the potential detrimental role of vasopressin on these markers for 
disease severity in ADPKD, but also in other patient groups. Part III is a synthesis of the previ-
ous parts. This part contains two manuscripts on intervention with a vasopressin V2 receptor 
antagonist in ADPKD.
Part I: Measurement of renal damage in ADPKD
Because the clinical course of ADPKD is highly variable22 (see also Figure 2 of the introduc-
tion), and all potentially effective experimental medicaments have side effects, exposing all 
ADPKD patients to these medicaments is not preferred. Ideally, treatment should be directed 
to patients at high risk for disease progression. To be able to identify such patients, there is a 
need for markers to assess disease severity. Part I describes our search for these markers. In 
nephrology, the most common way to assess disease severity is to measure glomerular filtration 
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and renal damage could be that direct measurement of vasopressin is problematic. More than 
90% of vasopressin in the circulation is bound to platelets, vasopressin is unstable in isolated 
plasma,51 and most vasopressin assays have a relatively limited sensitivity. For this reason, we 
chose to measure copeptin, which is recently measurable using an enzyme-linked immunosor-
bent assay (ELISA). Copeptin is the C-terminal portion of the precursor of vasopressin that has 
been shown to be a reliable marker of vasopressin secretion and a useful substitute for circula-
ting vasopressin levels.52-54
 
We first investigated, in a cross-sectional study, the association between vasopressin and albumi-
nuria in a large general population cohort, including 7593 subjects. Albuminuria is important 
because it is a predictor of cardiovascular mortality and progressive renal function deterioration, 
not only in diabetics, but also in the general population.55;56 It is assumed that urinary albumin 
excretion not only reflects glomerular damage, but is also related to systemic endothelial dys-
function. Treatments associated with lowering albuminuria result in a better renal57 and cardio-
vascular58 outcome. Identifying modifiable factors that cause a rise in urinary albumin excretion 
is therefore important, since intervention directed to these factors might be expected to result 
in a better renal and cardiovascular prognosis. In chapter 4, we show that in both males and 
females, a high concentration of copeptin is associated with a low 24h urinary volume and a high 
24h urinary osmolarity, consistent with normal physiology. Furthermore, this study shows that 
copeptin is associated with urinary albumin excretion: the higher copeptin, the higher urinary 
albumin excretion, again, both in males and in females. This association remained significant af-
ter adjustment for age and potential confounders, among which medication that could potenti-
ally influence both vasopressin (and thus copeptin) secretion and urinary albumin excretion. The 
association between copeptin and urinary albumin excretion was found to be most pronounced 
in older subjects. 
In an addendum to chapter 4, we elaborate on salt intake as a potential confounder for this as-
sociation. Higher salt intake could induce a higher plasma osmolarity and thus more vasopressin 
release, and a higher sodium intake is also associated with more albuminuria, but by another 
mechanism. The addition of sodium intake to our models however, did not materially change 
the association that we found between copeptin and albuminuria. This observation makes it less 
likely that high salt intake is the common factor that induces an increase in albuminuria as well 
as in vasopressin, and supports the suggestion that vasopressin per se is detrimental.  Although 
cross-sectional, the observed association between vasopressin and urinary albumin excretion is 
consistent with our hypothesis that vasopressin induces albuminuria. 
Of note, we did not find an association between copeptin and renal function deterioration 
during follow-up in these healthy subjects. Maybe this is caused by the fact that healthy subjects 
are not susceptible enough to experience vasopressin’s detrimental renal effects. We found that 
the association between copeptin and urinary albumin excretion was most pronounced in el-
derly, who probably already have some renal damage compared to the younger subjects. Also in 
experimental studies investigating the detrimental role of vasopressin, the animals under study 
albuminuria in ADPKD is of glomerular- or tubular origin. 
We found that urinary biomarkers from all segments of the nephron are elevated in ADPKD 
patients compared to healthy controls (chapter 3). The proximal tubular marker NGAL is asso-
ciated with both effective renal blood flow, and total renal volume, independent of albuminuria. 
Other associations that are independent of albuminuria are the associations of the proximal 
tubular marker β2 microglobulin and the distal tubular marker H-FABP versus effective renal 
blood flow, and of the proximal tubular marker KIM-1 and the inflammatory marker MCP-1 
versus total renal volume. 
These findings are of interest for at least three reasons. First, we found a striking correlation 
between IgG and albuminuria, which could suggest albuminuria in ADPKD is predominantly 
glomerular in origin. Second, we found the distal tubular damage marker H-FABP not to be 
associated with total renal volume. This is in contrast with literature suggesting the main site of 
cystogenesis is distal in the tubule34 (although the origin of cysts in early ADPKD remains a sub-
ject of debate35). Third, NGAL is the only proximal tubular marker that is associated with both 
effective renal blood flow and total renal volume in our study. An explanation for this phenome-
non could be that NGAL reflects not only proximal tubular damage, but also inflammation and 
distal nephron damage, as is suggested in literature.36 Based upon our study, we hypothesize that 
determination of urinary excretion of β2 microglobulin, H-FABP, KIM-1, MCP-1, but especi-
ally NGAL could have additional value in clinical practice to assess disease severity in ADPKD.
Part II: Vasopressin and renal damage severity
In this part, we investigated the potential detrimental role of vasopressin in causing renal 
damage in several patient groups. The antidiuretic hormone vasopressin is crucial for water 
regulation in the body. Its secretion is stimulated in response to an increase in plasma osmola-
rity or a decrease in plasma volume. Vasopressin mediates water reabsorption, thereby reducing 
water excretion,37;38 diminishing 24h urinary volume and increasing urinary osmolarity. Despite 
its biological relevance however, vasopressin might in theory also contribute to chronic kidney 
disease progression by its effect on renal hemodynamics, blood pressure, and mesangial and / 
or epithelial cells.39-41 Experimental studies showed that a sustained increase in vasopressin V2 
receptor stimulation results in an increased renal plasma flow and particularly in an increased 
GFR.42 This hyperfiltration might have deleterious consequences, in particular in diseased kid-
neys, resulting in renal hypertrophy,43 proteinuria,44 and accelerated renal function decline.45-47 
This proposed mechanism is supported by studies in rats with chronic renal failure, showing 
that increased water intake or chronic infusion of a vasopressin V2-receptor antagonist reduced 
proteinuria and lowered the incidence of glomerulosclerosis45;48 and tubulo-interstitial fibrosis.49 
Similarly, chronic infusion of a V2-receptor antagonist reduced albuminuria and kidney weight 
in diabetic rats.50 
Human data investigating the potential detrimental role of vasopressin on the kidney are, howe-
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flow, larger kidneys and more albuminuria. These associations were independent of age, gender, 
use of diuretics and GFR.
Part III: Vasopressin V2 receptor antagonists and prevention of progressive renal 
damage?
Our finding that copeptin is associated with disease severity in ADPKD supports the previously 
mentioned results of animal models for ADPKD, in which vasopressin-2 antagonists resulted in 
renoprotection16-18 and offers a good prospect for the large clinical intervention study that is 
currently being conducted with these agents. This study is called the TEMPO ¾ study (Tol-
vaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease 
and its Outcomes, phase 3 of 4). In chapter 7, the rationale and design of this trial are descri-
bed and also preliminary baseline data are presented.  This multicenter, double-blind, placebo 
controlled trial includes patients with ADPKD who have relatively preserved renal function 
(baseline estimated creatinine clearance ≥ 60 mL/min) and are anticipated to have progres-
sive renal disease. Primary outcome is the difference in rate of percent change in total kidney 
volume for tolvaptan compared to placebo. Secondary outcome parameters include time to 
multiple ADPKD progression events, among others time to a 33% increase in serum creatinine 
and worsening albuminuria. From March 2007 through January 2009, 1445 ADPKD subjects 
were enrolled world wide. In our center, the University Medical Center Groningen, 52 patients 
participate in this trial, making the UMCG the second largest participating center. Preliminary 
baseline data show that this study includes a large number of ADPKD patients (746 males and 
699 females, total 1445 patients) relatively early in their disease (estimated creatinine clearance 
is 105 ± 34 mL/min), with a high likelihood of disease progression, as suggested by their relati-
vely young age (38.7± 7.1 years) and large kidneys (median total kidney volume for all patients 
is 1.5 L). A blinded sample size re-calculation performed after 1000 subjects were enrolled, 
confirms that the trial has appropriate power to address the question whether the vasopressin V2 
receptor antagonist will be able to inhibit or reduce renal volume growth and improve clinical 
outcomes in these ADPKD patients and might be an effective therapeutic option for ADPKD 
patients in an early phase of the disease.
Although the effect on renal growth of a vasopressin V2 receptor antagonist is being studied in 
this randomized clinical trial at the moment, important questions will remain after completion 
of the TEMPO ¾ study. It will not be known whether the vasopressin V2 receptor antagonist 
will be effective in patients with lower eGFR. ADPKD is a progressive condition and probably 
the cysts that are formed early in life are the main contributor to eventual total cyst volume.63 It 
is therefore questionable whether start of treatment later in the disease will be able to delay or 
prevent long-term consequences as renal failure. Vasopressin V2 receptor antagonists are indeed 
believed to be preventive, not restorative. Furthermore, the dosages of the vasopressin V2 
receptor antagonist in the TEMPO ¾ study result in polydipsia, polyuria and nycturia,64 leading 
to disturbed night rest and decreased quality of life. Reducing these side effects is important 
because potentially life long treatment is warranted for ADPKD. Investigating whether lower 
dosages are associated with fewer side effects, but still significant efficacy in delaying disease 
have some form of renal damage (as a 5/6 nephrectomy45;46) before experiencing these detri-
mental effects of vasopressin.
We therefore investigated in 548 renal transplant recipients, median 6.0 years after transplan-
tation, the association between baseline copeptin and renal function decline during follow-up 
(chapter 5). In these renal transplant recipients, regulation and action of copeptin seemed to be 
consistent with normal physiology because we found, at baseline, a positive association between 
effective plasma osmolarity and copeptin concentration, and a negative association between 
copeptin and 24h urinary volume and fractional urea excretion. Moreover, we found a positive 
association between copeptin and urinary sodium concentration (as a surrogate for urinary 
osmolarity). 
In addition, baseline copeptin was significantly associated with change in estimated glomerular 
filtration rate (eGFR; calculated using the 4-variable MDRD formula59) during follow up (me-
dian 3.2 years) in these patients. In multivariate regression analysis, the association of copeptin 
at baseline with change in eGFR during follow-up remained significant after adjustment for age, 
gender, baseline eGFR, proteinuria and other known risk factors for renal function deteriora-
tion, suggesting that a high concentration of vasopressin may cause renal function decline. This 
is in line with results from animal experiments. A chronic reduction in plasma vasopressin con-
centration slowed the progression of renal failure in Sprague-Dawley rats with impaired renal 
function,45 whereas infusion of 1-Desamino 8-D-arginine Vasopressin (dDAVP) induced a rise in 
serum creatinine and in proteinuria in Brattleboro rats.46 
In ADPKD, vasopressin has been hypothesized to play a role in cyst formation. Vasopressin 
promotes 3-5-cyclic adenosine monophosphate (cAMP) production by acting on vasopressin V2 
receptors in the distal nephron and collecting ducts. This cAMP plays a major role in promoting 
cyst growth,60 for it stimulates both chloride-driven fluid secretion and activation and proli-
feration of cyst-derived cells.61 In line with this potential role of vasopressin in cyst formation 
in ADPKD are the findings in animal models of  polycystic kidney disease, where blocking the 
effect of vasopressin (and consequently decreasing cAMP levels) by either a pharmacological 
agent16-18 or by drinking more water62 led to reduction of cyst formation and renal function 
preservation.  So far however, no studies have looked at the association between endogenous 
vasopressin levels and disease severity in humans with ADPKD. 
We therefore investigated the association between copeptin and disease severity in 102 subjects 
with ADPKD (chapter 6). As markers of disease severity we studied effective renal blood flow, 
total renal volume and albuminuria. We found that in these ADPKD patients, plasma osmolarity 
was associated with copeptin concentration, suggesting a physiologic regulation of vasopres-
sin. In contrast to the situation in subjects of the general population (chapter 4) and in subjects 
with a renal transplant (chapter 5), copeptin concentration was not associated with 24h urinary 
volume, 24h urinary osmolarity or fractional urea excretion. This suggests a lack of physiologic 
effects of vasopressin. Most importantly, we found that copeptin levels were indeed associated 
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new drug, especially since therapy has to be given probably life-long for this chronic condition. 
The results in our animal model suggest that administration of a lower dosage will not only lead 
to, as intended, fewer side effects (polyuria), but unfortunately also to decreased renoprotec-
tion. To overcome this decreased efficacy, combination therapy could be instituted with other 
agents that are now being tested for ADPKD and that are expected to induce favorable effects 
by interfering with the same pathophysiological pathways as vasopressin V2 receptor antagonists, 
such as mTOR inhibitors68;69 and somatostatin analogues.11 These latter agents also have side ef-
fects that will limit the probability of lifetime use in high dosages. Future research is needed to 
investigate dose response curves with respect to both renoprotective as well as side effects of all 
single agents, and of combination therapy. 
The TEMPO ¾ study will not answer the question whether intervention with a vasopressin 
V2 receptor antagonist will also be effective in later phases of ADPKD. A clinical trial will start 
within short notice in our center, to assess short-term renal hemodynamic effects of vasopres-
sin receptor antagonist in subjects with ADPKD later in the disease (estimated GFR < 60 mL/
min). Our results in chapter 8 suggest that early intervention will be more effective than later 
intervention. After assessment of effect and safety in subjects later in the disease, the question 
will be who to treat? Should we treat all patients with ADPKD, or only certain subgroups? To 
prevent exposure to side effects of V2 receptor antagonists in patients with low risk for disease 
progression, we would encourage, based upon this thesis, to measure effective renal plasma 
flow, total renal volume, albuminuria and NGAL excretion. Whether these markers will reliably 
predict disease progression has to be investigated in future prospective research. Furthermore, it 
would be interesting to investigate whether adequate treatment of ADPKD will induce lowering 
of NGAL excretion. If this is the case, NGAL excretion could be used as a short-term marker of 
long-term therapeutic efficacy and even as a marker to titrate dosage of therapeutic strategies.
The finding that patients with more severe ADPKD have higher copeptin levels (chapter 6) indi-
cates that perhaps in these patients higher dosages of vasopressin-V2 receptor antagonist should 
be administered to effectively suppress endogenous vasopressin levels. In line, we observed 
in our animal study of ADPKD that after prolonged administration of a selective V2 receptor 
antagonist, both the physiologic as well as the renoprotective effects of vasopressin inhibitions 
diminished. What dosage of the V2RA to use could hypothetically be monitored by measuring 
variables known to be associated with the physiologic effects of vasopressin, as 24h urinary 
volume, 24h urinary osmolarity and / or fractional urea excretion. Titrating the dosage directed 
at obtaining a urinary osmolarity less than 300 mOsm/L for instance could be used as a measure 
of adequate vasopressin inhibition. Whether administration of higher dosages of a vasopressin 
V2 receptor antagonist to ADPKD patients with lower glomerular filtration will still induce 
lowering of urinary osmolarity and especially whether this will be safe are important questions 
that need to be answered. 
progression will therefore be important.
In an attempt to answer these questions, we administered a vasopressin V2 receptor antagonist 
to a tamoxifen-inducible kidney epithelium-specific Pkd1-deletion model of ADPKD (chapter 
8). This Pkd1-model has very high face validity to the human situation for most patients (85%) 
have a mutation in the PKD1-gene.65;66 Of note, the effects of a vasopressin V2 receptor anta-
gonist have never been studied in Pkd1- animal models. We found that indeed, the vasopressin 
V2 receptor antagonist induced a dose-dependent polyuria in this model. Treatment with this 
medicament had beneficial effects on cyst growth on short term. When given at similar high 
dose, prolonged administration of the vasopressin V2 receptor antagonist exhibited less phy-
siologic effect (polyuria), but also less renoprotection. Our results suggest that intervention 
with a vasopressin-V2 receptor antagonist should be instituted early in the disease course. The 
fact that diuresis was less increased after prolonged administration, together with the finding in 
chapter 6, that copeptin concentration is higher in more advanced ADPKD, suggests that it may 
be necessary to increase the dosage of the vasopressin V2 receptor antagonist when ADPKD 
progresses.
Future perspectives
We showed, in a cross-sectional study, that copeptin is associated with disease severity in 
ADPKD. This is in line with the hypothesis that vasopressin induces cyst formation in ADPKD. 
It would be informative to investigate in a prospective study whether copeptin is also associated 
with disease progression in ADPKD patients. Disease progression could be assessed in patients 
who have already advanced disease, as renal function decline. If the study is to be performed in a 
cohort of ADPKD patients early in the disease, the study should have long-term follow-up (>10 
years) to ensure that there are patients under study who experience renal function decline. This 
question is presently addressed in a cohort of ADPKD patients of whom long-term follow-up is 
available.4 Alternatively, disease progression should be monitored by measuring increase in total 
renal volume, for we confirmed in this thesis that GFR is not an appropriate marker of disease 
severity in early ADPKD. 
Even better than measurement of change in total renal volume is probably measurement of 
change in renal parenchymal volume.  A small-scale study shows that the association between 
change in parenchymal volume and change in GFR is stronger than between change in total 
renal volume and change in GFR.67 Also in our cohort of ADPKD patients, a number of patients 
have cyst formation mainly on the cortical side of the kidney, growing outward. These patients 
have a large portion of renal parenchyma preserved and concomitantly (near) normal renal 
function, despite the large renal volume that is caused by these cortical cysts (see also Figure 2 
of chapter 2).
The TEMPO ¾ study (chapter 7) will show whether intervention with a vasopressin V2 recep-
tor antagonist will be able to inhibit or reduce total renal volume growth and improve clinical 
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Samenvatting en toekomstperspectief
De huidige behandeling bestaat met name uit het voorkomen van complicaties van de ziekte, 
zoals het geven van bloeddruk verlagende medicatie in het geval van hoge bloeddruk. Op dit 
moment bestaat er geen behandeling die in staat is om de cystevorming af te remmen en daar-
mee de nierfunctie te behouden. 
De afgelopen jaren zijn er belangrijke ontdekkingen gedaan op het gebied van cystenieren. Zoals 
gezegd weten we inmiddels in welke genen de mutatie zit die de ziekte veroorzaakt. We weten 
in welke niet goed functionerende genproducten dit resulteert en hebben aanwijzingen over 
hoe dit uiteindelijk tot cystevorming leidt. De ontrafeling van deze mechanismen heeft geleid 
tot mogelijke aangrijpingspunten om cystevorming tegen te gaan of te verminderen. Eén van 
de mogelijkheden zou het geven van vasopressine V2 receptor antagonisten (afgekort als V2RA) 
kunnen zijn. Deze medicamenten blokkeren de werking van vasopressine door het blokkeren 
van de vasopressine V2 receptor. Dit is een receptor die alleen in de nier aanwezig is. 
Vasopressine is een lichaamseigen stof die ervoor zorgt dat je lichaam vocht kan vasthouden en 
niet uitplast. Vasopressine staat ook wel bekend als antidiuretisch hormoon, omdat het dus de 
diurese (produceren van urine) tegengaat. Zonder vasopressine zou je enorme hoeveelheden 
water moeten drinken om niet uit te drogen. Figuur 3 geeft de functie van vasopressine in het 
lichaam schematisch weer. Als de concentratie deeltjes in het bloed hoger wordt, of het vo-
lume van bloed afneemt (je droogt een beetje uit), wordt er door je hersenen vasopressine aan 
de bloedbaan afgegeven (dit gebeurt overigens nog voordat er een dorstprikkel ontstaat). Het 
vasopressine zorgt ervoor dat er water wordt teruggeresorbeerd in de nier, waardoor het uri-
nevolume omlaag gaat en de concentratie van afvalstoffen in de urine omhoog. Uiteindelijk gaat 
hierdoor de concentratie van het bloed naar beneden en het bloed volume omhoog, waardoor 
de afgifte van vasopressine weer geremd wordt. Zo ontstaat er een regelmechanisme waardoor 
het lichaam zichzelf in evenwicht kan houden wat betreft vochthuishouding. 
Samenvatting
ADPKD is de afkorting van Autosomal Dominant Polycystic Kidney Disease. Vrij in het Ne-
derlands vertaald betekent dit niet geslachtschromosoom gebonden, dominant overervende 
polycysteuze nierziekte, ofwel kortweg cystenieren. ADPKD is de meest voorkomende erfelijke 
nierziekte. Er zijn 2 genen ontdekt, die als ze beschadigd zijn (een mutatie bevatten), cyste-
nieren kunnen veroorzaken: het PKD-1 en het PKD-2 gen. De ziekte kenmerkt zich door de 
vorming van cysten (een soort vochtblazen) in een aantal organen, vooral in de nieren (Figuur 
1), waardoor de nier na verloop van tijd niet goed meer kan functioneren. 
Mensen met cystenieren ontwikkelen over het algemeen tussen hun 40e en 70e jaar ernstig 
nierfalen, waarvoor nierfunctie vervangende behandeling noodzakelijk is, zoals  dialyse of een 
niertransplantatie. Hierbij moet wel gezegd worden dat de ziekte uiterst variabel verloopt. 
Sommige patiënten komen op hun 20e levensjaar al in aanmerking voor nierfunctie vervangende 
behandeling, anderen overlijden op hun 90e levensjaar met een nog redelijk functionerende 
nier. Figuur 2 laat deze variabiliteit in leeftijd zien waarop nierfalen bereikt wordt. Uit deze 
afbeelding blijkt dat mensen die uit een familie komen waarin er een mutatie zit in het PKD-2 
gen over het algemeen op latere leeftijd nierfalen krijgen dan mensen met een PKD1-mutatie 
in de familie. Daarnaast valt op dat er verschil is tussen de families, de ene familie komt eerder 
in dialyse dan de ander. Tot slot, is er ook binnen de families variatie in de leeftijd waarop het 
nierfalen begint.
Figuur 2: variatie in leeftijd 
waarop nierfalen wordt 
bereikt. Uit Barua e.a., 
JASN, 2009.
Figuur 1: MRI opname van een man met cystenieren. Het niervolume 
van deze man is meer dan 3 liter. Voor gezonde mensen ligt het totaal 




lang ‘normaal’ blijft ondanks verlies aan nefronen door cystevorming, doordat de overgebleven 
nefronen extra hard gaan werken. Er is dus wel functionerend nierweefsel verloren, maar je 
kunt het niet meten. Figuur 4 illustreert dit fenomeen. Cystevorming, en dus vergroting van 
de nieren, is een bijna exponentieel verlopend proces (totaal niervolume in Figuur 4) waardoor 
er nefronen kapot gaan en de nierfunctie afneemt (‘echte’ nierfunctie). Echter, de de overge-
bleven nefronen kunnen dit een tijdlang compenseren door harder te werken dan anders, de 
zogenaamde reserve capaciteit van de nier wordt dan benut. Hierdoor wordt de nierfunctie niet 
slechter in het begin van de ziekte (gemeten nierfunctie in de figuur), terwijl er wel functione-
rend nierweefsel verloren is gegaan.
Kortom, in ADPKD zijn markers nodig voor ziekte-ernst en die zijn momenteel niet heel 
duidelijk voorhanden. Deel 1 van dit proefschrift beschrijft onze zoektocht naar markers die 
geassocieerd zijn met ziekte-ernst.
In hoofdstuk 2 hebben we gekeken naar de nierfunctie en de nierdoorbloeding bij ADPKD pati-
ënten van verschillende leeftijden en hebben die vergeleken met de nierfunctie en nierdoorbloe-
ding van gezonde personen van dezelfde leeftijd. Onze belangrijkste bevinding van dit hoofdstuk 
is dat al op jonge leeftijd (rond de 28 jaar) de ADPKD patiënten een verminderde nierdoor-
bloeding hadden in vergelijking met de gezonde personen. Hun nierfunctie was echter wel 
(bijna) hetzelfde. Dit bevestigt de aanname in de wetenschappelijke literatuur dat nierfunctie in 
een vroeg stadium van de ziekte geen goede maat is. Ondanks een (bijna) normale nierfunctie, 
hebben deze jonge cystenierpatiënten namelijk wel degelijk afwijkingen aan hun nieren, zoals 
een verminderde nierdoorbloeding, vergrote nieren, ze plassen een groter volume urine (wat er 
waarschijnlijk op duidt dat hun nieren minder goed water kunnen vasthouden en dus urine 
In diermodellen van ADPKD verminderde een V2RA de vorming en groei van niercysten. 
V2RA’s worden al gebruikt bij andere aandoeningen (bij een laag natrium in het bloed en bij 
hartfalen), waardoor we weten dat ze relatief veilig zijn en wellicht minder bijwerkingen hebben 
dan veel andere medicamenten waarvan gedacht wordt dat ze mogelijk de vorming van cysten 
zouden kunnen bestrijden.
Dit proefschrift richt zich op de rol van vasopressine bij het veroorzaken en/of verergeren 
van cystenieren. Het proefschrift is opgedeeld in drie delen. Het eerste deel beschrijft onze 
zoektocht naar geschikte variabelen om ziekte-ernst van ADPKD te meten. In het tweede deel 
wordt onderzocht of vasopressine een schadelijke rol heeft. Hier hebben we naar gekeken bij 
mensen met cystenieren, maar ook in andere (patiënt)groepen. Het derde deel tenslotte, is een 
samenvoeging van de twee eerdere delen. Hierin hebben we de effecten van het remmen van 
vasopressine bij ADPKD bestudeerd. 
Deel 1: Het meten van de ziekte-ernst in ADPKD
ADPKD verloopt bij elke patiënt anders. Bij de een houden de nieren op zeer jonge leeftijd 
op met werken, een ander bereikt dat punt misschien nooit (Figuur 2). Daarnaast hebben alle 
medicijnen bijwerkingen. Het zou daarom het beste zijn alleen medicijnen te geven aan patiën-
ten bij wie de kans groot is dat ze in korte tijd verergering van hun ziekte krijgen. Het is daarom 
belangrijk zulke patiënten te kunnen identificeren. Bij veel nierziekten wordt daarvoor de nier-
functie gebruikt. Met nierfunctie wordt dan het klaringsvermogen van de nieren bedoeld, ofwel 
het vermogen van de nieren om het bloed van afvalstoffen te zuiveren. Dit wordt uitgedrukt als 
de hoeveelheid bloed die per minuut door de nier van afvalstoffen kan worden gezuiverd. Hier-
voor geldt: hoe groter dat bloedvolume, hoe beter de nier werkt. Voor een gezond mens ligt dit 
rond de 120 ml/minuut. Er zijn echter aanwijzingen dat de nierfunctie in een vroeg stadium van 
cystenieren een onbetrouwbare maat is voor de ernst van de ziekte. Bij een normaal persoon 
bestaan de nieren uit 500.000 tot 1 miljoen zogenaamde nefronen. Dit zijn kleinst functione-
rende eenheden van de nier. Er wordt aangenomen dat de nierfunctie bij patiënten met ADPKD
Figuur 4: Hypothetisch verband tussen nierfunctie en niervolume in ADPKD.




mensen. Daarnaast wilden we bepalen of ze een relatie hadden met de ziekte-ernst (uitgedrukt 
als verminderde nierdoorbloeding en verhoogde niergrootte, omdat we in het vorige hoofdstuk 
konden bevestigen dat nierfunctie geen goede maat is voor ziekte-ernst. Nierdoorbloeding en 
niergrootte bleken mogelijk een betere maat te zijn). We vonden dat verschillende markers in 
de urine verhoogd waren ten opzichte van de gezonde personen. Zowel de markers duidend op 
algemene ontsteking, als die afkomstig uit de glomerulus, proximale- en distale tubulus waren 
verhoogd aanwezig in de urine van de ADPKD patiënten. Dit komt waarschijnlijk doordat alle 
onderdelen van de nier in enige vorm beschadigd zijn. Een aantal markers was geassocieerd met 
nierdoorbloeding of niergrootte. De marker NGAL, voornamelijk afkomstig uit de proximale 
tubulus, was als enige geassocieerd met zowel nierdoorbloeding als niergrootte. Cystenierpa-
tienten met een hoog NGAL gehalte in de urine hadden een verminderde nierdoorbloeding 
en vergrote nieren. Gebaseerd op deze bevinding, zouden we willen aanraden vooral NGAL te 
meten bij ADPKD patiënten om de ernst van hun nierziekte te beoordelen.
Deel 2: Vasopressine en nierschade
In dit deel hebben we gekeken naar de mogelijk schadelijke rol van vasopressine bij het veroor-
zaken van nierschade in verschillende (patiënt) groepen. Eerder is al genoemd dat vasopres-
sine heel belangrijk is voor het menselijk lichaam. Zonder vasopressine kan de nier geen water 
terugresorberen en zou je vele liters urine plassen en bijna continu moeten drinken om niet uit 
te drogen (Figuur 3). Uit experimentele studies (met cellen en dieren) komt echter naar voren 
dat vasopressine ook een schadelijk effect zou kunnen hebben op de nieren. Uit voorgaande 
studies blijkt dat als in ratten met chronisch nierfalen vasopressine wordt geremd (met medi-
catie of door ze heel veel water te laten drinken), het beter gaat met de nier. Wetenschappelijk 
onderzoek naar de relatie tussen vasopressine en nierschade bij mensen ontbreekt helaas. Dit 
zou kunnen komen doordat vasopressine moeilijk te meten is. Vasopressine is gebonden aan 
bloedplaatjes, is niet stabiel in plasma en veel bepalingen hebben een beperkte gevoeligheid 
(dat wil zeggen, de tests kunnen beneden een bepaalde grens de hoeveelheid vasopressine niet 
precies meten). Recent is er een test ontwikkeld welke copeptin meet . Copeptin is een stukje 
van de voorloper van vasopressine. Het is aangetoond dat de concentratie copeptin gelijk opgaat 
met de concentratie vasopressine. Copeptin is dus een soort afspiegeling van vasopressine, maar 
wel eentje die betrouwbaarder te meten is.
Hierdoor waren we in staat te kijken naar de mogelijke relatie tussen vasopressine (indirect 
gemeten door copeptin te bepalen) en nierschade in verschillende groepen. Eerst hebben we 
gekeken naar de relatie tussen vasopressine en eiwitverlies in de urine (albuminurie) in de alge-
mene bevolking (hoofdstuk 4). In Groningen wordt het PREVEND onderzoek verricht, waarbij 
in een grote groep personen in 1997 het eiwitverlies in de urine is gemeten, en waarin nagegaan 
wordt of dit eiwitverlies een voorspeller is van hart en nierziekten. Mede door dit onderzoek 
is vast komen te staan dat urine eiwitverlies inderdaad deze aandoeningen voorspelt. Bij 7593 
mensen uit dit onderzoek hebben we copeptin gemeten. Bij deze mensen afkomstig uit de 
bevolking, vonden we ten eerste dat mensen met een hoog vasopressine een laag urinevolume 
hadden. Dit is ook wat je verwacht, aangezien vasopressine ervoor zorgt dat de nieren water 
minder kunnen concentreren) en er zit meer albumine (een 
bepaald eiwit wat duidt op nierschade) in hun urine. Tevens geeft 
dit aan dat in een vroeg stadium van cystenieren beter nierdoor-
bloeding en niergrootte gemeten kan worden om te bepalen of er 
daadwerkelijk nierschade is.
Het meten van de nierdoorbloeding gebeurt met radioactieve 
merker stoffen die worden ingespoten en gemeten in bloed en 
urine. De niergrootte wordt bepaald met behulp van een MRI 
scan. Beide metingen nemen veel tijd in beslag, zijn belastend 
voor de patiënt en zijn duur. Het zou wenselijk zijn een mak-
kelijker te bepalen maat voor de ernst van nierschade te hebben. 
Door de cystevorming in de nieren ontstaat er een soort ontste-
king van diverse onderdelen van de nier. Zoals benoemd bestaat 
de nier uit vele nefronen. Een nefron bestaat weer uit een soort 
filter (de glomerulus), waar het bloed gefiltreerd wordt en waar 
afvalstoffen het lichaam kunnen verlaten, maar ook uit een soort 
buizensysteem (de tubulus) die aan de glomerulus vast zit, waar 
de voor-urine doorheenloopt alvorens die in de blaas terecht-
komt. In de tubulus vinden allerlei processen van resorptie en uit-
scheiding plaats, waardoor uiteindelijk de urine wordt gevormd 
zoals een mens die uitplast. Ook deze tubulus is weer op te delen 
in een stuk wat dichtbij het filter zit (de proximale tubulus) en 
een stuk wat juist verder bij het filter vandaan en dichter bij de 
blaas zit (de distale tubulus). Zie Figuur 5. Globaal bestaat een 
nefron dus uit 3 delen: de glomerulus (1), de proximale tubulus 
(2) en de distale tubulus (3).
Schade aan de verschillende onderdelen van het nefron maakt dat er stoffen worden afgegeven 
aan de voorurine, wat eventueel te meten is in de uiteindelijke urine. Deze stoffen zouden 
ideale markers zijn om ziekte-ernst te meten, omdat ze gemakkelijk te verkrijgen zijn uit urine 
en er dus geen bloed geprikt hoeft te worden. Bovendien is het aannemelijk dat juist in de urine 
stoffen gemeten kunnen worden die de ernst van een nierziekte weerspiegelen. Urine komt 
immers rechtstreeks uit de nier. Bij een aantal nierziekten is naar deze stoffen en ziekte-ernst 
gekeken.  Soms is er zelfs gekeken naar deze stoffen en de kans op ziekte-progressie. Ook bij 
cystenieren is er een aantal van deze stoffen gemeten. Maar altijd maar een per onderzoek, wat 
vergelijking van de waarde van deze stoffen moeilijk maakt. De metingen zijn bovendien tot nu 
toe gedaan in betrekkelijk kleine groepen patienten. 
Wij hebben daarom bij cystenierpatiënten markers gemeten in de urine die afkomstig zijn 
uit de glomerulus, uit de proximale- en de distale tubulus en algemene ontstekingsmarkers 
(hoofdstuk 3). We wilden bekijken of deze markers verhoogd waren ten opzichte van gezonde 
Figuur 5: Verschillende delen van 
het nefron. 1: glomerulus, 2: proxi-
male tubulus en 3: distale tubulus. 




overeen met onze verwachtingen. Immers, de hoge vasopressine spiegel zet de nieren van deze 
mensen aan water vast te houden, leidend tot een kleiner urinevolume. Vasopressine regulatie 
en –actie leek bij deze transplantatiepatiënten dus normaal te functioneren. Onze belangrijkste 
vraag was of er ook een verband was tussen vasopressine en nierfunctie-achteruitgang in de loop 
van de tijd. Inderdaad bleek het zo te zijn dat de mensen met de hoogste vasopressine spiegels 
het snelst achteruit gingen wat betreft hun nierfunctie. Dit zou kunnen betekenen dat een hoog 
vasopressine inderdaad nierfunctie achteruitgang veroorzaakt.
Eerder is al genoemd dat in diermodellen voor ADPKD een vasopressine V2 receptor antagonist 
de vorming van cysten verminderde. Oftewel: het remmen van vasopressine heeft een gunstig 
effect. Logischerwijs is vasopressine dan schadelijk voor de nier bij mensen met ADPKD. Tot nu 
toe was echter nooit naar gekeken naar vasopressine en ziekte-ernst bij mensen met deze ziekte. 
Wij hebben daarom de mogelijke relatie onderzocht tussen vasopressine in het bloed en de ernst 
van ADPKD. De resultaten van de102 patiënten met ADPKD bij wie we dit konden onderzoe-
ken staan beschreven in hoofdstuk 6. Als maat voor ziekte-ernst hebben we gekeken naar renale 
bloeddoorstroming, totaal niervolume en uitscheiding van albumine in de urine. We vonden 
ten eerste dat ook in deze ADPKD patiënten de concentratie van de hoeveelheid deeltjes in het 
bloed geassocieerd was met vasopressine concentratie. In tegenstelling tot de situatie bij gezon-
de mensen of transplantatiepatiënten, vonden we echter geen duidelijk verband tussen vasopres-
sine en de hoeveelheid en / of de concentratie van de urine. Dit zou een aanwijzing kunnen zijn 
dat vasopressine niet zijn normale fysiologische effecten heeft in deze patiënten. Het antwoord 
op onze belangrijkste onderzoeksvraag is dat er inderdaad een duidelijk verband bleek tussen 
vasopressine en ziekte-ernst: hoe hoger het vasopressine, hoe lager de bloeddoorstroming van 
de nieren, hoe groter de nieren en hoe meer albumine uitscheiding in de urine. Deze verbanden 
golden voor zowel mannen als vrouwen, van alle leeftijden. 
Deel 3: Kunnen vasopressine V2 receptor antagonisten nierschade bij ADPKD 
remmen?
Dat er een verband bestaat tussen vasopressine en ziekte-ernst in ADPKD past goed bij de eer-
der genoemde resultaten in diermodellen van deze ziekte. Hierin gaf het remmen van vasopres-
sine met behulp van zogenaamde Vasopressine V2 receptor antagonisten (V2RA) een gunstig 
resultaat. Dit biedt wellicht ook een goed vooruitzicht voor een grote klinische studie die op 
dit moment uitgevoerd wordt. Deze studie heet de TEMPO ¾ studie. TEMPO is een afkorting 
die staat voor Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic 
Kidney Disease and its Outcomes, phase 3 of 4. De studie onderzoekt of een V2RA (Tolvaptan, 
merknaam Samsca®) een gunstig effect kan hebben op de niergroei bij patiënten met ADPKD. 
In hoofdstuk 7 wordt de studie-opzet en de achterliggende gedachten bij deze opzet besproken. 
Aan deze studie mogen ADPKD patiënten meedoen die jong zijn, nog een goede nierfunctie 
hebben, maar al wel een groot niervolume. De reden hiervoor is dat verwacht wordt dat juist 
deze mensen een ernstiger beloop van hun nierziekte zullen hebben, waardoor het mogelijk zal 
zijn een eventueel gunstig effect van de studiemedicatie te vinden. Eén van de drie mensen die 
vasthouden, en je dus minder vocht via de urine verliest (Figuur 3). We vonden verder wat we 
verwacht hadden, namelijk dat mensen met een hoge vasopressine spiegel ook veel albumine in 
de urine hadden. Deze relatie was het sterkst aanwezig bij oudere mensen.
In een toevoeging op dit hoofdstuk (hoofdstuk 4.1) beschrijven we dat deze relatie tussen va-
sopressine en albuminurie onafhankelijk is van zoutinname. Je zou namelijk kunnen denken dat 
een hoge zoutinname leidt tot een hoge vasopressine spiegel (omdat door een hoge zoutinname 
de concentratie deeltjes in het bloed toeneemt, zie Figuur 3). Meer zoutinname zou daarnaast 
ook tot meer nierschade en albuminurie kunnen leiden, maar via een ander mechanisme. Dit 
verband is in eerder onderzoek aangetoond (overigens ook verricht als onderdeel van de PRE-
VEND studie).  De relatie tussen vasopressine en albuminurie zou dan een schijnverband zijn, 
want eigenlijk is zoutinname de onderliggende factor. In hoofdstuk 4.1 beschrijven we echter 
dat de eerder gevonden relatie tussen vasopressine en albuminurie onafhankelijk is van zoutin-
name, wat een schijnverband onwaarschijnlijker maakt.
We hebben ook gekeken of deze gezonde mensen met een hoge vasopressine spiegel ook in de 
tijd sneller achteruitgaan wat betreft hun nierfunctie dan mensen met een lage vasopressine 
spiegel. Dit was echter, tegen onze verwachting in, niet het geval. Wellicht dat dit veroorzaakt 
wordt doordat de gezonde nieren van gezonde mensen niet kwetsbaar genoeg zijn voor eventue-
le schade die vasopressine zou kunnen veroorzaken. We vonden het verband tussen vasopressine 
en albuminurie het sterkst in de oudste groep mensen die deelnam aan het PREVEND onder-
zoek, mensen die wellicht al enige vorm van nierschade hadden. Daarnaast, ook in de dierstu-
dies waarin eerder gekeken was naar de mogelijk schadelijke rol van vasopressine, hadden de 
muizen of ratten die bestudeerd werden ook altijd enige vorm van nierschade. 
Om beter te kunnen kijken naar het mogelijke verband tussen vasopressine en nierfunctie-
achteruitgang in de tijd hebben we daarom niertransplantatiepatiënten onderzocht. Mensen 
die een niertransplantatie hebben ondergaan hebben namelijk altijd enige vorm van nierschade. 
Deze nierschade kent verschillende oorzaken. Ten eerste is er slechts 1 functionerende nier, die 
voorafgaand aan de transplantatie een tijdje buiten een menselijk lichaam geweest is, waarbij die 
minder zuurstof heeft gehad. Ten tweede heeft de medicatie die noodzakelijk is om afstoting te 
voorkomen ook een nadelig bij-effect op de nier. In het Universitair Medisch Centrum Gronin-
gen worden al jaren lang veel niertransplantaties verricht, wat ons de mogelijkheid gaf de relatie 
tussen vasopressine spiegels en snelheid van nierfunctie-achteruitgang in de loop van de tijd 
te bestuderen (hoofdstuk 5). We hebben dit kunnen onderzoeken in 548 transplantatiepatiën-
ten. De tijd tussen bloedafname waarin copeptin (als maat voor vasopressine) bepaald is en het 
moment waarop we uiteindelijk de nierfunctie konden bepalen was ongeveer 6 jaar. We vonden 
allereerst dat mensen met een hogere concentratie deeltjes in het bloed (een hogere osmolari-
teit), een hogere vasopressine spiegel hadden. Dit is wat je verwacht te vinden; het hogere vaso-
pressine is bij deze mensen noodzakelijk om water vast te houden, om zo de osmolariteit weer 
omlaag te brengen (Figuur 3). Evenzo vonden we dat de mensen met een hoog vasopressine een 
kleiner urinevolume hadden dan mensen met een lage hoeveelheid vasopressine. Ook dit kwam 
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3 weken behandelen). Het op een later tijdstip geven van het medicament, of in een lagere dose-
ring, resulteerde wel in minder bijwerkingen (minder urine volume), maar helaas ook in minder 
bescherming tegen cystvorming. Als de behandeling die vroeg werd begonnen, in hoge dosering, 
voortgezet werd, werd het eerder gevonden gunstige effect op de nier minder duidelijk. Ook 
hadden de muizen later minder bijwerkingen van het medicament dan ze aanvankelijk hadden 
(zo dronken ze minder, gingen ze minder plassen en werd de urine weer geconcentreerder). Dit 
zou erop kunnen wijzen dat vasopressine niet helemaal onderdrukt is in deze muizen. Wellicht 
is het noodzakelijk in het vervolg een hogere dosering te geven van dit medicijn naarmate de 
ziekte vordert. 
deelneemt aan de studie krijgt tolvaptan, de ander krijgt placebo (een tablet die er hetzelfde uit-
ziet, maar geen werkzame stof bevat). Het slikken en geven van de medicatie gaat dubbel blind. 
Dat wil zeggen dat de deelnemer niet weet of hij/zij placebo of tolvaptan slikt, maar ook de on-
derzoeksdokters niet weten wat ze aan de patiënt geven. De studie zal drie jaar duren. Belang-
rijkste uitkomstmaat van de studie is het verschil in verandering van niervolume bij patiënten 
die tolvaptan slikken versus patiënten die placebo slikken gedurende de 3 jaar van deelname aan 
het onderzoek. Daarnaast wordt ook gekeken naar verschil tussen deze twee groepen in veran-
dering van nierfunctie, toename van albumine uitscheiding in de urine en nierpijn. Tussen maart 
2007 en januari 2009 zijn er wereldwijd 1445 ADPKD patiënten aan deze studie begonnen, 746 
mannen en 699 vrouwen. In het Universitair Medisch Centrum Groningen, zijn er 52 patiënten 
die deelnemen aan de studie. Ons centrum is daarmee het op 1 na grootste centrum. Tot nu toe 
hebben we alleen beschikking over de resultaten aan het begin van de studie. Inderdaad hebben 
deze 1445 mensen nog een goede nierfunctie. De klaring van hun nieren wordt geschat op 105 
mL/min, wat een bijna normale waarde is. Hierbij moet wel gezegd worden dat de spreiding in 
nierfunctie groot is, er zijn dus ook patiënten bij die een beduidend lagere nierfunctie hebben. 
Het niervolume is groot (mediaan 1,5 liter, ongeveer 5 keer zo groot als het niervolume van 
gezonde mensen) en de leeftijd laag (gemiddeld ongeveer 39 jaar). Omdat er zoveel patiënten 
deelnemen aan dit onderzoek en ze inderdaad jong zijn, een goede nierfunctie hebben, maar een 
groot niervolume, is de kans groot dat deze studie een antwoord zal kunnen geven op de vraag 
of vasopressine V2 receptor antagonisten een gunstig effect hebben op de nieren van ADPKD 
patiënten.
Als uit deze studie blijkt dat vasopressine V2 receptor antagonisten effectief zijn bij ADPKD, 
is er echter nog een aantal belangrijke vragen te beantwoorden. Aan de TEMPO studie mogen 
alleen ADPKD patiënten deelnemen als ze in een vroeg stadium van de ziekte zijn. De patiënten 
moeten namelijk jong zijn en nog een relatief goede nierfunctie hebben. Het blijft de vraag of 
dit medicament ook effectief is als er later in de ziekte mee begonnen wordt. Daarnaast geeft 
een V2RA toename van de wateruitscheiding, dus mensen moeten meer en vooral vaker plassen. 
Ook ’s nachts moeten ze daarvoor (vaker) hun bed uit. Dit is niet in elk beroep even makkelijk 
en zou daarnaast kunnen leiden tot een minder goede nachtrust en daarmee een vermindering 
van de kwaliteit van leven. Omdat behandeling met dit medicament waarschijnlijk gedurende 
het hele leven zal moeten plaatsvinden, is het belangrijk dat de bijwerkingen niet al te hinderlijk 
zijn. Het is daarom van belang te onderzoeken of lagere dosering van het medicament tot min-
der bijwerkingen zal leiden, maar daarnaast nog wel effectief is wat betreft gunstig beïnvloeden 
van het beloop van hun nieraandoening.
 
In een poging de vragen te beantwoorden over dosering en moment van toedienen, hebben we 
een vasopressine V2 receptor antagonist aan muizen gegeven die ADPKD hebben. Dit wordt 
beschreven in hoofdstuk 8. De ziekte in de muizen die wij gebruikt hebben, lijkt sterk op die bij 
mensen en wordt ook veroorzaakt door hetzelfde genetische defect (een mutatie van het PKD1-
gen). We vonden dat behandeling met een V2RA inderdaad resulteerde in een vermindering van 
de cystegroei en een vermindering van het niervolume bij deze muizen op korte termijn (d.w.z. 
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De volgende vraag is dan: wie moeten we behandelen? Aangezien ADPKD een erfelijke ziekte 
is, weten we soms al als kinderen heel jong zijn of ze ADPKD hebben. Moet dan direct behande-
ling gestart worden? Omdat de ziekte erg variabel is en om te voorkomen dat iedereen wordt 
blootgesteld aan bijwerkingen van medicijnen, zou het het mooist zijn als we zouden kunnen 
voorspellen wie vroeg in zijn leven moet gaan dialyseren of in aanmerking komt voor een trans-
plantatienier. Met andere woorden, wie het meeste baat heeft bij behandeling met een derge-
lijk medicament. Helaas kunnen we dat op dit moment nog niet. Wel kunnen we aanraden, op 
grond van onze bevindingen in hoofdstuk 3, te onderzoeken of NGAL een marker is die ziekte 
progressie wellicht kan voorspellen. Het zou ook interessant zijn te kijken of NGAL omlaag gaat 
op het moment dat behandeling aanslaat.
In dat geval zou NGAL gebruikt kunnen worden als marker om op korte termijn te kunnen 
beoordelen wat het effect van medicatie is op de lange termijn.
Onze bevinding dat mensen met ernstiger ADPKD hogere vasopressine spiegels hebben dan 
mensen met minder ernstig ADPKD (hoofdstuk 6), geeft aan dat deze mensen misschien hogere 
doses van een vasopressine V2 receptor antagonist zouden moeten krijgen om hun vasopressine 
spiegels volledig te onderdrukken. In de dierstudie (hoofdstuk 8) bleek ook dat het geven van 
een V2RA aan deze muizen gedurende langere tijd op den duur geen gunstig effect meer had, 
maar ook minder bijwerkingen gaf. Wellicht dat het ophogen van de dosis een oplossing zou zijn. 
Welke dosis dan het beste gegeven kan worden zou wellicht bepaald kunnen worden op basis 
van de concentratie van de urine (als de urine te geconcentreerd is, moet de dosering omhoog). 
Of dit altijd veilig is en echt werkt, zal in toekomstige studies uitgezocht moeten worden.
Naast de situatie in ADPKD, toonden we ook aan dat er een verband bestaat tussen hoge vaso-
pressine spiegels en albumine uitscheiding in de urine in gezonde personen. Bij mensen met 
een transplantatienier vonden we een verband tussen vasopressine en nierfunctie-achteruitgang 
(waarbij de mensen met de hoogste vasopressine spiegels de meeste albumine uitscheiding en de 
meeste nierfunctie-achteruitgang hadden). Ook in eerder verrichtte dierstudies zijn er aanwij-
zingen dat een hoog vasopressine slecht zou kunnen zijn voor de nier. Vasopressine zou mogelijk 
kunnen leiden tot een hoge bloeddruk en een hoge druk in de nier. Dit draagt bij aan de intrige-
rende gedachte dat acties die de vasopressine concentratie in het bloed remmen (door een V2RA 
te slikken, maar ook simpelweg door meer water te drinken) een gunstig effect zouden kunnen 
hebben op de nier bij mensen met een chronische nierziekte van andere oorsprong dan ADPKD. 
Kortom, uit deze laatste paragraven blijkt weer eens dat onderzoek weer nieuw onderzoek 
oproept. Maar ook wordt duidelijk uit deze samenvatting dat de hoop groeit dat er eindelijk een 
behandeling komt die nierfunctie achteruitgang kan vertragen bij patiënten met ADPKD.  
Toekomstperspectief
In dit proefschrift hebben we aangetoond dat copeptin geassocieerd is met ernst van ADPKD 
(hoe hoger de vasopressine concentratie, hoe ernstiger de ziekte). Dit past bij de theorie dat 
vasopressine ook daadwerkelijk groei van cysten in ADPKD bevordert. Het zou heel interes-
sant zijn te kijken of ADPKD patiënten die nu een hoog vasopressine hebben, er niet alleen op 
dit moment slechter aan toe zijn, maar ook sneller achteruitgaan in de loop van de tijd. Het is 
natuurlijk moeilijk hoe je dan achteruitgang in de tijd moet uitdrukken, zeker nu we weten dat 
nierfunctie lang ‘normaal’ blijft in deze ziekte, terwijl de nieren van deze patiënten in werke-
lijkheid wel achteruitgaan (Figuur 4). Achteruitgang zou daarom gemeten kunnen worden als 
nierfunctie-achteruitgang in een groep patiënten die al een gestoorde nierfunctie hebben. Ook 
zou dit onderzocht kunnen worden bij patiënten die in een eerder stadium van de ziekte zitten, 
maar dan door het niervolume te meten of door de mensen heel lang in de tijd te vervolgen. 
Op dit moment zijn we aan het kijken of we deze vraag (of er een verband is tussen vasopressine 
en nierfunctie-achteruitgang in ADPKD patiënten) kunnen beantwoorden met behulp van een 
groep ADPKD patiënten die ongeveer 15 jaar geleden aan een studie in het Universitair medisch 
Centrum Leiden hebben meegedaan.
Hopelijk zal de TEMPO ¾ studie gaan aantonen dat een vasopressine V2 receptor antagonist 
(V2RA) effectief is bij ADPKD wat betreft het remmen van groei van totaal niervolume. We 
zullen dan goed moeten kijken naar de bijwerkingen van dit medicament. Te meer daar het 
waarschijnlijk levenslang gegeven zal moeten worden. De resultaten in het diermodel (hoofd-
stuk 8) suggereren dat een lagere dosis misschien wel leidt tot minder bijwerkingen, maar helaas 
ook tot een minder gunstig effect op de nier. Om nog echt effectief te zijn, zou er gekeken 
moeten worden naar de mogelijkheid een vasopressine V2 receptor antagonist te combineren 
met andere medicamenten waarvan nu de effectiviteit bij cystenieren getest wordt. Te denken 
valt dan met name aan zogenaamde somatostatine-analogen. Belangrijk is te vermelden dat ook 
deze medicamenten bijwerkingen hebben. In toekomstig onderzoek zal er gekeken moeten gaan 
worden naar optimale medicatiedosis, zodat er wel effect is, maar zo min mogelijk bijwerkin-
gen. Het lijkt verstandig dit te onderzoeken van alle medicamenten apart, maar zeker ook van 
combinatietherapie.
Een andere vraag die door de TEMPO ¾ studie niet beantwoord gaat worden is of de vasopres-
sine V2 receptor antagonist ook nog effectief is in een later stadium van de ziekte. De resultaten 
uit hoofdstuk 8 suggereren dat eerdere interventie effectiever lijkt dan later. Binnenkort zal er 
in ons centrum een onderzoek starten waarin we willen kijken naar veiligheid en effectiviteit 
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Full colour images
Cyst ratio (upper panel) and kidney weight (middle panel) for experimental groups. Data are presented 
as means and standard errors of the mean. No statistically significant differences between the various 
ADPKD groups at week 6 were found. * indicates p<0.05 compared with wild-type. HD, high dose 
(0.1%). 
The lower panel shows representative kidney sections of an untreated iKsp-Pkd1del mouse and iKsp-
Pkd1del mouse treated with high dose V2RA at week 3 of the experiment. 
Panels A-D show kidney sections from an untreated iKsp-Pkd1del mouse, sacrificed at 3 weeks. Panels 
E-H show kidney sections from a mouse treated with a high dose V2RA for 3 weeks. Sections are stained 
for the proximal marker Megalin (A&E), the distal markers Tamm Horsfall Protein (THP, B&F), Aquapo-
rin-2 (AQ2, C&G), and lectin Dolichos biflorus agglutinin (DBA, D&H). * indicates positive staining of 
the cyst.
Chapter 8: Figure 4: Tubular segment identity of cysts.
Chapter 8: Figure 5: Renoprotective effects of the vasopressin V2 receptor antagonist  
(V2RA) at week 3 and week 6 of the experiment. 
Chapter 1: Figure 7: Hypothetical pathogenetic pathways in ADPKD. 
Pathways depicted in bold are upregulated, pathways depicted in grey are downregulated.
A. Depicts an epithelial cell of the kidney’s collecting duct of a healthy individual. As long  
as there is urine flow in the tubule, the cilium will bend, inducing a calcium influx   
through the polycystin complex. This in turn induces release of calcium from the endo  
plasmatic reticulum. Cyclic AMP is inhibited by this calcium.
B. Depicts this same cell, but now derived from an individual with ADPKD. Because of a  
defect in the polycystin complex, there is less calciuminflux, resulting in an increased   
intracellular cyclic AMP concentration. This will induce on the one hand more protein   
translation, causing a disturbed proliferation, adhesion, migration, differentiation and   
maturation of the tubulule cells and on the other hand more chloride dependent fluid  
production, enabling the cysts to grow. 
How these processes are interrelated is at this moment still unknown. Vasopressin V2   
receptor antagonists block the vasopressin V2 receptor (V2R) and thereby inhibit    
cAMP, inhibitors of mTOR inhibit protein translation. 
